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Abstract
Attempts to produce an effective vaccine against group B meningococcal disease have 
been unsuccessful due to poor immunogenicity of the capsular polysaccharide, and high 
variability in the currently identified outer membrane proteins. There is therefore a need 
to find other vaccine candidates.
It is clear from studies of bacteria such as Salmonella typhimurinm, that successful 
pathogens have the ability to specifically express genes in response to an in vivo 
environment. Many of these in v/vo-expressed gene products will contribute to 
virulence of the organism and may therefore be target antigens for development of new 
vaccines.
An in vivo promoter-probe strategy was developed using the Cre/lox recombination 
system to identify meningococcal promoters that are specifically expressed in vivo. The 
strategy employs the eve gene, which encodes a site-specific recombinase that targets 
two 34-base pair directly repeated lox sites. A vector, pUS1604, was constructed which 
contains two lox sites flanking a transcriptional terminator that separates the aph 
(encoding kanamycin resistance) coding sequence from its promoter. A promoterless 
eve gene was placed 011 a low copy number vector to limit the number of Cre molecules 
within each host bacterial cell. Expression of Cre is detected by its ability to recombine 
the two lox sites and reconstitute a functional kanamycin resistance gene.
The system was initially tested in E. coli by cloning a known regulated promoter from 
the tfraBAD operon that is induced by L-arabinose and repressed by D-glucose. 
However, the promoter failed to tightly control the regulation of eve gene expression,
resulting in partial loxP recombination, which produced a mixed population of 
streptomycin and kanamycin resistant cells within each colony. Also, attempts to place 
the system into the meningococcus were unsuccessful.
Efforts were made to tighten the regulation of the cre gene by placing the system into a 
different E. coli strain and test the system using a library of meningococcal genomic 
DNA fragments, as a compromise to show the experiments intended to isolate 
promoters. A vector, pUS1623, was constructed that would place the ere gene under the 
control of external promoters. A group B meningococccal genomic library was cloned 
upstream of the promoterless ere gene, with the inserted DNA fragments ranging from
0.1-1 kb in size. The library was introduced into the E.coli XL 1-Blue strain carrying 
pUS 1604, and the Cre/lox recombination event has been shown to behave as expected, 
yielding a proportion of kanamycin-resistant clones. This indicates that promoter-like 
sequences are driving Cre, which is seen through the kanamycin-resistant phenotype of 
the clone. Conversely, clones that remain streptomycin-resistant do not have promoter­
like sequences driving the expression of Cre. This streptomycin-resistant pool of clones 
was used to inoculate 50% serum/50% PBS liquid medium to identify group B strain 
meningococcal promoter sequences that drive Cre expression in this environment.
Several sequences found to induce Cre expression from the initial screen, and during the 
serum experiment were sequenced. The sequence data was next analysed for homology 
against the sequences on the group B meningococcal genome sequence database 
(http://www.tigr.orgk to identify the function of the contig from which the isolated 
sequence is found within the meningococcal genome. Finally, the sequences were 
analysed for prokaryote -35 and -10 consensus regions and orientated to determine the
direction of transcription relative to the ere gene and also to genomic open reading 
frames, to determine the likelihood of isolating actual promoters. Although the 
experiments carried out in E. coli do not give an accurate picture of the regulatory gene 
pathways in the meningococcus, the results give an insight into the suitability of the 
system as regards to its use in an IVET strategy.
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1. Meningococcal disease and its causative agent, Neisseria
meningitidis
1.1. M eningococcal disease
1.1.1. Introduction
Meningococcal disease remains a serious worldwide human health problem. High 
morbidity and mortality are associated with the disease. The incubation period is short 
(2-10 days), and epidemics may develop rapidly. Meningococcal disease manifests 
itself both as meningococcal meningitis and septicaemia. The bacterial causative agent, 
Neisseria meningitidis, is the most common cause of bacterial meningitis.
1.1.2. Transmission and colonisation
N. meningitidis can be isolated from the nasopharynx in approximately 10% of the 
general population in England and Wales, and is regarded as being a commensal 
organism of the human respiratory tract. Natural immunity arises from being a carrier, 
however carriage rates vary with age; 2% in children under 5 years old to 24% in 15-19 
year olds (Public Health Lab., 1995). Smokers are also more likely to carry 
meningococci.
Transmission occurs via large respiratory droplets, spread though aerosols (e.g. from 
sneezing, coughing), or through direct contact with respiratory secretions (e.g. from 
kissing). The incidence of the number of cases is the highest during winter in the 
Northern Hemisphere, as there is greater scope for transfer of the meningococci by 
coughing and sneezing. Infection by meningococci begins with the colonisation of the 
upper respiratory tract, and the meningococci are transferred from the carrier (who is
usually asymptomatic) to the recipient. It is not surprising that a high proportion of 
cases are the result of an outbreak, defined as being two or more cases associated in 
time and place (Last, 1988). During outbreaks of the disease, upto 80% of the 
population have their noses and throat colonised by the organism (Broome, 1986), yet 
only a small proportion of the population develops the disease. The disease mainly 
affects young children, who have not developed protective bactericidal antibody, 
however other age groups such as young adults and the elderly are susceptible to a 
lesser degree. The transition from carriage to infection may also result from an impaired 
immune status, such as preceding viral infections (Ramirez-Ronda et. a l, 1981), 
inhalation of dry, dusty air (Greenwood et. a l , 1987), and exposure to passive smoking 
among children (Stanwell-Smith et. al., 1994) have been associated.
1.1.3. Disease Pathogenesis
In 1918, Herrick proposed that there are three principle stages in the development of 
meningococcal disease; (i) mucosal colonisation and penetration, (ii) bacteraemia, and 
(iii) localised inflammatory response. Meningococcal infection initially starts with 
colonisation of the upper respiratory tract, mainly the nasopharynx and tonsils. The 
organism is transmitted via aerosol droplets from the carrier to the recipient. 
Meningococcal cell surface structures are critical in colonization, invasion and disease 
pathogenesis.
In order to cause disease, meningococci have to first penetrate the mucosal barrier of 
the host. It is not clear which bacterial or host factors facilitate meningococcal passage 
from the nasopharynx to the blood. Previous studies have shown that whilst acapsulate 
meningococci are frequently isolated from the nasopharynx, the encapsulated, piliated 
N. meningitidis are able to attach to non-ciliated cells and are more capable of damaging
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these cells than non-piliated meningococci (Stephens ef. al., 1983, 1986). Other surface 
proteins such as the class 5 OMPs may also play a role in attachment, by strengthening 
adherence and promoting bacterial entry into the host cell (Virji et. al., 1992, 1993). 
There may be capsule phase variation, from colonisation to adhesion, the bacteria 
switch between an acapsulate and encapsulated status. However, it is thought that 
encapsulation hinders penetration of the mucosal barrier, and so may require a down- 
regulation of capsule expression, enabling passage through the mucosal epithelium. 
This is followed by re-expression of the capsule, which consists of sialic acid, 
associated with virulence (Hammerschmidt et. al., 1996).
Cell adhesion is followed by a short period of bacterial adaptation and local 
proliferation, prior to the organism entering the cell by endocytosis. The encapsulated 
meningococci are transported through the cell in large membrane-bound phagocytic 
vacuoles, whilst non-encapsulated strains are able to cross the cell cytoplasm without a 
vacuole. Within 24 hours the meningococcus reaches the submucosa, close to local 
immune cells and blood vessels (Stephens et. al., 1993).
Mucosal colonisation invokes a general immune response, the exact mechanisms of 
which are unknown. Studies have shown that there is an increase in specific and cross­
reacting antibodies. It is a lack of the bactericidal antibodies in the general immune 
response that predisposes a person to systemic meningococccal disease, whereas the 
presence of such antibodies confers protective immunity (Goldschneider et. al., 1969).
Once the meningococcus reaches the subepithelium, it is able to gain access to blood 
vessels, and from here migrate from the mucosa into deeper tissues. The pili, which 
were required for adhesion to endothelial cells, are down regulated at this stage (Virji, 
et. al., 1991). After an adaptation period and penetration of the mucosa, the
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meningococcus is able to enter the blood via drainage from the lymphatic system. 
Pathogenic strains are characteristically encapsulated and possess a specific pattern of 
outer membrane proteins on their surfaces. The two factors may serve in evading the 
local immune response. The capsule also may partly protect invading meningococci by 
downregulating complement-mediated phagocytosis by local macrophages and 
granulocytes (Jarvis & Vedros, 1987). Furthermore, locally produced IgA antibody may 
act to block the bactericidal antibodies (Griffiss & Bertram, 1977), because it has been 
found that IgA is able to block IgG-mediated killing of a gonococcal strain (Apicella et. 
a l , 1986).
Inside the vascular compartment, the invading meningococci may be neutralised by 
circulating antibody, complement, and phagocytes. If not, the organism is then capable 
of multiplying to result in the development of the bacteraemic disease. During this stage 
of disease pathogenesis, encapsulation is required for the organism to disseminate, as 
the capsule protects against opsonisation and phagocytosis. It is also at this stage that 
the infected person shows symptoms of fever, general malaise, and nausea, due to the 
release of inflammatory mediators such as Tumour Necrosis Factor-a, and Interleukins- 
ip, 6, and 8. Their release is mediated by endotoxic lipopolysaccharides (LPS), which 
are present on the surface of the bacterium (Glauser et. a l, 1991; Quagliarello & 
Scheld, 1992).
Once in the blood, both bacterial and host factors may be important for bacterial 
survival and proliferation. Bacteraemia usually precedes symptoms of meningitis by 24- 
48 hours in most patients. Three outcomes are possible; meningococcal septicaemia 
(high fatality rate, 20-30%), meningococcal meningitis (low fatality rate, 2-4%), or
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(most commonly) a combination of both. The majority of cases are meningitis at 85%, 
with septicaemia accounting for 15% of total cases of meningococcal disease.
1.1.4. Septicaemia
Septicaemia involves secondary infection of the skin, meninges and other parts of the 
body. N. meningitidis can be isolated from blood cultures in the majority of cases. 
Herrick (1918) proposed that symptoms of the disease appeared at the same time as 
septicaemia, and 24 to 48 hours before symptoms of meningitis in most patients. Levels 
of circulating LPS endotxin produced as a result of septicaemia correlate with fatality 
rate. The severity of the disease is due to localised inflammatory response to various 
organs, particularly those involved in circulation, the kidneys, lungs and haematological 
system (comprising of cells and plasma components).
1.1.5. Meningitis
Meningitis results from N  menigitidis crossing the blood-brain barrier. Little is known 
about how and when the transition occurs, though it is thought that the meningococci 
traverse vessel walls in small veins or capillaries. Local inflammatory mediators such as 
TNF-a and IL-lp induced by increasing levels of LPS in the cerebrospinal fluid (CSF) 
may increase the permeability of the blood-brain barrier (Tunkel & Scheld, 1993). 
Although meningitis has a lower mortality rate than the septicaemic form, deaths can 
occur in patients that do not show any signs of septic shock, but have severe 
inflammation within the brain.
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1.1.6. Epidemiology
Meningococcal disease in Africa is mainly due to N. meningitidis serogroup A. There is 
a sharp rise in cases towards the end of the dry, dusty season, and a decline during the 
onset of the rainy season. Conversely, in temperate climates such as Europe and the 
USA, meningococcal infection is due to both N. meningitidis serogroups B and C. In 
these countries there is a seasonal peak of disease, with most cases occurring in the first 
quarter of the year. The annual incidence of meningococcal infection is about 1 -5 per 
100 000 of the population. Across Europe the disease is most prevalent in children 
under the age of 5, and nearly half of the infections in this age group occur in infants 
under 1 year old. Although serogroup B is responsible for most disease in Europe, 
serogroup C strains cause proportionately more infections in older age groups. This 
pattern of disease is similar in the USA. Disease notification figures in England and 
Wales have shown that the average rate of case fatalities has been 12% (calculated from 
the fatality rates of meningitis and septicaemia being 7 and 20 % respectively) (Jones & 
Mallard, 1993).
1.2. Neisseria meningitidis
1.2.1. Introduction
N. meningitidis was first isolated in 1887 by Anton Weichselbaum in Vienna, when 
examining specimen samples from several cases of meningitis. Since then, work has 
been carried out to show a variation in surface structures on the bacterium, giving rise to 
a meningococcal classification system.
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1.2.2. Surface structures and classification
N. meningitidis is a Gram-negative diplococcus which is closely related to the 
gonococcus (N. gonorrhoeae), the causative agent of the sexually transmitted disease, 
gonorrhea. The only known host for both species is man. There are certain surface 
structures common to both species thought to be involved in the pathogenesis of the 
respective diseases, including piliation, the possession of outer membrane proteins and 
lipooligosaccharides, and iron binding proteins.
Meningococci characteristically show a high level of ‘Webbing’, describing the 
shedding of outer membrane vesicles. These contain outer membrane proteins (OMPs) 
and lipopolysaccharides (LPS). Blebs are an important factor in the pathogenesis of 
meningococcal disease because they bind antibodies, therefore preventing the antibody 
binding to the whole bacterial cell. Also, blebs play a major role in the induction of a 
lipopolysaccharide-mediated septic shock. The variations in the OMPs are recognised in 
the current classification system, there being five different classes (1-5), based on 
differences in molecular weight. Meningococci also show a double membrane, which is 
an attribute of the Gram-negative bacteria. This sandwiches a layer of peptidoglycan 
between the two membranes.
1.2.3. Capsular polysaccharides
The outer membrane complex of the meningococcus consists of capsular 
polysaccharides, OMPs, LPS, and pili. The capsular polysaccharide (CPS) is the 
outermost organelle on the meningococcal surface and hence is a target for mucosal 
immunity and subsequently has been focused upon in various meningococcal vaccine 
studies. Structural differences in capsular polysaccharides are also included in the
present classification. There are 12 serogroups currently recognised (A, B, C, 29-E, H, 
I, K, L, W-135, X, Y, Z). Most disease however, is caused by serogroups A, B or C. 
Serogroup A is prevalent in Africa and is responsible for most epidemics, whilst 
sporadic outbreaks and endemic disease in Europe and North America are attributed to 
serogroups B and C.
Capsular polysaccharides are thought to be important virulence determinants, involved 
in the evasion of host defences, Much of the vaccine research against the disease has 
been targeted against the capsular polysaccharide, and there is a vaccine offering 
prevention to infections by groups A, C, Y, and W-135 meningococci. However, it is 
the group B meningococci that are the major cause of bacterial meningitis in the 
Western world.
The CPS of group B N. meningitidis and of Escherichia coli K1 (another pathogen) are 
homopolymers of sialic acid and are identical, both expressed as poly (2-8) a-linked N- 
acetylneuraminic acid (NeuNAc) (Liu et al., 1971). The CPS is an important virulence 
factor to both organisms, involved in the evasion of host defences, and enhancing 
survival of the organisms during invasion of the bloodstream and cerebospinal fluid 
(Swartley et. al., 1996). Group C meningococcal CPS is composed of poly (2-9) a- 
linlced NeuNAc, another homopoiymer of sialic acid. Although this differs from that of 
group B only by linkage, the group C CPS is immunogenic and is a licenced vaccine 
(Devi et. a l, 1991; Richmond el. a l, 1999).
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1.2.4. Lipooligosaccharides
The outer membrane complex of the encapsulated N. meningitidis cell includes a 
capsule and an outer membrane envelope, which is composed of proteins and 
lipooligosaccharides (LOS) incorporated in a lipid bilayer (Kim et. al., 1989). Sialic 
acid is also found as a modification of the meningococcal LOS. The terminal galactose 
residue of LOS can be substituted with sialic acid, which utilises available endogenous 
or exogenous cytidine-5’-monophospho- yV-acetylneuraminic acid (CMP-NeuNAc) as 
the sialic acid substrate (Mandrell et. al., 1991). Sialylation of LOS may also alter cell­
cell contact-dependent event important in the attachment to and invasion of human cells 
by meningococci (van Putten & Robertson, 1995).
It is believed that N. meningitidis requires a genetic switching event for capsule 
expression and endogenous sialylation of LOS in order to adapt to the host during the 
different stages of infection in order to evade the host’s defence mechanisms. 
Hammerschmidt et. al. (1996) showed that the organism is able to use a mechanism in 
which the siaA gene, which is involved in the synthesis of CMP-NeuNAc (required for 
both CPS synthesis and LOS sialylation), can be reversibly inactivated. This occurs by 
the insertion/excision of a naturally occurring insertion sequence element, IS 1301, 
thereby regulating both capsule expression and endogenous LOS sialylation.
Meningococcal LOS is composed of 1-6 components of molecular weights ranging 
from 3200-5100 kDa, It is composed of lipid A and a small oligosaccharide of up to 10 
monosaccharides. However, there is no O antigen side chain (Verheul el. al., 1993). 
Most meningococcal strains express more than one immunotype-specific epitope on the 
LOS, which therefore gives rise to a sub-level of classification where the strains have
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been designated ‘L’ numbers. N. meningitidis can be serologically divided into at least 
12 ’L’ types based on its LOS antigens (Tsai & Civin, 1991). It has been shown that the 
oligosaccharide portion of the LOS mimics human glyosphingolipid antigens found on 
the surfaces of various human cells, hence this molecular mimicry aids in evasion of 
host defences (Verheul et. al., 1993).
1.2.5. Outer Membrane Proteins: classes 1-3
The major outer membrane proteins (OMPs) are responsible for serological 
differentiation of strains (Fraseh et. al., 1985). They are expressed at high levels on the 
bacterial surface, and five different classes (1-5) are recognised. Classes 2/3 and 1 show 
antigenic variability that are further classified into serotypes and serosubtypes 
respectively. The class 1 meningococcal OMP is the 44-47 kDa PorA protein, whilst 
classes 2 and 3 OMPs are 37-42 kDa PorB proteins. Both PorA and PorB are porins that 
facilitate cation and anion passage across the cell membrane respectively (Tommassen 
et. al., 1990). All meningococci express either a single class 2 or class 3 protein as the 
major OMP. Classes 2 and 3 proteins are products of a single gene, porB (Hitchcock, 
1989; Minnetti et. al., 1998).
PorA is responsible for meningococcal serosubtype specificity, and generates a 
protective immune response. The sequences of the porA genes from different 
meningococcal strains of different subtypes reveals that sequence variation is mainly 
confined to two discreet variable regions designated VR1 and VR2 (McGuinness et. a l ,
1990). A model has been proposed that there are eight surface exposed loops in class 1 
and 2 proteins. The transmembrane regions are highly conserved, forming amphipathic 
transmembrane (3-sheets that have the eight hydrophilic surface exposed loops. The
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model suggests that loops 1 and 4 are the longest and provide the VR1 and VR2 regions 
respectively (Van Der Ley et. al., 1991). Monoclonal antibodies with subtype-specific 
bactericidal activity recognise epitopes found on either VR1 or VR2.
There is considerable antigenic diversity among group B strains, with approximately 20 
serotypes, based on variations in class 2 and 3 OMPs along with class 1 proteins that 
contain subtype-specific antigens. However, only a limited number of serotypes are 
associated with most serogroup B and C disease. Class 1 proteins containing the 
serosubtype-specific antigens show antigenic diversity, and are more immunogenic than 
class 2 and 3. The class 1 protein is effective in generating a protective immune 
response, as it has been found that monoclonal antibodies directed against the PorA 
protein give the most effective passive protection in an experimental infant rat model 
(Saukkonen et. a l, 1989). Also, experimental outer membrane protein vaccines have 
been associated with the induction of protective bactericidal anti-class 1 protein- 
antibodies (Zollinger et. al., 1991), however this antibody response is serosubtype- 
specific (Mandrell & Zollinger, 1989). This has led to vaccine designs incorporating 
different serosubtypes of PorA (see section 1.4.3).
The VR1 region of the porA gene is the target for the Polymerase Chain Reaction- 
Single-Stranded-Conformational-Polymorphism assay (PCR-SSCP) (Newcombe et. a l, 
1997). This is a non-culture based subtyping method to analyse clinical meningococcal 
strains involving PCR amplification of the target DNA, followed by SSCP analysis that 
is capable of highly sensitive detection of point mutations in the DNA. This method is 
used to the identify meningococcal strains from clinical specimens, which can then be 
used for epidemiological and disease surveillance purposes.
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Peptides from the VR regions in PorA are also targets of a serosubtyping method 
utilising monoclonal antibody recognition. This typing method uses peptides from the 
PI. 10 strain of meningococcus, and identifies strains by determining the immunological 
reactivities with the monoclonal antibody. (Suker et. al, 1996).
1.2.6. OMPs: classes 4 & 5
The class 4 outer membrane protein shares extensive homology with N. gonorrhoeae 
protein III, which elicits blocking antibodies that prevent the killing of serum-resistant 
strains by bacterical antibody (Klugman et. a l , 1989; Rice et. al., 1986). Indeed, N. 
meningitidis class 4 protein does not show antigenic variation and induces antibodies 
that are able to block the other bactericidal antibodies acting against meningococcal 
antigens (Munckley et. al., 1991). Furthermore, the class 4 locus encodes the structural 
gene nnpM, which has been shown to form complexes with the lactoferrin receptor 
LbpA, transferrin receptor TbpA and the siderophore receptor FrpB. These complexes 
then act to stabilise the oligermeric form of the iron-regulated proteins (Prinz & 
Tommassen, 2000).
The 26-30 kDa class 5 OMPs, Opa and Opc, are heat-modifiable proteins that show 
changes in molecular weight when subjected to 37°C and 100°C temperatures, and 
analysed by SDS-PAGE. These are thought to be important in bacterial adhesion to, and 
invasion of host cells (Aho et. a l, 1991). They are also hypervariable and can undergo 
antigenic shift during infection and phase changes between and within strains. This 
property enables the meningococcus to evade the host immune response (van der Ende 
et. al., 1995).
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N. gonorrhoeae expresses Opa proteins, but have not been found to express Opc 
proteins. Gonococcal Opa proteins are thought to be involved in increased bacterial 
adherence to human epithelial and endothelial cells, and polymorphonuclear leukocytes 
(Virji & Everson, 1981, Virji & Heckels, 1986). N. meningitidis Opa and opc proteins 
are also involved . in mediating bacterial invasiveness of both endothelial and epithelial 
cells (Viiji et. al., 1992; Virji et. a l, 1993).
1.2.7. OMPs Induced Under Iron-Limitation Conditions
During conditions of iron starvation, meningococci are able to sequester any available 
iron from the host, which has bound to human iron-binding proteins, via the organism’s 
lactoferrin, transferrin, or ferric binding receptors that are expressed as OMPs. Some of 
these OMPs are expressed at similar levels of that of the major OMPs, such as the 
70kDa OMP (FrpB). Meningococci also express two different transferrin-binding 
proteins (Tbp-1 and Tbp-2). These along with FrpB are heterogeneous. Conversely, the 
lactoferrin-binding proteins (Lbps) appear homogeneous amongst different strains 
(Danve et. al., 1992; Cartwright, 1995).
Another protein that plays a major role in aquiring iron is the 37kDa Fe-binding protein 
(Fbp). It is able to bind one molecule of Fe3+. Fbp is homogenous among different 
meningococcal strains. It is thought that Fbp acts as a substrate binding protein and iron 
transport occurs via the intermediate FrpB to the receptors in the outer membrane. FrpB 
may be acting as an intermediate possibly by releasing iron bound to different host 
proteins, or by forming a channel through which the released iron is transferred across 
the outer membrane (Dyer et. a l, 1988).
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1.2.8. Pili
Another neisserial surface structure is the pilus. Pili are filamentous protein structures 
that are involved in adhesion to cells and DNA transformation, and have been observed 
on the surfaces of pathogenic N. gonorrhoecie as well as N. meningitidis. Gonococcal 
pili are mainly composed of of multimers of the protein pilin, which range from 17-22 
kDa in molecular weight. All gonococcal pili share extensive homology and react with 
the monoclonal antibody SMI (Virji & Heckels, 1983). Even though there is a great 
degree of homology between gonococcal pili, these structures do show antigenic 
variability and phase variation. Gene expression of the major pilus subunit, pilin, occurs 
at the pilE  locus. The 5’ gene sequence encodes for a highly conserved region of the 
pilin protein, incorporating the SMI epitope, together with a variable region at the 3’ 
end of pilE  (Virji et. al., 1989).
There are two distinct classes of meningococcal pili and their major subunit, pilin, 
which have been designated as classes I and II. Most N. meningitidis strains express 
class I pili, which show extensive homology with the gonococcal pili, and also reacts 
with the SMI monoclonal antibody (Heckels, 1989).
The PilC protein is another pilus-associated protein expressed by the gonococcus and 
meningococcus. Two forms of this protein exist (PilCl and PilC2) as it is subject to 
phase and antigenic variation, both of which are required for adherence to human 
epithelial and endothelial cells (Aho et. al., 1997). Both the PilE and PilC proteins are 
necessary in converting linear plasmid DNA (containing the neisserial 10 base-pair 
uptake sequence) into a DNase-resistant form. It is suggested that both phase variable 
Pil E and Pil C proteins act on the bacterial cell surface and are required by both
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neisserial pathogens for epithelial cell adherence and DNA competence (Jonsson et. al., 
1991).
Class II pili are unrelated to N. gonorrhoeae pili. They do not react with SMI 
monoclonal antibody and are antigenically different to class I. Class II pili have smaller 
subunit molecular weights of 15-17 kDa (Rudel et. al., 1995). Furthermore, there is no 
evidence o fpilE  expression in class II pili. This finding, together with the differences in 
size, antigenicity, and cell adhesion properties between classes I and II pili suggests that 
there may be fundamental differences between the two meningococcal pili classes 
(Potts & Saunders, 1988).
1.2.9. DNA competence
Both N. meningitidis and N. gonorrhoeae are naturally competent for DNA 
transformation. This results in the bacteria exhibiting genetic diversity through 
recombination between incoming DNA from the environment, and the bacterial 
chromosome. Competence for DNA transformation in both species is dependent on 
whether the bacterial cell is piliated. Studies have shown that pilin null mutations 
(insertions, deletions, and nonsense mutations) display very low levels of DNA 
transformation, compared with high levels when piliated bacteria are used (Diaz et. al., 
1984). Furthermore it is widely thought that both organisms only take up DNA 
containing the neisserial DNA uptake signal sequence. This is a 10-base pair 
recognition sequence (5’-GCCGTCTGAA-3’). In the serogroup B strain MC58 
(McGuiness et. al., 1991), 1910 uptake signal sequences have been identified 
throughout the genome, with approximately equal numbers on each strand (Tettellin et. 
al., 2000). Many of the neisserial uptake sequences occur in palindromic inverted
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repeats and are part of transcriptional terminators, present downstream of open reading 
frames (Goodman & Scocca, 1988).
There is however, evidence to suggest that DNA does not need an uptake sequence in 
order to transform into N. gonorrhoeas, albeit at a lower transformation efficiency, in 
both piliated and non-piliated cells (Stein, 1991). In fact, transformation of non-piliated 
cells probably occurs solely as an uptake sequence-independent mechanism. However, 
piliated cells are likely to show a selective advantage over non-piliated cells. In piliated 
cells it has been proposed that there may be two mechanisms operating: one that utilises 
the uptake sequence, and one that does not. Firstly, it may be that the pilus and its 
components require the presentation of the uptake sequence receptor on the cell surface, 
and secondly, the pilus is needed to transport DNA into the cell once the DNA has 
bound to the receptor (Boyle-Vavra & Seifert, 1996). Evidence to support the 
hypothesis for an uptake sequence-independent mechanism, is the observation that there 
is a residual level of DNA (minus the uptake sequence) taken into the cells (Elkins et. 
a l, 1991). Although these experiments have been carried out using N. gonorrhoeas, it 
may well be that the same mechanisms are utilised by N. meningitidis.
1.3. Host immunity
1.3.1. Introduction
Meningococcal disease can affect any age group, but it is young children that are most 
at risk, due to a lack of protective immunity against the organism. Protective immunity 
correlates with the development of bactericidal antibodies, which are not present in the 
very young. The IgG antibody is the main bactericidal antibody directed against the 
meningococcus. This is present in newborn infants, acquired from the maternal
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circulation. However, this passive immunity is replaced by an inducible antibody 
response, able to persist throughout life.
1.3.2. Natural immunity
The mechanism for acquisition of natural immunity is still somewhat unclear but may 
arise from the induction of antibody against a non-pathogenic species of Neisseria, N. 
lactamica. This acapsulate organism colonises the nasopharynx but does not 
disseminate and cause disease. However, N. lactamica colonisation induces antibodies 
that are bactericidal against different meningococcal serogroups and subtypes (Gold et. 
al., 1978). Children above 4 years old may also acquire immunity through colonisation 
by N. meningitidis. Most will be non-pathogenic strains because they are not capsulated, 
or they do not express capsular polysaccharides, which confer pathogenic potential. 
These strains also induce antibody, which are serogroup and serotype specific. Disease 
is thought to occur in older individuals when pathogenic bacteria invade against a 
background of low or no immunity against the invading strain, due to the absence of 
bactericidal antibodies acquired through carriage of non-pathogenic strains.
The fact that there is a high degree of meningococcal colonisation of the nasopharynx, 
indicates that mucosal immunity is limited. This is evident by the fact that antibodies 
raised against pilin epitopes are rarely found in patient convalescent sera (Stephens et. 
al., 1988), although attachment of meningococci to host cells involves the pili. The 
class 5 OMP, Opc, is also expressed at high levels during colonisation (Achtman et. cd.,
1991), inducing a circulating anti-Opc antibodies response (Rosenqvist et. al., 1993).
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1.3.3. Humoral immunity
Goldschneider, Gotschlich and Artenstein (1969) examined bactericidal activity 
(immune lysis) of human serum. They found an inverse correlation between age-related 
occurrence of disease, and age-specific prevalence of serum bactericidal activity. 
Moreover, this bactericidal activity was serotype-specific. Two components are 
required as part of humoral immunity to prevent bacterial dissemination: an intact 
complement pathway, and the induction and persistence of bactericidal antibody.
Complement activation can either be antibody-independent or dependent, and both 
complement pathways may be activated through bacterial binding to different pathway- 
initiating components. Antibody-independent complement activation involves 
meningococcal cell surface structures that provide receptors for initiator complement 
components. Antibody-dependent complement activation against Neisseria involves 
specific antibody molecules that contain binding sites for various complement 
components. The antibody molecules direct activation of complement onto the bacterial 
cell surface, therefore concentrating activation to a particular area. However, the IgA 
antibody blocks immune lysis. It may do this by displacing IgG (the isotype that binds 
epitopes on the lipo-oligosaccharide (LOS) structures on the meningococcal cell 
surface) from antigen binding sites (Griffiss, 1975; Griffiss & Goroff, 1983).
1.3.4. Mucosal immunity
A possible explanation for the absence of mucosal immunity induced during 
colonisation is that the meningococcus (and gonococcus) produces an IgAi protease. 
However, avirulent strains also produce IgAi, and this enzyme does not cleave IgA2, 
which is more copious on mucosal surfaces. IgAi proteases are also inactivated by
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antibody other than IgA (Lowell et. al., 1980). Therefore, the question of natural 
mucosal immunity against the meningococcus remains unclear. However, studies have 
shown that intranasal administration of outer membrane vesicle vaccines (section 1.4.7) 
induces persistent local mucosal and serum bactericidal antibodies in humans and mice 
(Haneberg et. al., 1998; Saunders et. al., 1999). Also, after vaccination with the groups 
A/C polysaccharide and conjugate polysaccharide group C vaccines (sections 1.4.3 and 
1.4.4), an increase in local IgA salivary antibody is seen (Zhang et. al., 2000).
1.4. Vaccines
1.4.1. Introduction
Vaccines consist of components that originate from microorganisms or other parasites, 
and are able to induce an immune response to the disease caused by that infectious 
agent. The ideal vaccine would promote effective resistance against the disease in 
question, that lasts as long as possible. It would also be safe with as few side effects as 
possible. A vaccination programme should provide protection within a community, and 
a widespread vaccination programme should eradicate the incidence of disease. This has 
happened in the case of the viral disease smallpox. These infections are restricted to 
humans and so have been eradicated because all human infection has been prevented 
through the global vaccination programmes. Other diseases such as cholera, diphtheria 
and typhoid have been brought under control with the arrival of vaccines, especially in 
the developed countries where public hygiene has improved greatly in the twentieth 
century. Furthermore, the ideal vaccine should be stable, and remain viable during 
storage and transport. Freeze-dried vaccines can be transported without the need for 
refrigeration, which is a particular advantage for products required in the tropics. The
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ideal vaccine should also be relatively cheap, so it can be available for large-scale, 
worldwide use.
Meningococcal disease is restricted to humans. Therefore, a vaccination program could 
eradicate the disease if all human infection is prevented. Once individuals have had 
meningococcal disease and recovered, they acquire bactericidal antibodies and T cell 
memory, which together act to clear future infections from the body. As a result, 
meningococcal disease does not re-occur in patients who have recovered. The aim of 
vaccination is to induce this level of protective immunity.
1.4.2. Meningococcal vaccines
As described above, there is clear evidence of natural immunity by bactericidal 
antibody, although the target of that immunity is unclear. Efforts to develop a vaccine 
have focussed on using components of the meningococcus as immunogens to promote a 
protective immune response in vaccines. However in some individuals, immunity fails 
to develop, possibly due to lack of exposure to cross-reactive antigens. The aim of 
vaccination is to promote effective immune responses in the vaccines. Various types of 
vaccines have been developed. These will be reviewed in the following sections, 
explaining why some are more suitable than others.
1.4.3. Tetravalent non-conjugated polysaccharide vaccine
The first successful vaccine was produced using purified capsular polysaccharides 
(CPS) isolated from N. meningitidis groups A and C, Y and W-135, and was found to 
induce good antibody response to all four antigens (Ambrosch et. a l , 1983). The vaccine 
has been successfully used to control several epidemics.
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It was not certain how to use the tetravalent CPS vaccine in sub-Saharan Africa because 
major epidemics of meningococcal disease occur regularly, especially during the dry 
season. Greenwood and Wali (1980) studied the incidence of outbreaks in northern 
Nigeria. They vaccinated all individuals over 1 year old in nine villages where two 
cases of the disease had occurred, and compared the incidence of disease after 
vaccination with the incidence of disease in seven villages that did not have the 
vaccination programme. The spread of the disease stopped quickly in the villages that 
had the vaccine programme as a result. The researchers concluded that whilst the supply 
of vaccine was limited in this part of the world, most disease occurred in the 5-15 year 
old age group. Therefore, selective vaccination in this age group in the affected areas 
could significantly reduce the incidence of the disease. However, a limitation of this 
strategy was that good disease surveillance was required.
In the developed world the vaccine has been used to control epidemics in Canada in 
1991 due to serogroup C, and New Zealand in 1987 due to serogroup A. In Canada, 
there were seven cases of serogroup C disease in teenagers within a community, with 
four deaths. As a result, a mass vaccination programme was carried out (Gemmill,
1992). In New Zealand a selective vaccination programme using a monovalent 
serogroup A form of the CPS vaccine was conducted, targeting children between 3 
months and 13 years of age. The children aged 2-13 years received a single dose, whilst 
26% of the younger children received a second dose. It was found that in the older 
children who had a single dose, and the younger children who had two doses, the 
vaccine efficacy was 100%. However in the younger children who only had a single 
dose, the estimated efficacies at 3 months and 1 year after vaccination were 52% and 
16% respectively (Lennon et. al., 1992).
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The outcomes of these vaccination programmes were used to make general 
recommendations for controlling outbreaks of serogroups A and C disease in the 
developed world. Three or more cases occurring within a geographically defined 
population constituted an outbreak and within these communities, schools or institutions 
the at-risk population (defined by the age range in which the cases occurred) were 
vaccinated. Booster immunisation was only required if the outbreak persisted.
However, this vaccine is flawed in four ways; firstly it is serogroup-specific, and does 
not offer protection against serogroup B antigens. This is because the CPS of group B 
meningococci [poly (a2-8NeuNAc)] does not elicit serum antibodies in most adult 
humans (Wyle et. al., 1972). Secondly immunity is short-lived, and thirdly, there is a 
lack of response by young children under 2 years of age especially to group C 
(Ala’Aldeen & Cartwright, 1996). Therefore the CPS vaccine is not suitable for routine 
immunisation of infants, the age group most at risk. Finally, if a second contact with N. 
meningitidis occurs, then memory T cells are required for a rapid immune response. 
However, the tetravalent non-conjugated CPS vaccine does not induce immunological 
memory because the immune responses to CPSs are T-cell independent.
1.4.4. Conjugate polysaccharide vaccine
Development of a conjugate polysaccharide vaccine (attachment of CPS to protein 
carrier) against Haemophilus influenzae type b, (Flib, another causative organism of 
bacterial meningitis) proved to be extremely successful in eradicating this form of 
meningitis. It worked to induce T-cell dependent IgG responses in young children, 
giving higher antibody titers, and priming for immunological memory resulting in better
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protection and long lasting immunity in infants and young adults, and in other age 
groups through reduction of Hib carriage and transmission. Consequently, work has 
been carried out to develop a meningococcal CPS conjugate vaccine by coupling groups 
A and C CPS to the tetanus toxoid, and a non-toxic variant of the diphtheria toxin, 
CRM197. Trials in the UK and Gambia have found that administering vaccine booster 
doses showed evidence of induction of immunological memory (Fairley et. al., 1996; 
Leach et. al., 1997).
Following on from phase 2 trials in 1999 it was reported that a new meningococcal C 
conjugate (MCC) vaccine is well tolerated and immunogenic in infants. The infants 
were primed with the vaccine at the ages of 2-4 months. After 2 doses the total antibody 
levels and bactericidal antibody levels had increased when the infant reached 5 months 
(>2pg ml"1). By the age of 14 months, the bactericidal antibody levels had fallen 
significantly. However, 12 months later, the infants showed similar antibody levels as 
previous (>2pg ml’1) when given a booster, confirming the generation of memory B 
cells for long-lived protection (Richmond et. al., 1999).
During autumn 1999, the new MCC vaccine was administered to infants and teenagers 
(who are considered to be at-risk age groups) in a national UK vaccine program. As a 
result, over the second half of 2000, there has been a 90% fall in cases amongst infants 
less than 1 year old, and the 15-17 year old age group, and also a 75% decrease across 
all the age groups who have been immunised (Department of Health Press Release, Jan. 
2001). These results are extremely encouraging, and now the vaccine is offered to all 
children in the UK under the age of 18 years.
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1.4.5. Serogroup B polysaccharide vaccines
The group B CPS is a poor immunogen, because it fails to induce an adequate
protective antibody response. There have been several attempts to enhance
immunogenicity of group B vaccines with little success. These include; (i) non- 
covalently complexing the polysaccharide to OMPs (Moreno et. al., 1985), (ii)
modifying the conjugate polysaccharide chemically and then conjugating the
polysaccharide to a protein carrier (tetanus toxoid) (Jennings et.al., 1986; Jennings et. 
a l, 1987).The first type of vaccine induced transient increases in IgM antibody but 
failed to induce a bactericidal antibody response. The second type was found to induce 
a bactericidal IgG anti serogroup B antibody response in mice using Freund’s complete 
adjuvant with two injections, whilst a third gave a good booster response. However, 
there are concerns over the possibility of an autoimmune response because serogroup B 
CPS is cross-reactive with human neural cells (Finne et. al., 1983; Troy, 1992; 
Hayrinen et. al., 1995), making this vaccine unsuitable.
1.4.6. OMP vaccines
It has been found that in the case of serogroup B infections, bactericidal antibodies are 
directed against lion-capsular surface antigens (Frasch & Chapman 1973; Jones & 
Eldridge, 1979). Therefore various vaccine preparations directed against serogroup B 
meningococcal strains have used OMPs as the vaccine component to provoke an 
immune response.
As reviewed in sections 1.2.5 and 1.2.6, there are 5 classes of outer membrane proteins 
present on the surface of the meningococcus. Serogroup B meningococcal strains show 
considerable antigenic diversity. This is because there are approximately 20 different
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serotypes which are based on the variations in the classes 2 and 3 OMPs. However, only 
a limited number of serotypes are associated with most of the meningococcal disease 
associated with serogroups B and C. Additonal antigenic diversity is seen in the class 1 
proteins that contain the subtype-specific antigens, and these seem to be more 
immunogenic than the class 2 and 3 proteins.
The first OMP vaccines comprised of meningococcal outer membranes that had most of 
the LPS component removed by solubilisation with detergent. The proteins were then 
isolated and resuspended in 0.9% sodium chloride, and were visibly particulate with the 
aggregated outer membranes. The vaccines were evaluated in adults and children with 
2-3 doses. They were deemed safe in both adults and children, but they failed to 
stimulate bactericidal antibodies (Zollinger et. al., 1978).
1.4.7. OMV vaccines
Meningococci release large amounts of pure outer membranes into culture broth either 
as blebs, or as vesicles during normal growth (Devoe & Gilchrist, 1973; Frasch & 
Peppier, 1982). Zollinger et. al. (1978) went on to prepare soluble outer membrane 
vesicle (OMV) vaccines by combining the protein with meningococcal serogroup C 
polysaccharide. The LPS fraction was selectively removed, leaving the membranes 
intact and soluble. The researchers found that the inclusion of the group B 
polysaccharide produced a significant increase in bactericidal antibodies against both 
serogroup B and C meningococcal strains (Rosenqvist et. al., 1983). However, when 
determining the immune response to serogroup B, it was found that children under 6 
years of age did not respond as well compared to older children and adults. By adding
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an aluminium hydroxide adjuvant it was found that the vaccine was more immunogenic 
and safe in humans (Frasch et. al., 1987).
1.4.8. Cuban OMV vaccine
Three conventional OMP/OMV vaccines have been manufactured and subjected to 
clinical trials. The first is a vaccine developed in Cuba. This was directed against 
meningococcal serogroups B and C, and contained LPS depleted outer membranes from 
the serogroup C, serotype 4, serosubtype PL 15 strain. The vaccine had a high molecular 
weight protein complex, and also contained the adjuvant aluminium hydroxide.
Cuban school children were given two doses of the vaccine, which were separated by 6- 
8 weeks. There was an 83% protective efficacy provided by the vaccine, and the study 
demonstrated that the antibodies induced to non-capsular surface antigens can protect 
against meningococcal disease (Sierra et. al., 1991).
The Cuban vaccine was then used in two trials in Brazil. Doses were given to children 
between 3 months and 9 years of age. Both trials demonstrated that the vaccine 
produced high protective efficacy (71-74%) in the children aged 4 years and above, but 
low efficacy (up to 28%) in the younger children who are most at risk from serogroup B 
disease (De Moraes et. a l, 1992).
1.4.9. Norwegian OMV vaccine
A second vaccine developed in Norway was made from LPS-depleted outer membranes 
of serogroup B, serotype 15, serosubtype P 1.7,16 strain. It contained 6% high molecular 
weight protein, but no meningococcal polysaccharide. Two doses were given to
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schoolchildren, 6 weeks apart. The protective efficacy was 57% and there were 110 cases 
reported during the 7 months following the second dose (Bjune et. al., 1991). Meyer 
Naess et. al. (1998) compared human T-cell responses with serum IgG antibody levels 
after 3 vaccine doses in adult volunteers. T cells regulate the antibody response, and are 
necessary for the induction of immunological memory. From their study, the 
researchers concluded that the Norwegian OMV vaccine induces a strong proliferative 
human T cell response against meningococcal group B OMV and Por A vaccine 
components, also increasing the proportion of memory T-helper cells, and that this T 
cell response is accompanied by a serum IgG response.
1.4.10. Chilean OMP vaccine
In Chile a serogroup B, serotype 15, serosubtype P I.3 vaccine was prepared. It 
contained purified OMPs that were essentially free from LPS, was non-covalently 
complexed to meningococcal polysaccharide, and contained the aluminium hydroxide 
adjuvant. Two doses were administerd to individuals aged between 1-21 years old. An 
overall protective efficacy of 51 % was found, but again this was age dependent, with no 
protection seen in the younger children (Zollinger et. a l, 1991).
These studies show that whilst the vaccine induces an antibody response to the 11011- 
capsular surface antigens, providing significant protection against serogroup B 
meningococcal disease, the protection is age-dependent, with very little protective 
efficacy in younger children who are most at risk. The protection offered by the various 
vaccines is short-lived, although booster vaccinations may prolong the duration of 
protection considerably. Furthermore, in Norway and Cuba, group B meningococcal
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disease is limited to a single strain, whilst disease in the UK tends to be due to high 
variability in the strains (Poolman et. al., 1986; Jones & Kaczmarslci, 1992).
1.4.11. Multivalent OMV vaccine
The major problem associated with OMP vaccines is the limited range of protection 
offered because of the type-specific antibodies that are induced. However, it has been 
found that by inserting multiple class 1 genes into the chromosome of a single group B 
strain, a broader range of protection results. By using a mutant of the group B strain 
H44/76 which is deficient in the class 3 OMP (Tommassen, et. al., 1990), researchers in 
the Netherlands have replaced the class 3 protein with another class 1 protein from 
another strain with a different subtype. This produced a multivalent vaccine strain, 
inducing protection from two type-specific antibodies (Van der Ley & Poolman, 1992). 
The researchers also found that outer-membrane vesicle (OMV) vaccines are superior to 
OMP vaccines in the development of the multivalent vaccine, probably because the 
OMV is able to preserve and expose the class 1 epitopes with surface loops in the native 
way.
The multivalent OMV vaccine was prepared from two vaccine strains, each expressing 
three PorA proteins; class 4 and 5 OMPs, and an 82kDa OMP, but not expressing class 
3 OMP, B polysaccharide, or lacto-V-neotetraose. Each PorA protein expressed two 
surface exposed loops 1 and 4, which are targets for bactericidal antibodies. This 
produced a hexavalent PorA OMV vaccine containing serosubtypes representing the 
majority of case isolates in many countries. 90% of the vaccine consisted of PorA, and 
10% was endotoxin, acting as an adjuvant and antibody inducing properties (Claassen 
et. al., 1996). The vaccine was used in phase 1 trials to immunise adult volunteers, and
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was considered safe for further use, with approximately half of the volunteers showing a 
fourfold increase in bactericidal antibody induction against the strains expressing the 
different serosubtyes of PorA (Peeters et. al., 1996). Recently, the results from phase 2 
trials have been reported. They show that after three vaccinations there were increased 
levels of IgG against OMV and increased bactericidal activity in two age groups of 
children (2-3 years and 7-8 years), with the highest levels in the younger age group (de 
Kleijn et. al., 2000). However, the protection offered is only directed against the 
serosubtypes included in the vaccine, and only two of these are immunodominant, 
inducing a protective antibody response. Therefore, there is the possibility that a 
widespread vaccination programme would cause genetic drift favouring the selection of 
different meningococcal PorA variants (Martin et. al., 2000).
Another possible problem associated with a PorA vaccine, stems from the observation 
of the existence of a naturally occurring insertional inactivation of the porA gene by the 
insertion sequence IS 1301. This insertion element is involved in reversible 
encapsulation in Neisseria by insertion into and excision from the siaA gene 
(Hammerschmidt et. al., 1996). Newcombe et. al., (1998) discovered the ISJ301 
element when they analysed a clinical blood specimen from a 12-year-old child 
(diagnosed with meningococcal meningitis) by PCR-SSCP (section 1.2.5) to examine 
the meningococcal porA  gene. The analysis showed that the IS/397 element had 
inserted within the VR1 region of the porA  gene in an identical position and orientation 
to that described for a type C strain that had previously been isolated in Canada (Ahrin 
et. al., 1998). Furthermore, the isolate did not cross-react with any anti PorA antibodies, 
indicating that porA  gene expression had been insertionally inactivated by the IS 
element. As the isolate came from a clinical specimen, this indicated that the porA
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mutant strain was virulent and able to cause disease. Therefore, a PorA vaccine would 
not protect against such a mutant, and an immunisation program with a PorA vaccine 
would risk selecting for the porA  mutant strains.
1.4.12. Other vaccine candidates
So far vaccines based on OMPs/OMVs show some signs of success, yet they have poor 
efficacy in young children. Other vaccine candidate antigens include the transferrin- 
binding proteins, Tbpl and 2 (see section 1.1.5), which are the main components of 
transferrin receptors. Both are exposed on the surface of the organism, are 
immunogenic, and show broad cross-reactivity, which is ideal for eliciting an immune 
response (ATAldeen & Cartwright, 1996). Also, antibodies that recognise the surface 
structures are bactericidal to homologous and many heterologous meningococcal 
strains. Anti-Tbp antibodies inhibit transferrin binding, the essential iron-acquisition 
from the host cell, and growth of the organism when only transferrin is the iron source. 
Therefore, antibody directed against Tbp could interfere with chelation and iron-uptake 
from transferrin, thereby inhibiting in vivo growth and survival of the organism 
(ATAldeen, Bordello, 1996).
Another vaccine candidate is LOS, which is present on the outer membrane. There are 
two approaches to the use of LOS in a meningococcal vaccine; the use of alkaline 
detoxified LOS, and LOS oligosaccharide conjugate vaccines. The LOS immunotypes 
of carried and invasive meningococci are different. The immunotypes L3 or L3,7 are 
expressed in 65-90% of serogroup B N. meningitidis (Zollinger & Moran, 1991). 
However, the conjugate vaccines that have been developed have not been shown to 
induce bactericidal antibodies in mice (Verheul et. al., 1993). On the other hand,
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Zollinger suggested that there are a number of advantages in using a vaccine containing 
detoxified LOS in combination with detergent treated OMVs, including effective 
solubilization of the detergent-treated OMVs, inclusion of additional immunogenic 
epitopes, and increased vaccine specificity (Zollinger & Moran, 1991).
1.4.13. Live and killed vaccines
A number of the viral vaccines consisting of living attenuated virus (e.g. live polio 
Sabin vaccine ), have been used to eliminate or effectively control levels of the 
respective diseases. However, this strategy is not yet possible in attempting to combat 
meningococcal disease. This is simply because the process of attenuation must be taken 
far enough so that the vaccine does not cause disease, yet must not be taken too far, 
because the bacterium may then fail to replicate fully enough to induce a protective 
immune response. Too little is known about which virulence factors may be suitable for 
attenuation, that at present, development of a live attenuated vaccine is unlikely in the 
near future.
Another possibility may be to use the non-pathogenic N. lactamica in a live vaccine. 
Several OMPs have been found to be common to N. lactamica and N. meningitidis, 
including two major antigens of 55 and 32 kDa (Troncoso et. al., 2000). Furthermore, 
carriage of this species has been found to induce protective IgG and IgM antibodies that 
cross-react with meningococcal OMPs (Kremastinou et. al., 1999).
Virulent microorganisms are inactivated to produce killed vaccines. If inactivation has 
been incomplete, then vaccination would produce infection. Examples of killed 
organisms in vaccines include the polio (Salk), cholera and typhoid vaccines. However,
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in the case of the Tab vaccine for typhoid, large numbers of killed Salmonella are used. 
As a result, this vaccine contains large amounts of endotoxin. Therefore, killed 
meningococcal vaccines clearly would not be a suitable as levels of endotoxin lipid A 
correlate with meningococcal disease severity, causing host inflammatory response, 
septic shock, damage of blood vessels, and multi-organ failure.
1.4.14. N. meningitidis genomics
The genome of group B strain H44/76 strain has recently been fully sequenced and 
annotated (Tettelin et. al., 2000). The sequence analysis data shows that there are 2,158 
predicted coding regions (83% of genome), to which 53.7% have been assigned a 
biological role. One characteristic of the group B meningococcal genome is that there 
are 3 Islands of Horizontal Transfer (IHTs) defined by: (i) different G-C content to the 
rest of the genome, (ii) insertion near tRNA genes and (iii) flanked by insertion 
sequences. These criteria indicate that the IHTs are the result of DNA transfer from 
other bacterial species.
Another feature of the genome shows there are clusters of genes that encode proteins of 
related function. Such clusters include colonisation (type IV pilus, opa, ope), capsule 
biosynthesis (sia, ctr) and iron acquisition (tbp,fbp , Ibp, limb, hem). Many of the genes 
involved in pathogenesis, transposition, or whose function is unknown, are present in 
duplicates and are subject to phase variation, more than any other bacterial pathogen 
studied to date.
The publication of the genome sequence has already prompted the discovery of novel, 
potential group B vaccine candidates. Pizza et. al (2000) expressed 350 antigens and
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used the proteins to immunise mice. They proceeded to identify surface exposed 
proteins from the immune sera that are highly conserved across a range of 
meningococcal strains, and that were also able to induce a bactericidal antibody 
response. From this study they were able to identify seven proteins that induce 
complement-mediated bactericidal activity in similar magnitude to the response induced 
by the OMV preparation previously used in the Norwegian OMV vaccine preparation 
(section 1.4.9). One of these proteins was a lipoprotein similar to the E. coli membrane- 
bound lytic transglycosylase A.
Another study by Sun et. al. (2000), employed signature-tagged mutagenesis as a high- 
throughput method to analyse gene function. They generated a library of 2,880 insertion 
mutants containing the signature tags, and injected the library into rats. After 24 hours, 
the mutants were recovered and the tags hybridised to identify genes displaying 
attenuated function (reduced hybridisation signal) by comparison with the inoculum 
bacteria. The procedure was repeated and resulted in the isolation of 108 attenuated 
mutants. Of these, 22 were tested in direct competition with the wild type strain to 
compare the systemic infection capability of the isolate.
All of the mutants tested were found to show decreased survival in the rat host 
compared with the wild type strain. The functions of the mutated genes were next 
determined. This analysis showed that many of the genes isolated encoded known 
virulence factors (e.g. genes required for capsule synthesis, lipopolysaccharide 
synthesis, iron-regulation). However, novel genes were also identified using this 
approach. These included ntrY  (part of a two-component regulatory system), hfq 
(related to E. coli Flost Factor 1 which influences mRNA stability), and other genes
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involved in amino acid biosynthesis, surface-exposed transport proteins 
(autotransporters e.g. IgAl protease), and ATP binding cassettes (required for invasive 
infection).
Both of these studies demonstrate the immense benefits of the completion of the group 
B genome sequence, and already show that the discovery of novel group B vaccine 
candidates has been greatly accelerated.
1.4.15. Conclusion
The MCC polysaccharide vaccine is a breakthrough in controlling group C disease, 
however, there is an urgent need to find a vaccine directed against group B disease. The 
conventional OMP/OMV vaccines developed have been shown to induce a bactericidal 
antibody response against serogroup B infection. However to date, there has been little 
success in developing an effective vaccine to provide adequate protection in young 
children, the group who are most at risk from the group B disease. The protection 
provided by the OMP/OMV vaccines was short-lived as there was little booster effect 
seen after the second doses had been administered. Furthermore, the OMP/OMV 
vaccines provided type-specific protection, whereas the ideal vaccine should induce 
broadly protective antibodies. The PorA vaccine trials have shown to provoke an 
increase in bactericidal antibody production in young children, but again, the protection 
offered is only against the serosubtypes that are present in the vaccine. This therefore, 
would not provide the protection needed in certain countries including the UK, where a 
variety of strains cause the disease.
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A possible way of producing a vaccine that would work to produce effective, broad and 
long-term protection that is not age-dependent may be to find proteins that are 
specifically expressed during an infection, that could be used as components in a 
vaccine. Examples may include iron-regulated, heat shock proteins, or previously 
unidentified proteins. With the completion of the genome sequence, the opportunities to 
find suitable vaccine candidates has become greater because it allows easier 
identification of genes. The aim of this project is to develop a system to search for 
potential vaccine candidate antigens by using a genetic reporter system designed to 
identify genes that are expressed in vivo.
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2. In vivo expression technology using Cre/loxP recombination
2.1. Introduction
During an infection, bacterial pathogens must be able to adapt to the in vivo 
environment of the host, and therefore the pathogen requires mechanisms, which enable 
the organism to survive, replicate and grow. It is these particular strategies that 
distinguish pathogenic bacteria from commensal bacteria. Such mechanisms include: 
nutrient acquisition, evasion of the host immune system, and tolerance to hostile 
environmental conditions (e.g. variations in pH, superoxide stress, iron depletion). 
Consequently, the organism expresses proteins that are induced, specifically in the host 
environment, and it is these in vzvo-induced proteins that enable the pathogen to persist 
and cause disease.
As discussed earlier, there is an urgent need to develop a vaccine against group B 
meningococcal disease. Known virulence factors such as the OMPs and CPS have been 
used in previous vaccines, but so far these have not been successful in attaining long- 
lived protective immunity. Hence, there is a need to find novel antigens expressed by 
the organism that could be useful as vaccine candidates.
2.1.1. Genetic tools to identify virulence genes
Newly developed molecular and cellular techniques are now being applied to determine 
novel virulence factors of many human pathogens such as Salmonella typhimurium 
(Mahan et. al, 1993), Pseudomonas aeruginosa, (Wang et. a l, 1996), and 
Staphylococcus aureus (Lowe et. a l , 1998).
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Genetic methodologies include: (i) use of reporter genes [lacZ gene, choramphenicol 
acyltranferase gene (cat), luciferase genes (lux), and green fluorescent protein (gfp), 
reviewed by Harb & Kwaik, 1999]; (ii) 2-dimensional gel electrophoresis (Lee & 
Horwitz, 1995; Buchmeier & Heffron, 1990; Abshire & Neidhardt, 1993); (iii) 
Polymerase Chain Reaction (PCR) techniques (arbitrary-primed and differential 
display-PCRs, RNA subtractive hybridization, and degenerate-primer PCR with direct 
sequencing, reviewed by Quinn et. al.., 1997; Harb & Kwaik, 1999; Handheld & 
Levesque, 1999); (iv) Signature-tag mutagenesis, (Plensel el. a l, 1995); (v) phage 
display (Marshall, 1995; Blank et. al., 1996); (vi) Microchip array technology (Service, 
1998; Service, 1998); and (vii) In vivo expression technology (IVET) (Mahan, et. al., 
1993; Slauch et. a l, 1994; Mahan, et. a l, 1995).
Some of these genetic approaches have centred on the identification of bacterial 
antigens for vaccines produced by the pathogen during growth in laboratory media, or 
in vitro models such as tissue culture. However, these in vitro environments may not 
always be ideal in identifying potential virulence factors, as they can be very different 
to the in vivo environment of the host. Consequently, the organism may be expressing 
different sets of genes when growing in the two environments.
2.1.2. IVET: a novel genetic approach
Mahan et. a l (1993), pioneered a genetic system termed 'In Vivo Expression 
Technology’ (IVET). The major advantage of this technique was that it allowed for the 
first time, the study of the bacterial response to the actual host environment. By using a 
gene expression system within the host tissue itself, the method allowed for selection of 
genes that are specifically expressed during an infection.
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The researchers constructed transcriptional fusions of Salmonella typhimurium gene 
fragments from a genomic library, to a pronroterless purA-lacZY operon via the BglW 
site in the suicide plasmid, pi VET 1. The pool of fusions was integrated into the 
chromosome of a Apur A mutant strain of S. typhimurium, that shows attenuated growth 
in vivo. These purA-lacZY-contexmng strains were then injected intraperitoneally into a 
BALB/c mouse, recovered from the spleen after three days, and the process was 
repeated in a second mouse. The recovered cells were grown on MacConkey agar to 
identify the red phenotype of Lac+ (and therefore PurA+) cells (Figure 2.1).
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Figure 2.1. IVET system to select for ivi genes in S. typhimurium  (Diagram from Malian et. al., 1993)
Indeed, there was an increased percentage of Lac7PurA+ cells recovered from the in 
vivo environment of the mouse (86%), than the control cells grown in an exclusively in 
vitro environment (33%). The shift toward Lac cells showed the selection of strains 
containing fusions to promoters that were transcriptionally active in vivo. However, the 
cells displaying the Lac'/PurA* phenotype (white cells growing on MacConkey agar.
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but were able to survive in the mouse) caused the most interest as they survived in the 
in vivo environment, but showed little expression in vitro. These cells contained library 
fragments displaying promoter activity that were specifically induced in the mouse, and 
the authors termed as ‘ivV (in vivo-induced). These library fragments were sequenced, 
and one of the ivi genes, was identified as fadB, encoding an enzyme involved in fatty 
acid oxidation, which may be used by S. typhimurium to fight fatty-acid-based defences 
of the host (Mahan et. al., 1995).
The system described is useful because the purine auxotrophs of S. typhimurium grow 
poorly in vivo, but when active promoters are fused to a promoterless pur A gene, this 
promotes survival of the organism. This strategy is limited for use in a purA' strain, 
however. A variation on this ‘promoter trap’ strategy used S. typhimurium carrying a 
promoterless cat gene to which a library was fused (Mahan et. al., 1995). The pool of 
bacteria carrying the library fusions to the cat gene was then inoculated into mice that 
were treated with the antibiotic chloramphenicol to select for active promoters that were 
able to switch on the cat gene, which in turn conferred resistance to the antibiotic.
2.1.3. Other IVET systems
Another strategy used in S. typhimurium, involved fusions of library fragments to green 
fluorescent protein (GFP), to identify differentially expressed genes. This method used 
the fluorescence-activated cell sorting (FACS) to identify promoters that were 
selectively expressed when the organism was used to infect a macrophage model 
(Valdivia & Falkow, 1997). This method is involved in the study of bacterial interaction 
with cells, rather than in vivo infection models.
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An analagous system to that used in S. typhimurinm has been described in Pseudomonas 
aeruginosa (Wang et. al., 1996). This uses a ApurEK mutant strain of the bacterium, 
which is unable to grow in the absence of purine. A library of transcriptional fusions 
were made to a promoterless purEK  operon and integrated into the chromosome of the 
P. aeruginosa ApurEK mutant strain. To distinguish genes that are specifically 
inducible in vivo from those constitutively expressed, bacteria recovered from a mouse 
infection model were screened for growth on minimal media supplemented with a 
limited amount of purine. Large colonies represented purine independent-growth, 
selecting for constitutively expressed promoters, whilst small colonies represented 
bacteria that require purine for growth, meaning that the purEK  operon was transcribed 
by promoters that were active in vivo.
Another IVET approach, is to use genetic recombination as a reporter of gene activation 
in vivo. Camilli et. al. (1994), used constructs containing transcriptional fusions to a 
promoterless copy of the InpR gene. This gene encodes the site-specific recombinase 
(also known as the Tesolvase’ gene) of transposon y§ (Newman & Grindley, 1984). 
Resolvase recognises specific DNA sequences known as 'res' sites, and mediates a 
recombination event between the two, resulting in the excision of a stretch of 
intervening DNA between the two res sites. The researchers placed an active 
tetracycline-resistance gene between two res sites, and introduced this cassette into the 
chromosome of Vibrio cholerae. They then screened for active promoters induced 
during cholera infection in an infant mouse by transcriptionally fusing library fragments 
to the promoterless resolvase gene. Promoter fragments able to induce gene expression 
in vivo, were detected by the sensitivity to tetracycline because the action of the y8 
resolvase targetting the res sites resulted in the deletion of the tetracycline-resistance
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gene, changing the bacterial phenotype. Similarly, in Staphylococcus aureus, the y5 
resolvase was used to identify ivi genes by screening for the deletion of a kanamycin- 
resistance marker (Lowe et. al., 1998).
Another site-specific recombinase used in an IVET strategy is Cre, isolated from 
bacteriophage PI. This enzyme recognises two 34-base pair repeat sequences called 
loxP sites (Ambremski & Hoess, 1984; Hoess et. al., 1982), causing a recombination 
event resulting in the deletion of the intervening DNA. Altier and Suyemoto (1999), 
have successfully used this to identify S. typhimurium genes that are specifically 
expressed during interaction of the organism in cultured epithelial cells. They cloned a 
promoterless cre gene (without a ribosomal binding site) into a low copy number 
plasmid, downstream of a pair of trp terminator sequences (to prevent read-through 
transcription) and a unique cloning site. The cre gene was transcriptionally fused to a 
promoterless lacZ gene.
Two loxP sites were integrated into the chromosome of a S. typhimurium recD strain 
flanking a npt gene conferring kanamycin-resistance, and a sacB gene conferring 
sucrose sensitivity. This allowed for selection between presence of the cassette (by 
kanamycin-resistance), or action of Cre recombining the loxP sites and deleting the 
cassette so that the resulting phenotype of the bacteria was kanamycin-sensitivity and 
sucrose-resistance. An S. typhimurium DNA library of transcriptional fusions to the cre 
gene was made and constitutively expressed promoters were excluded from the 
experiment by a pre-selection on kanamycin. The remaining kanamycin-resistant 
transformants were allowed to invade the cultured epithelial cells, and the intracellular 
population was then tested for sucrose-resistance to select for loxP recombination.
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As the cre gene was transcriptionally fused to a promoterless lacZ gene that codes for 
the enzyme (3-galactosidase, this made it possible for a further back-check to find 
whether or not the promoters selected initially in vivo were also induced in vitro after 
cell growth in laboratory media. If X-gal (5-bromo-4-chloro-3-indolyl-(3-D- 
galactopyranoside) is added to the agar, then the cells that harboured an active lacL 
gene were blue and cells that had an inactive lacZ gene were white. The clones that 
contained promoters induced in vivo could then be further selected by blue/white 
screening of the bacterial cells to find if the lacZ gene was expressed or not. Selection 
of only the white colonies would then indicate that growth in vitro had not induced lacZ 
gene transcription by the promoters. Consequently, the authors were able to confirm the 
selections of promoters in sucrose-resistant cells were exclusively induced in vivo.
Candidate plasmids were re-exposed to the epithelial cells to examine the ability of each 
to induce loxP recombination, and finally these were tested in tissue culture medium 
without the epithelial cells. The successive rounds of screening isolated 10 clones that 
showed elevated Cre expression during interaction with the epithelial cells, and lower 
expression in laboratory medium only. Of these 40-90% of the intracellular bacteria 
were sucrose-resistant. One clone was isolated that contained a 2.8kb fragment. This 
was sequenced, and 3 predicted open reading frames (ORFs) were found. Sequence 
homology analysis has shown that ORF2 shares 39% identity with the Ail family of 
membrane-spanning proteins of Yersinia enterocolitica, which is implicated in serum 
resistance and penetration of bacteria into cultured cells (Wachtel & Miller, 1995). The 
other two ORFs showed homology to two S. typhimurium virulence proteins, Rck 
(resistance to complement killing) (Heffernan et. al., 1994), and PagC (bacterial 
survival in macrophages) (Miller et. al., 1989).
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2.2. Introduction to Cre-loxP  recombination
2.2.1. Role in the life cycle of bacteriophage PI
Bacteriophage PI is a temperate virus that has lytic and lysogenous phases in its life 
cycle. During the lysogenic phase, the prophage of phage PI rarely integrates into the E. 
coli host chromosome, usually existing as a ‘unit-copy’ plasmid (Ikeda & Tomizawa, 
1968). Unit-copy plasmids are found in the E. coli host, present at very low copy 
number. Examples include; sex factors, antibiotic-resistance factors, plasmid factors, 
and the plasmid prophages of certain bacteriophages. They are precisely replicated and 
segregated to daughter cells despite having a low copy number. This results in prophage 
PI being maintained at one to two copies per host cell (Ikeda & Tomizawa, 1968).
In order for wild-type PI plasmid to be maintained efficiently in host cells, a site- 
specific recombination event between PI DNA molecules occurs which is catalysed by 
the Cre protein. During site-specific recombination, the DNA molecule is cut at the 
loxP sites, and opposing ends are religated. Therefore, specific rearrangements of the 
DNA molecules are created in a series of catalytic steps, in which there is no synthesis 
or degradation of the DNA. The DNA binding proteins that catalyse these reactions play 
a major role bringing the ends together. The loxP sites are short, containing sequences 
that are recognised by the protein(s) involved. There are two families of site-specific 
recombinase: the resolvase-invertase family, and the integrase family. Cre belongs to 
the integrase recombinase family.
This ‘Cre-loxP' site-specific recombination mechanism, serves two roles in the viral life 
cycle. Firstly, it is involved in the circularisation of the linear PI DNA in order to enter 
the host. Secondly, it is involved in the breakdown of PI DNA molecule dimers that can
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form as a result of replication or homologous recombination. Therefore, the system 
ensures correct segregation of P 1 plasmid molecules to daughter cells at cell division 
because if PI dimers existed at cell division, only one of the daughters would inherit the 
PI DNA, and consequently would be lost in the lysogenic state (Austin et. al., 1981).
2.2.2. Cre and loxP
Cre is a 38 kDa protein, that is able to catalyse the site-specific recombination between 
two lox? sites, each of which are 34 base pairs (bp) in length. Each loxP site comprises 
of two 13 base-pair inverted repeat sequences separated by an 8 base-pair spacer region 
which serves as a binding site for Cre (Hoess & Abremski, 1984). The Cre-mediated 
loxP recombination reaction is highly efficient with no other phage or host components 
required in vivo or in vitro (Abremski, et. a l, 1983). Upon recombination between two 
loxP sites on the same molecule the /ox-flanked DNA segment is excised. Both intra- 
and intermolecular Cre-mediated recombination can occur on either supercoiled or 
linear DNA (Sauer & Henderson, 1988).
2.2.3. Recombination mechanism
An integrase strand exchange mechanism involves the two DNA strands cut at fixed 
points in the site recognition sequence, that are staggered by 6-8bp, so that cleavage 
produces recessed 3’ ends. Protein-DNA linkages at the sites are phosphodiester bonds 
between the 35 end of the cleaved DNA and the hydroxyl group of a conserved tyrosine 
residue on the protein. The integrase recombination event produces an intermediate 
substrate, where one pair of strands has been exchanged whilst the other remains non­
recombined. This stage is similar to that of the Holliday junction formed during 
homologous recombination. As a result, the integrase recombination has two stages,
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each cutting, rejoining with a new strand for strand exchange (Marshall Stark et. al.,
1991).
In the described fashion, Cre recombinase binds to the loxP sites and cuts the substrate 
to form covalent 3’-phosphotyrosine intermediate substrates, which are antiparallel to 
each other. The 5’-hydroxyl groups that have been released by the cleavage of the 
phosphodiester bonds become nucleophiles in a strand exchanging reaction, and these 
attack the phosphotyrosine residues of the other DNA substrate. This reaction produces 
a four-way Holliday-junction intermediate. The following round of cleavage, rejoining, 
and strand exchange results in the Cre/loxP recombination products. The whole process 
involves four Cre recombinase molecules for every two loxP sites. It is thought the Cre 
undergoes subtle allosteric changes at the carboxy termini of its subunits that are able to 
then coordinate the cleavage, rejoining, and strand exchange reactions of the reaction 
(Guo et. al., 1997) (Figure 2.2).
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Figure 2.2. A. The Cre-loxP  recombination reaction. B. loxP  cleavage site. (Diagram from Guo et. al., 1997)
2.2.4. Heterospecific lox sites
Whilst Cre-mediated recombination between two bacteriophage loxP sites occurs 
extremely efficiently, a second recombination event involving a loxP site on the PI 
plasmid, and a loxB site on the host DNA, is less efficient. This loxP/loxB 
recombination allows for integration of the plasmid into the bacterial chromosome 
(Sternberg & Hamilton, 1981; Sternberg et. al., 1981), and two hybrid sites (loxL and 
loxR) are generated. Furthermore, because PI DNA is able to integrate into loxB in both 
orientations, two sets of loxL and loxR site are produced. These different lox sites are 
not the same because each has its own characteristic Cre-mediated recombination 
efficiency; loxP and loxL efficiently recombine, whereas loxB and loxR do not. It has 
been suggested that the size of the spacer region is critical; loxP and loxL have an 8bp 
spacer region, whilst loxB and loxR have a 9bp spacer region (Hoess et. al., 1982).
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However, the point of crossover between the loxP and loxB sites still occurs in the 8bp 
spacer region (Abremski et. al., 1983).
In short, only pairs of lox sites that are identical in the central 6 bp of the core region are 
ideally suited for recombination, and sites that have non-identical core sequences 
(heterospecific lox sites) do not efficiently recombine with each other (Sauer, 1996).
2.3. Cre/loxP  technology
The simplicity of the of site-specific recombination mechanism of the Cr e/loxP system 
has been exploited by a growing number of researchers for both in vitro and in vivo 
applications. Depending on the orientation and position of the loxP sites, relative to 
each other, the result of the recombination event can be pre-detennined. A direct 
orientation of the two-loxP sites located on a linear molecule results in deletion and 
circularisation of the flanked DNA (Dale & Ow, 1991; Wagner et. al., 1997), whilst a 
direct orientation of the loxP sites located on a circular molecule allows for integration 
(Fukushige & Sauer, 1992; Baubonis & Sauer, 1993; Albert et.al, 1995) of the plasmid. 
Inversion of the /axP-flanked DNA occurs if the sites are located in opposite orientation 
(Medberry et. al. 1995), and interchromosomal recombination promotes translocation 
reactions (Qin et. al. 1994; Smith et. al., 1995).
2.3.1. Cr el lox recombination in mammalian genetic research
One of the major applications has been in genetic manipulation of the mouse genome, a 
field of research that is largely implicated in immunology, cancer biology, and 
development that ultimately leads to greater understanding of human genetics. Genes 
can be mutated or deleted from the mouse genome by homologous recombination in
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embryonic stem (ES) cells. However, a drawback in using this system is that many of 
the genes being studied are essential for embryonic development, and so genetic 
manipulation results in the production of non-viable embryos. In order to avoid this 
problem, strategies have been developed to delete or mutate the genes in the mouse as 
opposed to in the ES cells. Cre and the FLP recombinase from yeast (another integrase 
family member) are exploited in such strategies. Such strategies can be made to be 
tissue-specific, inducible, and time-specific.
One such strategy used Cre to delete a /oxP-flanked gene in a tissue-specific manner. 
Gu et. al (1994) successfully used the Cve/loxP system to inactivate the DNA 
polymerase [3 gene (pol/3) in just the T cells of mice, but not in any other tissue, an 
example of a tissue-specific knockout of a mouse gene. They did this by flanking a 
mouse pol/3 gene with two loxP sites, and then mated this mouse with another 
transgenic mouse that had Cre placed under the control a T-cell-specific promoter, 
rendering Cre to be specifically expressed in T-cells only. This resulted in the 
generation of a double transgenic mouse whose polp  gene was inactive only in T-cells, 
therefore allowing the researchers to study the effect of DNA polymerase (3 on the 
development of T and B-cells. This had previously been impossible through the 
conventional approach of making a knockout mouse lacking a functional pol/3 gene 
because the enzyme is essential for mouse development, with standard pol/3 knockout 
mouse embryos unable to survive.
However, there were still major problems associated with this approach even though 
Cre activity was restricted to T-cells only. The function of the pol/3 gene could only be 
interpreted by comparing wild-type mice expressing pol/3, with pol/3A mutant mice. The
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phenotype of the mutant strain needed to be /j>o//?-deficient from an early stage and 
throughout development. However, problems arose when it was found that the mutant 
strain was able to compensate for the deletion of pol/3 by showing no obvious 
phenotypic variation from that of the wild-type, and that lacking a functional pol/3 gene 
was in some instances lethal to the developing embryo, making it impossible to study at 
later stages.
To counteract this, Kuhn et. al. (1995) placed Cre under the control of an inducible 
promoter from the mouse mxl gene. The mxl gene product contributes to the defence of 
viral infections and is not normally expressed in healthy mice. However the promoter 
can be induced to high levels of transcription quickly by interferon (IFN). Although the 
promoter is not tissue-specific, it was only active when the mouse was treated with IFN. 
When mice containing the mxl-eve cassette were crossed with mice containing the 
/oxP-flanked pol/3 gene, all the embryos were able to survive, and the researchers were 
able to delete the pol/3 gene at specific times in the double transgenic offspring simply 
by administering IFN.
Another inducible gene targeting strategy utilizing CrdloxP  recombination in mice was 
described by Lakso et.al (1992). They introduced the simian virus 40 (SV40) tumor- 
causing oncogene that was made dormant by inserting a synthetic loxP flanked STOP 
cassette between it and a promoter that would turn on the oncogene in the mouse eye 
lens. Mice that contained this cassette did not have eye tumors, however when mated 
with mice that carried an active cre gene, the double transgenic offspring all got eye 
tumours. After recombination has taken place, the remaining loxP site does not interfere 
with expression of the target gene.
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The two examples show that as the recombination event depends on whether the cre 
gene is active, this allows for the researcher to introduce a gene of interest into the 
mouse, and activate it when required. Placing the cre gene under the control of an 
inducible promoter and also the target transgene under the control of another 
specifically induced promoter allows this.
A problem that has been encountered when placing cre under the control of a native, 
mammalian tissue-specific promoter is that such a promoter may be expressed at low 
levels in other tissue types, or at times during development when it is not required to 
turn on cre. Under these circumstances it may be necessary to use synthetic promoters 
to control Cre expression. One example has been to place the cre gene under the control 
of a tetracycline-regulated promoter that is tightly regulated (Sauer, 1998). This system 
is positively and negatively regulated by the of the binding or release of tTa 
(tetracycline-controlled transactivator, from the VP 16 protein of herpes simplex virus) 
with the Tet operator sequence within the promoter. Therefore, transcriptional 
activation of the promoter only occurs in cells expressing tTa. In the absence of 
tetracycline, the tTa binds to the operator to prevent transcription of the cre gene that is 
under the control of the promoter. However, addition of tetracycline prevents binding of 
tTa to the operator. Therefore, oncethe mouse is administered a dose of tetracycline, the 
tTa is prevented frombinding to the operator sequence in the promoter, therefore failing 
to terminate gene expression, and as a result the cre gene becomes active, but only in 
the presence of the antibiotic.
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2.3.2. Other models
Cr e/loxP technology is not restricted to mammalian genetic research. It has been 
utilised by plant and yeast genetic researchers also. The production of transgenic plants 
is used to study the function and regulation of genes through integration of the genes of 
interest into the plant genome. Albert et. al (1995) used Cre-mediated integration of 
transgenes at a lox site situated on the genome of tobacco, by direct transfer to 
protoplasts. However, in many plant species, there are no protocols for the cultivation 
and regeneration of protoplasts. Instead, a widely used method for gene transfer into 
plants is by the natural gene transfer system of the bacterium Agrobacterium 
tumefaciens, which does not require protoplasts. A. tumefaciens naturally transfers part 
of its Ti (tumor-inducing)-plasmid, called the T (transferred)-DNA, to plants. The 
CrdloxP  system has been used to obtain targeted integration of the T-DNA from A. 
tumefaciens into the genomes of Arabidopsis thaliana (Vergunst & Hooykaas, 1998), 
and this method should prove to be a useful tool in plant biotechnology research.
2.3.3. Potential applications
Another potentially powerful application of Crq / I o x  recombination takes advantage of 
the existence of heterospecific lox sites where Cre could be used to genetically 
manipulate all eukaryotic genomes. Sauer (1996) reported three major applications in 
the yeast Saccharomyces cerevisiae, which could also be used in all eukaryotes, (i) By 
placing heterospecific lox sites at defined locations in a genome, and using a specific 
core sequence on the lox target plasmid, it is possible to selectively target integration of 
a transgene by Cre-mediated recombination at different chromosomal lox sites at 
different loci. The outcome of this would be direct integration to the corresponding 
locus.
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(ii) Using different pairs of heterospecific sites would allow simple Cre-mediated gene 
deletion at different chromosomal loci without any complicating chromosome 
inversions, translocations or larger deletions. This method would be particularly useful 
when removing a selectable marker used for selection during integration of exogenous 
DNA through homologous recombination, as its promoter and enhancer elements may 
interfere with expression of adjacent genes. To do this would simply require the 
unwanted stretch of DNA to be flanked by the lox sites.
(iii) Finally, eukaryotic genomes have been found to contain several functional 
heterospecific lox sequences which can support Cre-meditaed recombination at up to 
100% of the efficiency of the native loxP sites in bacterial assays (Thyagarajan et. al., 
2000). Such sites, especially if located at nonessential positions in the chromosome, 
would allow for specific Cre-mediated gene targeting by placing the required gene onto 
a target vector carrying a heterospecific lox site. Sauer has suggested that such a 
powerful strategy could be used in human gene therapy, as it would eradicate the 
problem of random DNA integration, only permitting exact stable integration of 
exogenous DNA at a defined genomic locus.
The IVET system described earlier by Mahan and co-researchers could only be used in 
S. typhimurium, as it required a ApurA strain of the bacterium. Obviously an IVET 
system that could be used to identify ivi genes in a variety of bacterial species and 
strains, would be extremely powerful.
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2.3.4. Aims of the project
The aim of this project was to develop an IVET system that could easily be introduced 
into various bacterial species, using a selection system whereby transient promoter 
expression would cause a permanent and selectable change in the phenotype of the 
bacterial host. This system would then be used to identify in vivo regulated promoters 
from N. meningitidis group B strain H44/76 (Holten, 1979).
The proposed system consists of a promoterless cre gene with its own ribosomal 
binding site and ATG start codon carried on a low copy number plasmid. Two loxP 
sites would be cloned to flank a transcriptionally active streptomycin resistance gene 
and two transcriptional terminators (jQ fragment, Prentlci & Krisch, 1984). This loxP- Q  
fragment cassette would then be cloned into a plasmid containing the aminoglycoside 
phosphotransferase gene (aph gene, conferring kanamycin resistance), at a site which 
would separate the coding region of the aph gene, from its own functional promoter. 
The resulting plasmid would be streptomycin resistant and kanamycin sensitive. This 
construct was to be placed on a high copy-number plasmid. It was expected that 
transcriptional fusion of active promoters to the cre gene would induce loxP 
recombination resulting in excision of the Q  fragment, and the reconstitution of the 
kanamycin resistance gene. Therefore the change in phenotype of the host from 
streptomycin to kanamycin resistance would then indicate promoter activity (Figure 
2.3).
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Figure 2.3.
This thesis describes the initial stages of the strategy. The aims were to introduce the 
system into E. coli cells and to test that it worked. The transformed cells were then 
exposed to an ex vivo model of healthy human serum, to identify library gene fragments 
from the kanamycin-resistant pool of clones that activated Cre recombinase production 
in the serum environment.
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3.Materials and Methods
3.1. Materials
All media was obtained from Difco or Oxoid and chemicals from Sigma unless 
otherwise stated. Appropriate media and chemicals were autoclaved at 121 °C under 
15psi pressure for 15 minutes. Alternatively, solutions were sterilised by filtration 
through a 0.2pm Minisart filter unit. Water used for molecular biology applications was 
purified using an Elga water purification system (USF Ltd.) and autoclaved, whilst 
water used in media and diluting some buffers was filtered by reverse osmosis.
3.1.1. Growth media
Luria Bertani (LB) broth: Bacto tryptone 1.0% (w/v), yeast extract 0.5% (w/v), NaCl 
85mM, pFI7.5.
LB agar: As LB broth with bacteriological agar 1.5% (w/v).
Nutrient Broth Number 2: 2.5% (w/v).
SOB: Bacto tryptone 2.0% (w/v), yeast extract 0.5% (w/v), NaCl 8.0mM, KC1 2.5mM, 
M gS04 20mM.
SOC: Sterile 20mM glucose was added to SOB.
Columbia Agar Base (CAB): 3.9% (w/v).
5% Blood agar: CAB cooled to 50°C after autoclaving and 5% sterile defibribinated 
horse blood (TCS Microbiology) was added.
5X M9 salts: 6.4% (w/v) Na2HPO4.7H20, 1.5% KH2 P 0 4 (w/v), 0.25% NaCl, 0.5% 
NH4C1.
M9 minimal broth: 20% 5X M9 salts (v/v), 0.2% 1M M gS04, 0.4% glucose, 0.01% 
1M CaCl2.
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M9 minimal agar: As M9 minimal broth, autoclaved and aseptically added to 2% 
bacteriological agar (1:1 ratio) at 50°C.
RM media: 2% casamino acids, autoclaved and cooled to 50°C. Aseptically added 
supplements 5X M9salts, 1M MgCb, 20% glucose, thiamine (lOmg m l'1), appropriate 
antibiotics (see below).
3.1.2. Media supplements
Xgal (5-bromo-4-chloro-3-indolyl-(3-D-galactopyranoside): 40pg ml"1 dissolved in 
dimethyl- formamide. Filter sterilised, stored at -20°C in the dark.
IPTG: (isopropyl-1-thio-p-D-galactoside) lOpg ml"1. Filter sterilised, stored at -20°C. 
Glycerol: 0.02% (v/v).
Glucose: various concentrations.
Ampicillin: lOOpg m l'1. Filter sterilised, stored at -20°C.
Kanamycin: 30pg ml" . Filter sterilised, stored at -20°C.
Streptomycin: 25pg ml"1. Filter sterilised, stored at -20°C.
Chloramphenicol: 25pg m l'1. Filter sterilised, stored at -20°C.
3.1.3. General buffers
6X Loading buffer: 40.0% (w/v) sucrose, 0.25% (w/v) bromophenol blue.
Buffered phenol/ chloroform/ isoamyl alcohol: 25:24:1 ratio (v/v), pH8.0. 
Phosphate-Buffered Saline (PBS): 137mM NaCl, 2.7mM KC1, 4.3mM Na2HP04, 
1.4mM KH2P 0 4, pH7.3.
50X TAE: 270mM tris, 7.0mM EDTA, 1.15% (v/v) glacial acetic acid.
Tris/EDTA (TE): lOmM tris/HCl pH8.0, ImM EDTA pH8.0.
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Transformation buffer (TB): lOmM Pipes, 15mM CaCL, 250mM KC1, adjusted to pH 
6.7 with 1M KOH, then added 55mM M11CI2. Filter sterilised, stored at 4°C.
3.1.4. Plasmid DNA miniprep solutions
Solution 1: 50mM glucose, 25mM Tris/FICl pH8.0, IO111M EDTA.
Solution 2: 0.2M NaOH, 1% (w/v) SDS.
Solution 3: 60% (v/v) 5M potassium acetate, 11.5% (v/v) glacial acetic acid.
3.1.5. Southern blotting buffers and solutions (digoxigenin system)
Denaturation solution: 0.5NNaOH, 1.5MNaCl.
Neutralisation solution: 0.5M Tris-HCl, 3M NaCl, pH7.5.
20X SSC: 3M NaCl, 0.3M sodium citrate, pH7,0.
Standard Buffer 1: 0.15M NaCl, 0.1M maleic acid, pH7.5 with solid NaOH.
Blocking Reagent (Roche Diagnostics Ltd.): 10% (w/v) blocking reagent in standard 
buffer 1 was dissolved by heating and autoclaved. Stored at -20°C.
Prehybridisation Buffer: 5X SSC, 0.1% (w/v) N-lauroylsarcosine, 0.02% (w/v) SDS, 
1.0% (v/v) blocking reagent.
Hybridisation Buffer: As prehybridisation buffer with digoxigenin-labelled DNA (5- 
25ng m l'1).
2X Wash: 2X SSC, 0.1% (v/v) SDS.
0.1X Wash: 0.1X SSC, 0.1% (v/v) SDS.
Buffer 2: 1.0% (v/v) Blocking reagent in standard buffer 1.
Washing Buffer: 0.3% (v/v) Tween 20 in standard buffer 1.
Anti-DIG antibody-alkaline phosphatase conjugate (Roche Diagnostics Ltd.): 0.01% 
(v/v) in buffer 2.
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Buffer 3: lOOmM Tris-HCl, lOOmM NaCl, 50mM MgCl2, pH9.5.
CSPD (Roche Diagnostics Ltd.): 1.0 % (v/v) in buffer 3.
Probe Stripping Solution: 0.2N NaOH, 0.1% (v/v) SDS.
3.1.6. SDS-PAGE and Western blotting buffers and solutions
2X Loading buffer: 75mM Tris-HCl (pH 6.8), 5% p-mercaptoethano 1, 2% SDS, 10% 
glycerol, 0.1% bromophenol blue
4X Resolving gel buffer: 1.5M Tris-HCl (pH 8.8), 0,4% (w/v) SDS 
4X Stacking gel buffer: 0.5M Tris-HCl (pH 6.8), 0.4% (w/v) SDS 
5X Running buffer: 0.5M Tris base, 0.55M glycine, 1% SDS
Coomassie brilliant blue stain: 0.15g Brilliant blue G, 25ml methanol, 5ml acetic acid, 
70mls sterile water
Destaining buffer: 10% acetic acid, 30% methanol
Transfer buffer: 39mM glycine, 48mM Tris base, 20% methanol
Ponceau S stain: 2g Ponceau S, 30g trichloroacetic acid, 30g sulfosalicylic, sterile
water to lOOmls
10X Tris Buffered Saline (TBS): 50mM Tris-HCl (pH 7.6), 137mM NaCl 
Membrane blocking solution: 2% BSA in IX TBS 
TBS-Tween: 0.1% Tween-20 (v/v) in IX TBS
3.1.7. SDS-PAGE gels
12% resolving gel: 30% acrylamide, 1.5M Tris (pH 8.8), 10% SDS, 10% ammonium 
persulphate, TEMED, sterile water
5% stacking gel: 30% acrylamide, 1.0M Tris (pH 6.8), 10% SDS, 10% ammonium 
persulphate, TEMED, sterile water
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3.1.8. Bacterial strains
Table 3.1
Strain Comments
E. coli DH5a snpE44, AlaclI169 (<f>80lacZA15), hsdR17, 
recAl, endAl, gy>rA96, thi-1, re/AJ (Hanahan 
1983).
E. coli JM110 F \ traD36, lacf1, A(lacZ)M15, 
proA+B+/rpsL(Str'), thr, leu, tin, lacY, galK, 
galT, ara.flniA, dam, dcm, A(lac-proAB), 
supE44 (Yanisch-Perron et. al., 1985).
E. coli XL 1-Blue F’,::Tn/0, proA*B+ , laq’’A(lacZ)M 15/recA 1, 
endAl, g)>rA96, (Nal1), thi, hsdR17, (i'k’hiU), 
supE44, relAl, lac
N. meningitidis Holten, 1979
B H44/76
3.1.9. Plasmids
Table 3.2
Plasmid Reference
pUC19/pUC18 Yanisch-Perron et al., 1985
pACYC184 Chang & Cohen, 1978
pBAD-TOPO Invitrogen
pACYCaraCre Fisch et. a l 1996
pUS900 Dellagostin, 1994
pkan loxQcre Docherty, 1997
pHP45omega Prentki & Krisch, 1984
with Q  interposon
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3.1.10. Table of oligonucleotide primers
Table 3.3
Oligonucleotide name Type Sequence (5’-3’)
HPloxanneal 1 Annealing CCGCTCGAGGGACCTAATA
ACTTCGTATAATGTATGCT
AT
Hploxanneal2 Annealing CCGCTCGAGGGTCGACATA
ACTTCGTATAGCATACATT
Universal forward Sequencing CCCAGTCACGACGTT
GTAAAACG
Universal reverse Sequencing AGCGGATAACAATTT
CACACAGG
HPloxl PCR CCCAAGCTTCTCGAGGGAC
CTAAT
HPlox2 PCR GCTCTAGAGGTCGACATAA
CTTC
HPlox3 PCR GGGGTACCGGACCTAATA
ACTTC
HPlox4 PCR GGAATTCTCGAGGGTCGAC
AT
HPcremcs+ PCR CCCAAGCTTCCCGGGCTGC
AGCCATGCCAATTTCACAG
TAAG
HPcrebcl- PCR CCCTGATCATATCAACTAA
TTATAGCAATCATT
pBAD forward Sequencing ATGCCATAGCATTTTTATC
C
HPT4termPst+ PCR AACTGCAGGTCGACTCTAG
TG
HPT4tennPst“ PCR AACTGCAGTTTATGCTTGT
AAACCGTTTTGT
HPantimcs PCR CACTCGTTGCATCGA
HPlib+4 PCR/Sequencing TCAGCCCCATACGAT
ATAAG
Uptake FT Annealing AATTCGCCGTCTGAA
GAGCT
Uptake RR Annealing GCGGCAGACTTC
HPuptakecheck Sequencing TGCTGCAAGGCCATTAAGT
T
HPKOl PCR GGAATTCCATATGCTCTGC
CTGACGGAACGG
HPK02 PCR CCTTAAGGACCGGAC
ACATCAAAAAAAC
HPK03 PCR AAGGCCTTGTTCGCC
GGTATCGGGC
HPIC04 PCR CCACATGTTCGCCCT
CGGAGTCGGC
HPKAN+ PCR ATGGATGCTGATTTATATG
GG
HPCreNoATG+ PCR AACTGCAGTCCAATT
TACTGACCGTACAC
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3.2. Methods
General techniques in molecular biology, which are briefly described, were performed 
according to Maniatis et al. (1989) unless stated otherwise.
3.2.1. Small-scale preparation of plasmid DNA
Plasmid DNA was routinely extracted from E.coli by alkaline lysis. A 3ml 16-18 hour 
culture was centrifuged at 3000rpm for lOminutes and the supernatant discarded. The 
remaining pellet was resuspended in 150pi of solution 1 followed by addition of 300pl 
of freshly prepared solution 2. The contents were mixed by inversion and placed on ice 
for 5 minutes. 225pi of solution 3 was added, followed by inversion mixing and 
incubation on ice for a further 5 minutes. The mixture was centrifuged at 13000 rpm for 
5 minutes to remove precipitate. The supernatant was extracted and incubated with 
RNAse A (final concentration 20pg m l'1) at 37°C for 20minutes. Plasmid DNA in 
solution was purified by phenol/chlorofonn/isoamyl alcohol extraction, and then 
precipitated and resuspended in 30-50pl TE buffer or sterile water (stored at -20°C). 
Plasmid DNA was also extracted using QIAprep Spin Miniprep and QIAfilter Plasmid 
Midi kits (Qiagen) according to manufacturer’s instructions.
3.2.2. Chromosomal DNA extraction from N. meningitidis
N. meningitidis colonies were grown overnight on a 5% blood agar plate at 35-37°C, 
6% C 02. The culture was resuspended in 3.5mls TE buffer, and 1ml 50% sucrose in 
lOOmM TE (pH8.0) was added. Then 0.25ml 1M Tris (pI48.0), 0.1ml 0.5M EDTA, and 
0.1ml lysozyme (50mg ml"1) were added, the lysate was mixed well and incubated on 
ice for 30 minutes. Next, 0.6ml 10% SDS was mixed in, and 20pl proteinase K (20mg 
m l'1) was added and the suspension incubated at 55°C for 1 hour. This was followed by
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phenol/chloroform (1:1) extraction and ethanol precipitation with 2 volumes ice-cold 
ethanol and 0.1 volume 3M sodium acetate (pH5.2) for 30 minutes at-20°C. The DNA 
was then removed with a tip, transferred to an microfuge tube (Eppendorf), and washed 
in lml 70% (v/v) ethanol. The DNA was pelleted, dried, resuspended in 500jal TE, and 
left to dissolve at 4°C overnight. The following day, the DNA was treated with RNAse 
A (final concentration 10pg m l'1), incubated at 37°C for 30 minutes, and then re­
extracted with phenol/chloroform and ethanol precipitated, washed, dried, and 
resuspended in 1 OOpl TE.
3.2.3. Agarose gel electrophoresis
Routine DNA analysis was performed using agarose gel electrophoresis. Gels of 
appropriate concentration (w/v) were prepared in IX TAE and subjected to 
electrophoresis at 5-10 V cm’1 in a horizontal submarine gel tank (BioRad). Gels were 
then stained in an ethidium bromide bath (0.5pg m l'1 in IX TAE). DNA was observed 
using an ultra-violet transilluminator and photographed on gel documentation systems 
(UVP Imagestore 5000 and Pharmacia Biotech VDS).
3.2.4. Quantifying DNA in aqueous solution
The concentration and purity of DNA was determined by spectrophotometry (HeAiOSa 
spectrophotometer, UNICAM) at 260:280nm wavelengths. A pure solution of DNA has 
a peak absorbance at 260nm, and a 260:280nm ratio of 1.8 (Maniatis et. al., 1989). The 
concentration of DNA was calculated according to the relationship A26o= l is equivalent 
to 50pg m l'1 of double stranded DNA or 33jng m l'1 of oligonucleotide.
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Whenever accuracy was not required, the quantity of DNA was estimated. This was 
done by visually comparing the intensity of the DNA band of interest (after agarose gel- 
elecrophoresis) with that of an appropriate DNA molecular weight marker (Roche 
Diagnostics Ltd. & Promega) containing known amounts of DNA.
3.2.5. Purification of DNA from agarose gels
Specific DNA fragments were excised from agarose under UV transillumination and 
purified using the Qiaquick gel extraction kit (Qiagen) according to manufacturer’s 
instructions.
3.2.6. Phenol/Chloroforin/Isoamyl alcohol extraction of DNA
Phenol/chloroform/isoamyl alcohol and DNA solution were mixed in the ratio of 
25:24:1. Samples were centrifuged at 13000 rpm for 5 minutes. The upper aqueous 
layer containing the DNA was extracted and retained.
3.2.7. DNA precipitation
To a given volume of DNA in solution 0.1 volume 3M sodium acetate and 2 volumes 
100% (v/v) ice-cold ethanol was added. Samples were placed at -20°C for 18-24 hours 
and centrifuged at 13000 rpm for 10 minutes at 4°C. The supernatant was discarded and 
the DNA pellet was washed with 70% (v/v) ethanol. The resulting pellet was air dried 
and resuspended in an appropriate volume of sterile water or TE buffer.
3.2.8. Restriction endonuclease digestion of DNA
DNA was digested with the required restriction endonuclease in the appropriate IX 
restriction buffer and incubated at the enzyme’s optimum temperature. The total
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reaction volume was altered according to the amount of DNA to be digested. Roche 
Diagnostics Ltd. and New England Biolabs supplied restriction endonucleases and 
buffers.
3.2.9. Converting a 5’-overhang to a blunt end terminus using Klenow 
Polymerase
Following purification, DNA was resuspended in Klenow IX buffer containing 40 pM 
of each dNTP and 0.1 mg ml"1 Bovine Serum Albumin (BSA). 1U of Klenow 
Polymerase (Roche Diagnostics Ltd.) per mg of DNA was added. The reaction was 
incubated at room temperature for 10 minutes, and was heat inactivated at 75°C for 10 
minutes.
3.2.10. Dephosphorylation of DNA
DNA was dephosphorylated using 1 unit calf intestinal alkaline phosphatase (CIP) in 
the supplied IX buffer (Roche Diagnostics Ltd.). The reaction was first incubated at 
37°C for 30-60 minutes. The reaction was terminated by inactivation of the enzyme at 
75°C for 10 minutes.
3.2.11. Ligation of DNA fragments
DNA fragments were ligated in a 3:1 molar ratio of insert DNA to vector using T4 
DNA ligase (Gibco BRL) in the supplied IX buffer. The reaction was incubated at 14°C 
(cohesive end ligations) and 8°C (blunt end ligations) for 18-24 hours.
3.2.12. Oligonucleotides
Synthetic oligonucleotides were purchased from Sigma-Genosys.
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3.2.13. Polymerase Chain Reaction (PCR)
PCR amplification was performed using the Perkin Elmer GeneAmp System 2400 and 
9700 thermal cyclers. A standard reaction contained lOmM each dNTP (dATP, dGTP, 
dCTP, dTTP), 0.5pM each oligonucleotide primer, lng DNA template and 1U Taq 
DNA polymerase in IX PCR buffer (Qiagen). Typical PCR reaction conditions 
consisted of an initial denaturation step at 94°C for 5 minutes. This was followed by 30 
cycles consisting of denaturation at 94°C, primer annealing at 50-68°C (depending on 
optimal primer annealing temperature) and extension at 72°C (30 seconds per 500bp of 
PCR product to be amplified). The final cycle was extension at 72°C for 7 minutes.
When using primers with a high chance of formation of hairpin loops, 1U of 
HotStaiTag™ DNA polymerase (Qiagen) was used in the PCR reaction, and the initial 
denaturation step was carried out at 95°C for 15 minutes.
During PCR amplification of genes, 1U of the high fidelity Pwo DNA polymerase 
(Roche Diagnostics Ltd.) was used instead of Taq. A  typical PCR reaction was carried 
out in IX PCR buffer containing MgSCfi (final concentration 1.5 - 4.0mM).
3.2.14. Automated DNA sequencing
DNA was sequenced on an Applied Biosystems 373A automated sequencer using the 
dye terminator cycle sequencing method by Roy Jadubansa (Molecular Microbiology 
Group).
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3.2.15. Preparation of high transformation efficiency E. co/i DH5a heat-shock 
competent cells
A single colony was inoculated into 5ml SOB broth and incubated shaking overnight at 
20°C. The culture was used to inoculate 125mls SOB with a 1/1000 (v/v) dilution and 
grown shaking at 20°C for approximately 24 hours to an optical density at 600nm 
(OD6oo) of 0.6. This was measured using a HeXIOSa spectrophotometer (UNICAM). 
The culture was cooled on ice for 10 minutes before centrifugation at 2500rpm for 10 
minutes, 4°C in a Beckman GPR centrifuge. The cells were resuspended in 2X 20mls- 
ice cold TB and incubated on ice for 10 minutes, before being spun down at 2500rpm 
for 10 minutes at 4°C. The pellet was gently resuspended in 2X 5mls-ice cold TB and 
0.35mls fresh Dimethyl Sulphoxide (DMSO) and left on ice for 10 minutes. Aliquots 
were immersed in liquid N2 and stored at -70°C. Most competent cells were routinely 
made by Sue Wall (Molecular Microbiology Group).
3.2.16. Transformation of E. coli competent cells
0.1-10ng of DNA was added to 50jli1 of competent E. coli DH5a cells and placed in ice 
for 30 minutes. Cells were heat-shocked at 42°C for 45 seconds and immediately placed 
in ice for 2 minutes. Recovery of cells was achieved by addition of 80 j l l I  SOC and 
incubation at 37°C (shaking, 250rpm) for 60 minutes prior to selection of transformants 
on LB agar supplemented with the appropriate antibiotics.
3.2.17. Preparation of electrocompetent E. coli cells
A lml volume from an overnight culture in LB was used to inoculate 19mls LB. This 
was shaken at 250rpm for approximately 2 hours to achieve an OD600 between 0.5-1.0.
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The culture was placed on ice for 15 minutes, and then centrifuged at 2500rpm, 4°C to 
pellet the cells. The cells were then resuspended in 20mls ice-cold sterile water, and re­
centrifuged for 15 minutes at 2500rpm. The process was repeated 3 times, resuspending 
in lOmls water, then 1ml 10% glycerol, and finally 200pl 10% glycerol respectively. 
Aliquots were quickly frozen in an Industrial Methylated Spirits (IMS)/dry ice bath and 
stored at —70°C.
3.2.18. Electroporation of electrocompetent cells
An aliquot (40 j l l 1) of competent cells were electroporated with 0.1-5ng of DNA in 
electroporation cuvettes with a 2mm gap (Eppendorf) using the BioRad GenePulser 
(voltage 2.5 kV, capacitance 25 pFD, resistance 200Q). Cells were then recovered in 
200pl of SOC at 37°C for 1 hour and transformants selected at 37°C on LB agar 
supplemented with the appropriate antibiotics.
3.2.19. Transformation of N. meningitidis
A  single colony of N. meningitidis was streaked onto a blood agar plate and grown at 
35°C, 6% CO2 overnight. The following day, the colonies were examined under the 
microscope for uniform piliation by selecting the small, sharp-edged colonies.
100ml of liquid MH broth was equilibrated at 35°C, 6% CO2 and prior to use 1ml of 
100 x Vitox supplement (Biomerieux) and 0.7ml 1M M gCf was added. Single colonies 
were scraped from the plate and inoculated into the broth so that the approximate cell 
concentration was 107-198 cells ml"1. The culture was then aliquoted into 0.5ml 
portions. Approximately 50ng of DNA was added to each tube and 5pi water was added
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to the negative control. The tubes were shaken to mix the contents, and then incubated 
at 37°C for 30mins without shaking.
4.5ml of prewarmed MH broth containg the above mentioned supplements was added to 
the transformation cultures and the tubes were then sealed and wrapped in parafihn and 
incubated at 37°C for 4-5 hours in a tumbler. 5pi, 50pl and 500pl volumes were spread 
onto blood agar plates and incubated for 1-2 days at 35°C, 6% C 0 2.
3.2.20. Southern Blotting
Following electrophoresis, DNA was transferred from agarose gels onto positively 
charged nylon membranes (Roche Diagnostics Ltd.) by capillary action. The agarose 
gel was initially depurinated with 0.25M HC1 for 5 minutes followed by two 15 minute 
washes in denaturation solution and neutralisation solution. The gel was then placed 
faced down on three strips of 20X SSC-saturated filter paper (Whatman 3M) on a 
platform with the ends of the paper dipping into a bath of 20X SSC. The gel was 
overlaid with the nylon membrane, two sheets of filter paper and tissue paper 
approximately 10 cm thick. This ‘sandwich’ was weighed down with a brick and left for 
18-24 hours to allow full transfer of DNA onto the membrane.
3.2.21. Digoxigenin labelling of DNA
The materials and protocols were supplied by Roche Diagnostics Ltd. DNA was 
labelled with Digoxigenin-11-dUTP using the random primed method according to 
manufacturer’s instructions. Boiling and rapid cooling to produce single stranded DNA 
created the DNA template. Random hexanucleotides were annealed to prime synthesis 
of the complementary strand using Klenow enzyme with DIG-11-dUTP and dNTPs.
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The concentration of labelled DNA was estimated by the emitted light intensity detected 
on radiographic film as compared to that emitted by labelled control DNA for a dilution 
series of both samples.
3.2.22. DNA detection by hybridisation
The membrane was initially incubated in prehybridisation buffer at 68°C up to 4 hours 
followed by incubation in hybridisation buffer overnight at the same temperature. It was 
then treated twice with 2X wash solution at room temperature for 5 minutes and twice 
with 0.1X wash solution at 68°C for 15 minutes.
Detection of DIG-labelled nucleotides hybridised to membrane-bound DNA was 
achieved with a chemiluminescent reaction according to manufacturer’s protocols. The 
membrane was initially treated with buffer 2, to prevent non-specific binding of 
antibody, followed by incubation with anti-DIG antibody fragments conjugated to 
alkaline phosphatase. Finally, the substrate CSPD was added to the membrane, which 
was wrapped in Saran wrap before being exposed to X-ray film (Kodak X-Omat AR). 
The CSPD was cleaved by any bound alkaline phosphatase thus emitting light 
detectable on the X-ray film, which was then developed.
3.2.23. Arabinose induction assay
2mls of RM medium containing streptomycin, ampicillin, and chloramphenicol was 
inoculated with a single DH5a colony containing both lox and Cre plasmids and grown 
overnight shaking at 250 rpm to OD600 1.0-2.0. The following day 6 tubes were labelled
1-6, each containing 4.5mls RM medium with ampicillin and chloramphenicol. These 
were inoculated with 0.5ml overnight culture and grown at 37°C, shaking at 250rpm to
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an OD600 of approximately 0.6. lml Time= 0 (To) samples were taken from each tube, 
centrifuged at 13000rpm for 30s and the pellets were stored at -20°C. Stock solutions of 
10-fold serial dilutions of 20% L-arabinose (Table 3.4) were added to the remaining 
cultures in each of the tubes.
Table 3.4
Tube Stock Solution Volume (ml) Final Concentration
1 20% 0.05 0.2%
2 2% 0.05 0.02%
3 0.2% 0.05 0.002%
4 0.02% 0.05 0.0002%
5 0.002% 0.05 0.00002%
6 20% glucose control 0.05 0.2%
The cultures were grown at 37°C, shaking (250rpm) for 4 hours, then lml T4 samples 
were taken from each tube, centrifuged at 13000rpm for 30 seconds and the pellets 
stored at -20°C. Serial 10-fold dilutions were prepared (neat-10"6), and 0.1ml from each 
dilution was plated out onto LB agar plates containing (i) strep/amp/chlor, and (ii) 
kan/amp/chlor. The plates were incubated at 37°C overnight and numbers of colonies 
were counted.
3.2.24. SDS-PAGE gel electrophoresis
The frozen pellets from the arabinose induction assay were thawed and diluted two-fold
in 2X loading buffer, boiled for 5 minutes, and the required amounts were loaded onto a
polyacrylamide gel [Protogel1 M, National Diagnostics: 30% acrylamide, 0.8%
bisacrylamide (37:5:1)]. SDS-PAGE gels were cast using a Bio Rad mini gel system
(Mini-PROTEAN II dual slab cell). A 12% polyacrylamide concentration was used in
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the resolving gel for effective separation of the 34 kDa Cre protein. Electrophoresis was 
carried out at 180V until the loading dye reached the lower edge of the gel. After 
electrophoresis, the gel was stained in Coomassie brilliant blue stain.
3.2.25. Transfer of proteins onto nitrocellulose membrane filters
Following electrophoresis the gel, a Hybond™-C super nitrocellulose membrane 
(Amersham International PLC), and two sheets of extra-thick filter paper were soaked 
in transfer buffer for 10 minutes. Transfer was carried out using a Semi-DryrM blotter 
(Bio Rad). A ‘sandwich’ of filter papers, nitrocellulose membrane, and gel was 
assembled, and transfer of the protein was carried out at 10V for 30 minutes. Blotted 
membranes were stained with the transient, washable dye Ponceau S, to detect total 
protein transfer.
3.2.26. Immunoblotting
The nitrocellulose membrane was gently swirled in 1% membrane blocking solution 
(w/v) for 1 hour at room temperature. A suitable dilution of the primary Anti-Cre- 
Antibody (Novagen) was added in 0.5% blocking solution (w/v), and swirling was 
continued for a further hour. The membrane was washed twice in large volumes of 
TBS-Tween each for 10 minutes, then twice in 0.5% blocking solution (w/v) each for 
10 minutes.
The membrane was then incubated for 30 minutes with 20mU m l'1 POD-labelled 
secondary antibody, streptavidin (Roche Diagnostics Ltd), diluted with 0.5% blocking 
solution (w/v). Meanwhile, the detection reagent was prepared by mixing prewarmed
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(25°C) substrate solution A with starting solution B (Roche Diagnostics Ltd) in a ratio 
of 100:1, and incubating for an additional 30 minutes at room temperature.
After incubation, the membrane was washed 4 times in large volumes of TBS-Tween 
for 15 minutes each before chemiluminescent detection according to the manufacturer’s 
instructions. The premixed detection reagent was added to cover the membrane, and 
incubated for 60 seconds. Excess reagent was drained off and the blot was wrapped in 
Saran wrap before being exposed to X-ray film (Kodak X-Omat AR), which was 
developed.
3.2.27. Serum assay
Serum aliquots used in the experiment were incubated at 56°C for 12 minutes to heat 
inactivate complement, prior to use. 20pi volumes of library stocks (stored at -70°C) 
were thawed and inoculated into 2ml volumes of 50% serum/50% PBS, and 100% PBS, 
in approximate 1:1 ratios of library cells m f1. The cultures were incubated shaking at 
37°C, 250rpm for 3 hours, and then plated in 10-fold serial dilutions (neat-1 O'6) onto LB 
agar containing (i) streptomycin (25 pg ml"1), ampicillin (100 pg m l'1) and 
chloramphenicol (25 pg ml"1), and (ii) kanamycin (50 pg ml"1), ampicillin (100 pg m l'1) 
and chloramphenicol (25 pg ml"1). The plates were incubated at 37°C overnight and 
numbers of colonies were counted.
3.2.28. Replica plating
After the transformation procedure, the colonies were grown until they were the size of 
pinpricks. A dilution plate was chosen that contained approximately 1000 colonies that 
were spaced apart so that the individual colonies could be seen.
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A nitrocellulose membrane cut to the size of the plate was placed gently onto the plate. 
Three asymmetric pinprick marks were made around the edge of the membrane. The 
nitrocellulose membrane was then carefully lifted from the kanamycin plate to pull off 
the colonies. This membrane was turned colony side up and placed onto a clean glass 
slide with 2 layers of 3MM paper. Next, a nylon membrane was cut to the size of a plate 
and pre-wet on LB agar (without antibiotics). This was then carefully placed onto the 
nitrocellulose membrane and the 3 asymmetric pinprick marks were located from the 
bottom nitrocellulose membrane layer and repeated in the top nylon membrane layer. A 
clean metal plate was placed on top and firm, even pressure was applied so there was 
transfer of colonies from the nitrocellulose membrane to the nylon membrane. The 
nylon membrane was then lifted away carefully and placed, colony side up, onto a LB 
agar plate containing the antibiotics streptomycin (25 pg m l'1), ampicillin (lOOpg ml"1), 
and chloramphenicol (25 pg m l'1). The process was repeated using a fresh nylon 
membrane that was placed onto another LB agar plate containing kanamycin (50pg ml" 
’), ampicillin (lOOpg m l'1), and chloramphenicol (25pg m l'1). The nitrocellulose 
membrane was placed colony side up onto a LB agar plate containing kanamycin (50pg 
m l'1), ampicillin (lOOpg m l'1), and chloramphenicol (25pg m l'1) and this master plate 
was stored at 4°C. Both of the replica plates were incubated at room temperature 
overnight to ensure a slower growth of colonies. This procedure was repeated 10 times 
so that approximately 10,000 colonies were replicated onto streptomycin.
The following day the nylon membranes were checked to see whether the colonies that 
had grown appeared to be similar sizes. The membranes were then taken off the plates
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and the colonies were killed by placing the membranes onto 3MM paper soaked with 
95% ethanol, and then were dried in an oven.
In order to clearly see the dead colonies, the membranes were stained with Ponceau S 
red stain for 2 minutes and then rinsed in sterile water. Once dry, the stained 
membranes were photocopied onto acetate, so that the position of the colonies from the 
streptomycin and kanamycin plates could easily be compared with each other by 
superimposing one copy on top of the other corresponding copy. The aim was to 
identify colonies that had grown on kanamycin, but not on streptomycin.
3.2.29. Sequence analysis
Several kanamycin resistant clones were chosen for sequence analysis of the cloned 
library fragment. Plasmid DNA was extracted and PCR using 15ng pi*1 of each of the 
primers HPlib+4 and HPantimcs (section 3.1.10) amplified the region containing the 
cloned library fragment, which was subsequently PCR purified and 1 OOng was given for 
sequence analysis.
The data was entered into the grasta sequence search program using the TIGR (The 
Institute for Genomic Research) database (http://www.tigr.org/l to identify sequence 
homology against the complete genome sequence of N. meningitidis Serogroup B, strain 
MC58 (Tetteline/. a l, 2000).
The position and orientation of the library fragments were determined relative to N. 
meningitidis genomic open reading frames (ORFs). The locus sequences identified as 
being of high (>80%) identity to the published sequence were analysed using the Vector
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NTI (version 4.0) software package, to identify which of the sequence insert fragments 
were upstream of an ORF. Potential promoters were analysed for the -10 and -35 
consensus sequences using the Neural Network Promoter Prediction (NNPP) software 
at the website http ://www.fruitflv.org/seq tools/promoter.html.
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4. Results: LoxP  vector construction
4.1. Introduction
The original strategy to identify meningococcal promoters induced under in vivo 
conditions involved construction of a single plasmid vector, using pUC19 as the 
backbone to incorporate all the genetic elements of the design. The vector, pkanloxOcre 
(Figure 4.1), was supplied by L. Docherty (Ph.D. student, MGL). This vector had been 
constructed using sequences encoding a promoterless cre gene, two loxP sites, O  
fragment, and aph gene (encoding kanamycin resistance) from the respective parent
■y
plasmids; pRH200 and p91ox cm (MRC Human Genetics Unit, Western General 
Hospital, Edinburgh), pHP45/2 (Prentki & Krisch, 1984), and pUS900 (O. Dellagostin, 
MGL). The design of the vector was such that the Q  fragment (flanked by the two loxP 
sites) was positioned to separate the aph promoter and ATG start codon [P(aph) +ATG] 
from the open reading frame (ORF) of the aph gene.
P (b/o)
OR I
P(cph)
+ATG
laxP
qoh ORF 
without ATG
Figure 4.1. Diagram o f the plasmid vector pkanJoxOcre
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Therefore, it was hoped that after Cre-mediated loxP recombination, the Q  fragment 
would loop out from the vector, allowing the aph promoter and ATG to recombine with 
the aph ORF to reconstitute a fully functional gene that would provide resistance to 
kanamycin.
However, it emerged from Dr. Docherty’s work that the promoterless cre gene showed 
promoter activity without a test promoter driving expression. This was detected because 
the clones containing the plasmid were streptomycin-sensitive, due to the ‘looping out’ 
of the Q  fragment. An explanation for this is that because the cre gene had been cloned 
into the high copy-number plasmid pUC18, the chance of promoter activity occurring 
from upstream sequences was high.
Furthermore, once loxP recombination and excision of the Q  fragment had taken place, 
clones containing the vector were remaining kanamycin sensitive. Sequence data 
showed that lox recombination had occurred and the ATG start site was out of frame, so 
the gene was non-functional. It was therefore decided to construct another vector 
system.
4.2. Two-plasmid strategy
It was decided to place the cre and the loxP elements onto separate plasmids, with a low 
and high copy number respectively. The target cre/loxP IVET system is illustrated in 
Figure 4.2. The components of the system are; (i) the cre gene, (ii) two loxP sites, (iii) 
Q  fragment, (iv) aph gene (encoding kanamycin resistance), (v) cat gene (encoding 
chloramphenicol resistance), (vi) p i5A origin of replication (ori), and (vii) pMBl ori. 
The first plasmid would contain the cre gene, and would be placed on a low copy
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number vector with the pi 5A ori, to reduce the level of expression of Cre. The second 
plasmid would contain a cassette consisting of the Q  fragment flanked by two loxP 
sites, that separates the functional coding region of the aph gene from its promoter. This 
would be placed on a high copy number vector with the pMB 1 ori.
Cloning Site
Q
T4 temn
oat p « * * )
(ATG
Figure 4.2. Schem atic diagram s o f respective cre  and loxP plasmid vectors
The plasmid pACYCaraCre (MRC Centre for Protein Engineering, Cambridge), carried 
a promoterless cre gene with ribosomal binding site (RBS), cloned downstream of an 
araBC operon (Figure 4.3). The inducible araC gene (Engelsberg et. al., 1965; 
Greenblatt & Schleif, 1971) regulates both positively and negatively, the araB promoter 
(Lee et.al, 1974), which in turn controls the cre gene. The plasmid backbone is derived 
from the cloning vector pACYC184. This vector carries the P15A replicon, which has a 
low copy number in E.coli (10-12 copies of plasmid per host cell, Maniatis et al, 1989). 
The P15A replicon allows the vector and its derivatives to co-exist in cells containing 
other vectors such as pBR322 and pUC19 that carry the pMBl (or ColEl) replicon 
(Chang & Cohen, 1978). It was decided therefore to utilise this vector for Cre 
expression.
P15AORI
aph without ATGT4 tefm
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P15AORI
P(orcrB)
araC
cat
Figure 4.3. Diagram o f the plasmid vector pACYCaraCre
The loxP sites were to be cloned into a vector derived from pUC19, which has a high 
copy number of between 500-700 copies per host cell (Maniatis et al, 1989). These two 
inverted repeat sequences flank a functional streptomycin resistance gene and two T4 
terminator sequences ( f2 fragment). The loxP-fl fragment cassette was then to be 
subsequently cloned into the Xho\ site in the aph gene (encoding kanamycin resistance) 
of pUS900, separating the aph gene from its promoter and ATG start codon, thereby 
disrupting the aph gene. This would produce a plasmid that carried the loxP-Q cassette, 
conferring streptomycin resistance. However, once Cre-mediated loxP recombination 
occurs, the Q  fragment would loop out, resulting in the aph gene gaining functionality, 
with its open reading frame now under the transcriptional control of the aph promoter as 
a result of the recombination event. Therefore upon Cre-mediated recombination, the 
/oxP-containing plasmid would shift from conferring streptomycin resistance, to 
conferring kanamycin resistance.
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4.3. Investigation whether recombined loxP  site gives functional aph 
gene
As illustrated in Figures 2.3 and 4.2, the proposed IVET system requires an aph gene 
separated from its transcription and translation signals by the loxP-Q cassette with 
trancriptional and translational terminators. Cre-mediated recombination would remove 
the loxP-Q cassette, leaving a single loxP site within the aph coding sequence. The 
recombination event is illustrated in Chapter 2, Figure 2.3.
Obviously, a crucial point is that the resulting aph gene is still able to confer kanamycin 
resistance. To test this, it was decided to artificially insert a synthetic loxP site into the 
aph gene and test its subsequent functionality. The next step was to construct the 
synthetic loxP site. This would involve annealing two primers, HPloxanneall and 
HPloxanneal2 together, and extending using DNA polymerase I (Klenow) to produce a 
double stranded piece of DNA containing the loxP site flanked by two Xho\ restriction 
sites (Figure 4.4), that would be inserted into a functional aph gene.
Hptoxemneall Klenow extension
5 ' CCGlCTC GAGlGGA CCT AAC TTC GTA IAA TGT ATG CTaT I  3'     ►
ATJOl <1 —— loxP  1> Xho 1
< 3' jjUGLBG m , STT C M jfc  agc tg g igag c tc ig c c  5"
Klenow extension ,, ,Hpbxanneal2
Figure 4.4. Schematic diagram to show synthesis o f  synthetic loxP  site by primer annealing and Klenow  
extension
As can be seen, the primers are mixed prior to extension (Figure 4.5, lane 4) and 
extended (Figure 4.5, lane 5). The extension product was ethanol precipitated (Figure
4.5, lane 6), and digested with Xho\ (Figure 4.5, lane 7).
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Figure 4.5. Electrophoresis o f the two HPIoxanneal primers (after annealing, extension, precipitation and 
digestion with X ho\) through a 15% acrylam ide gel stained with ethidium bromide
Lane 1: phiX 174 marker (300ng)
Lane 2: HPIoxanneal 1 primer (200ng)
Lane 3: HPloxanneal2 primer (200ng)
Lane 4: HPIoxanneal 1 & 2 mixed primers prior to extension (400ng) 
Lane 5: Klenow extension (lpg)
Lane 6: Precipitation (200ng)
Lane 7: Digested with Xho\ (lOOng)
The digested DNA was then cloned into the Xho\ site of the aph gene of pUS900, 
separating the promoter from the ORF of the gene to produce the plasmid pUS1601 
(Figure 4.6).
P(qc/J+ATG
Xho I
Figure 4.6. Diagram o f the plasmid vector pUS1601
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As mentioned in the introduction, data from Dr. Docherty’s work indicated that upon 
loxP recombination, the resulting plasmid did not gain resistance to kanamycin due to 
the ATG start codon being out of frame with the rest of the gene. Therefore, it was 
essential to make sure that the ATG start codon of the aph gene in pUS1601, remained 
in frame with the open reading frame through sequence analysis.
Figure 4.7 shows the sequence of the start of the aph gene in the parent plasmid 
pUS900 and the two sequences of the disrupted aph gene with one copy of the loxP site 
in pUS 1601, which would result from the cloning procedure as there are two possible 
orientations in which the synthetic loxP site can be cloned. The ATG start codon in the 
aph coding sequence is shown in red, the XIw 1 site (into which the synthetic loxP site is 
cloned) is shown in pink, and the 7 bases of the open reading frame of the aph gene 
(immediately following the cloning site are shown in blue. The cloned synthetic loxP 
site in pUS1601 (shown in green), was hoped to simulate the DNA sequence once the 
two loxP sites in the system have recombined leaving a single loxP site within the aph 
gene. Therefore the remaining single loxP site must interrupt the coding sequence in 
such a way that does not affect the functionality of the reconstituted aph gene. It was 
essential the codons following the cloned DNA fragment were in the same frame 
relative to the ATG start codon, as in pUS900.
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Predicted sequence:
Parent plasmid pUS900 (functional aph gene with correct reading frame)
5' ATG AGC CAT AT T CAA CGG GAA ACG TCT TGC TCG AGG CCG CGA 3'
Two possible outcomes of the daughter plasmid pUS1601 (cloned synthetic loxP site into aph  gene, still 
with correct reading frame)
5' ATG AGC CAT AH CAA CGG GAA ACG TCT TGC TCG AGG GAC CTA ATA ACT 
TCG TAT AAT GTA TGC TAT ACG AAG HA TGT CGA CCC TCG AGG CCG CGA 3'
Or
5' ATG AGC CAT AH CAA CGG GAA ACG TCT TGC TCG AGG GTC GAC ATA ACT 
TCG TAT AGC ATA CAT TAT ACG AAG HA TTA GGT CCC TCG AGG CCG CGA 3'
Red: ATG start codon of aph gene 
Blue: Coding sequence of aph gene 
Pink : Xho\ site 
Green: loxP sequence
Figure 4.7. Predicted sequence o f functional aph  gene in pUS1601 containing the synthetic loxP site cloned into 
the X h o \  site o f pUS900
The pUS 1601 construct was sequenced to make sure the reading frame was correct. 
Figure 4.8 shows the sequence data showing the loxP site cloned into the Xho\ site. The 
orientation follows the second predicted sequence shown in Figure 4.7, maintaining the 
correct reading frame.
Figure 4.8. Sequence data o f pUS1601 showing that a single synthetic loxP site has been cloned that maintains 
the correct reading frame o f the aph  gene.
84
It was then necessary to determine whether the presence of a single loxP site (that 
resulted from the recombination event) did not affect the expression of Aph from the 
reconstituted aph gene. If the aph gene functionality is not affected by the presence of 
the single loxP site, then the number of colonies isolated on kanamycin plates should 
be similar to the number of colonies isolated on ampicillin plates. Resistance to 
ampicillin is provided by the bla gene, which is also present on the plasmid. To test this, 
lng of pUS 1601 was transformed into 3 x 50pl aliquots of competent DH5a cells. 
Following the transformation procedure, the transformed cell culture was serially 
diluted 10-fold, and triplicates of lOOpl of each dilution plated (Neat-10-6) onto LB agar 
containing ampicillin (lOOpg m l'1), kanamycin (50 pg m l'1), and kanamycin and 
ampicillin together. The average plate counts of colonies recovered on each antibiotic 
are shown in Table 4.1.
T a b le  4.1
Antibiotic Average count (cfu m l')
Ampicillin 129
Kanamycin 120
Ampicillin + Kanamycin 126
The numbers of transformants recovered on the antibiotics were very similar, indicating 
that the presence of the loxP site within the aph gene did not affect resistance to 
kanamycin.
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4.4. PCR amplification of upstream and downstream loxP  sites to 
flank Q  fragment
As can be seen from Figure 4.2, construction of target lox plasmid requires insertion of 
two lox? sites flanking the Q  fragment. To achieve this, it was necessary to amplify 
lox? sites with tailored restriction sites.
Using pUS1601 as the template, two sets of oligonucleotide primers were used to 
amplify two loxP sites with specific restriction sites by PCR. The oligonucleotide 
primers HPloxl& 2 were used in the PCR reaction to produce the 70bp product 
PCRloxl (Figure 4.9, lane 2), whilst the primers HPlox3 & 4 were used in the PCR 
reaction to produce the 68bp product PCRlox2 (Figure 4.9, lane 3).
b p
194 
118
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Figure 4.9. Electrophoresis o f the PCRlox 1 and PCRIox2 PCR products through a 15% acrylam ide gel 
stained with ethidium bromide
Lane 1: phiX  174 (300ng)
Lane 2: PCRloxl (upstream site) (lOOng)
Lane 3: PCRlox2 (downstream site)(lOOng)
Both PCR products also contained a Xho\ site so that the entire cassette could be cut out 
on a Xho\ fragment and cloned into the unique Xho\ site in the aph gene in pUS900.
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This would subsequently separate the open reading frame of the gene from its promoter, 
rendering it non-functional because of the interuption to the open reading frame. The 
design of the HPlox primers ensured that once CrdloxP  recombination event had 
occurred (leaving a single loxP site separating the promoter from open reading frame), 
the aph gene would be functional. This was because the ATG start codon would in 
frame with the rest gene, and the resulting plasmid following the recombination event 
would have the same sequence as pUS1601.
4.5. LoxP  vector construction
The aim was to remove the Q  fragment from pHP45/2 (Prentki & Krisch, 1984), and 
transfer the fragment into the BamH 1 site of pUC18 to produce pUS1600 (Figure 4.10) 
which was confirmed by restriction analysis (Figure 4.11). The lox? sites would then 
subsequently be inserted to flank the Q  fragment.
First the 2.6kb plasmid pUC18 was linearised with BamH 1 (Figure 4.11, lane 2), whilst 
plasmid pHP45Q was also digested with BamH 1 to release the 2kb and 2.2kb fragments 
(Figure 4.11, lane 3). The 2kb fragment from pFIP45Q was next excised from a 1% 
agarose gel and the DNA was extracted, ligated to pUC18, and transformed into E. coli 
DH5a cells. The plasmid DNA was extracted from clones, and restriction digestion 
with BamHl (Figure 4.11, lane 4) demonstrated it had the expected structure for 
pUS1600, by releasing the 2.6kb and 2kb fragments.
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T4 term BanH I
T4 term  /to r f t  |
P(t>to)
T4 term
B w ri\  1
Figure 4.10. Diagram showing plasmid construction o f pUS1600
kb
23.0
9.4
6.5 
4.3
2.3
2.0
Figure 4.11. Electrophoresis o f B am H l digests to confirm the construction o f pUS1600 (by releasing the two  
constituent DNA fragments from the two parent plasm ids) through a 1% agarose gel stained with ethidium  
bromide
Lane 1: X Hindlll (200ng)
Lane 2: pUC18 digested with BamHl to give 2.6kb fragment
Lane 3: pHP45Q digested with BamHl to release 2.2kb and 2.0kb fragments
Lane 4: pUS1600 digested with BamHl to release 2.6kb and 2.0kb fragments
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Primers HPlox 1 and 2 were used to PCR the upstream loxP site with Pst\/Xhol sites 
(incorporated into HPlox 1) and an Xba\ site (incorporated into HPlox2). Primers 
HPlox3 and 4 were used to PCR the downstream loxP site with a Kpn 1 site 
(incorporated into HPlox3) and Xhol/EcoRl sites (incorporated into HPlox4). The two 
synthetic loxP sites amplified from pUS1601 were then directionally cloned upstream 
(on a Pst\-Xba\ fragment) of the Q  fragment to generate pUS1602 (Figure 4.12a) and 
then downstream (on a Kpn\-EcoR\ fragment) of the Q  fragment to generate pUS1603 
(Figure 4.13a).
DNA sequencing (Figures 4.12b & 4.13b) confirmed the structure of the loxP sites in 
the resulting plasmids.
pcrioxl
70  bp
Q
Figure 4.12a. Construction o f plasmid vector p(JS1602
Figure 4.12b. Sequence data to confirm the upstream PC R loxl site has been cloned correctly into the Pstl and 
X ba\ sites o f  pUS1600 to generate PUS1602
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Figure 4.13a. Construction o f plasmid vector pUS1603
EcoRI Xho\ loxp Kpn\
Figure 4.13b. Sequence data to confirm the downstream  PCRIox2 site has been cloned correctly into the K pn l 
and E coK \ sites o f  pUS1602 to generate pUS1603.
The next step was to excise the loxP-I2 cassette and insert it into the aph gene to 
construct pUS1604 (Figure 4.14). The 2.2kb loxP-Q cassette was cut out on a Xho\ 
fragment (Figure 4.15, lane 3 lower band), and the DNA fragment cloned into the Xho\ 
site in the aph gene in the 3.9kb pUS900 (Figure 4.15, lane 2) to yield pUS1604. This 
cloning step resulted in the aph promoter and ATG start codon being separated from the 
rest of the aph gene (ORF) by the loxP-Q cassette, thereby rendering the aph gene non­
functional. The ligated DNA was transformed into E. coli DH5a cells, and the 
pUS1604 plasmid DNA was extracted from the clones. Restriction digestion with Xho\
produced the 3.9kb and 2.2kb fragments, demonstrating it had the expected structure for 
pUS1604 (Figure 4.15, lane 4).
t a *  Xho I
T4 term a ph  ORf without AIG
ATG P (<¥*>) 
qpO fragment
Figure 4.14. Construction o f plasmid vector pUS1604
1 2  3 4
Figure 4.15. Electrophoresis confirm ing construction o f pUS1604 (by releasing the two constituent DNA 
fragments from the two parent plasm ids) through a 1% agarose gel stained with ethidium bromide
Lane 1: X Hindlll (200ng)
Lane 2: pUS900 digested withAfcoI to give a 3.9kb fragment
Lane 3: pUS1603 digested with Xhol to release 2.6kb and 2.2kb fragments
Lane 4: pUS1604 digested With Xhol to release 3.9kb and 2.2kb fragments
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If pUS1604 was to function as a reporter system to detect Cre expression, then it should 
show the following stable characteristics in the absence of Cre expression. Expression 
of Cre should result in cell resistance to the antibiotic kanamycin (Figure 2.3). It was 
therefore necessary to check the antibiotic resistance of pUS1604, in the absence of Cre 
expression to find if the cells would remain completely streptomycin resistant, or 
whether there was a background level of kanamycin resistance.
4.6. Determination of basal level of kanamycin resistance shown by 
clones containing pUS1604 in the absence of Cre recombinase
A culture of E. coli DH5a cells containing pUS1604 was checked to confirm that the
antibiotic resistance of the plasmid was stable in the absence of cre. A stable pUS1604 
plasmid (containing two loxP sites) would provide antibiotic resistance to ampicillin 
and streptomycin, and remain kanamycin sensitive (Figure 4.14).
The culture was grown to an OD6oo (mid-log phase). Triplicates of 100pi of each 
dilution were plated onto different combinations of antibiotics to determine the level of 
background kanamycin resistance without the action of Cre recombining the two loxP 
sites. The plates were incubated overnight at 37°C. The following day, the average plate 
counts were taken, which are shown in Table 4.2. The plate count results from the 
various antibiotic plates were compared to the plate count results from the ampicillin 
plates because the bla gene that encodes resistance to this antibiotic should be stable at 
all times within the plasmid, regardless of whether loxP recombination has occurred or 
not.
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Table 4.2
Plate antibiotics Average count (cfu ml'1) Proportion of total no. 
transformants recovered (%)
Ampicillin 2.1 x 109 100
Streptomycin 1.8x10* 85.7
Kanamycin 5.9 x 10° 0.28
Streptomycin + Kanamycin 7.3 x 10° 0.34
The average counts recovered on the various antibiotic plates were compared to the 
average count recovered on the ampicillin plates. High numbers of streptomycin 
resistant colonies were recovered, in similar numbers to the counts from the ampicillin 
plates. Less than 0.5% of cells were recovered on kanamycin-containing plates, relative 
to the numbers recovered on the ampicillin plates. This was the expected result showing 
high numbers of colonies recovered on streptomycin and low numbers of colonies 
recovered on kanamycin in the absence of Cre recombinase. As the insertion of the loxP 
cassette also disrupts the reading frame of the aph gene and it would be expected that 
the cells would become sensitive to kanamycin because the lack of aph gene 
transcription. The low levels of numbers of kanamycin resistant colonies seen may be 
due to low levels of background recombination, or low levels of promoter activity (due 
to leakage from the streptomycin resistance gene through the T4 transcriptional 
terminator) driving low levels of aph gene expression. Although, the open reading 
frame for the aph gene is disrupted it is possible that the truncated Aph protein retains 
some activity.
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5. Results: Primary testing with cre plasmid
5.1. Introduction
The cre plasmid system was designed to identify meningococcal promoters that are 
induced during in vivo growth. To test the ability of the system to isolate inducible 
promoters, the system was tested using a well-characterised inducible promoter in E. 
coli. The vector pACYCaraCre illustrated previously in Figure 4.3 contains a 
promoterless cre gene transcriptionally fused to the araB promoter, which is regulated 
by the araC gene product.
The araB promoter present in the vector, is part of the araBPYD operon from S. 
typhimurium. Although the DNA sequences of the araB promoter and araC gene 
diverge from those in E. coli, complementation analysis has shown that cloned araB 
and araC genes from S. typhimurium complemented araB and araC mutant strains of 
E.coli and vice versa (Horwitz et. al., 1981).
The AraC protein is a transcriptional regulator that can form a complex with L- 
arabinose. In the presence of the sugar, AraC binds to two adjacent sites (aral\ and 
aral-i) that are in close proximity to the tfraBAD operon. Also, cyclic AMP (cAMP) 
complexes with cAMP activator protein (CAP) and binds to the DNA to further 
stimulate AraC binding to Ii and I2.
In the absence of L-arabinose, the AraC protein binds to the aral i site and the ara02 
site (located at a considerable distance from the araB AD  operon). The result of this 
binding event is the formation of a loop structure, preventing transcription (Figure 5.1). 
Basal transcription levels can be further repressed by introducing glucose to the growth
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medium. Glucose decreases cAMP levels, which in turn decreases the binding of CAP, 
required for activation.
Transcription
Figure 5.1. Schematic diagram of the regulation o f the P b a d  promoter (Invitrogen 1999 Product Catalogue)
The L-arabinose araBC operon is regarded as a tightly regulated inducible promoter 
system for use in gene expression studies, which is why this system was opted for in 
order to test the cre/loxP IVET system.
5.2. Introduction of pACYCaraCre into E. coli DH 5a cells 
containing pUS1604
The pACYCaraCre plasmid was electroporated into competent E.coli DH5a cells that
had already been transformed with pUS1604 (Chapter 4, Figure 4.14). The cells were
recovered in both SOC and the minimal RM media (containing glucose as the only
carbon source), and grown at 37°C for 1 hour. Cells were plated on LB agar plates
containing (i) streptomycin (25pgmr‘) and chloramphenicol (25pgmr’), or (ii)
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kanamycin (SOpgml"1) and chloramphenicol (25pgml"1), and incubated at 37°C 
overnight.
The numbers of colonies recovered on both types of media showed that there was 
growth in the order of 104cfu m l'1 on plates containing kanamycin, yet no growth on 
plates containing streptomycin. This suggested that the cre gene in pACYCaraCre was 
transcriptionally active although the ciraBC operon had not been induced with 
arabinose, and also had been repressed with glucose whilst the cells were recovered in 
RM media. Four kanamycin resistant colonies were grown overnight in LB culture and 
the lox and cre plasmids in each sample were extracted. The four plasmid samples were 
then digested with the restriction enzyme Seal which cuts once to linearise both the lox 
and cre plasmids.
The Seal digests were examined on a 1% agarose gel to check the sizes of the two 
plasmids (Figure 5.2), alongside separate lox and cre plasmids also cut with Sea 1 as the 
controls. The linear pACYCaraCre plasmid would run at 4.91cb (Figure 5.2, lane 6), 
whilst the linear pUS1604 would run at 6.1kb (Figure 5.2, lane 8) if there was no loxP 
recombination and the D. fragment was present. However, if loxP recombination had 
occurred, then the Q  fragment would loop out, resulting in a plasmid with the same 
structure as pUS1601 (Chapter 4, Figure 4.6) with a size of 3.9kb (Figure 5.2, lane 7). 
The gel confirmed that the Q  fragment had looped out (due to loxP recombination) as 
seen from the four samples in Figure 5.2, lanes 2-5 which all show the loxP plasmid 
rumring at a size of 3.9kb.
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Figure 5.2. Electrophoresis through a 1% agarose gel showing that Cre-m ediated loxP recombination has 
occurred in E. coli DH 5a cells transform ed with both pUS1604 and pACYCaraCre plasmids
Lane 1: XHindlU (400ng)
Lanes 2-5: Seal digests to linearise pUS1604 and pACYCaraCre plasmids extracted 
from the kanamycin resistant clones. DNA fragments running at 4.9kb and 3.9kb 
Lane 6: pACYCaraCre Seal digest running at 4.9kb 
Lane 7: pUS1601 Seal digest running at 3.9kb 
Lane 8: pUS1604 Seal digest running at 6.1 kb
5.3. Discussion
The above experiments indicate that in the E. coli test system the araBC operon appears 
to be active, even under conditions where it should be repressed. It is known from other 
systems that the Cre recombinase is very active in only very small amounts. It appears 
therefore that even low levels of transcription driven by the ara promoter under 
conditions of repression are capable of driving expression of Cre sufficient to 
recombine the lox? sites in pUS1604.
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6. Results: Cre vector construction
6.1. Cre gene under control o f Pbad promoter
As the cre gene in pACYCaraCre appeared to be transcriptionally active at all times, it 
was decided to construct a new vector containing a promoterless cre gene, downstream 
of a transcriptional terminator. The terminator was to be piaced between the test 
promoter and the cre gene coding sequence. All transcriptional terminators are known 
to be ‘leaky’ in the sense that they do not completely shut off transcription. Therefore 
the reason for placing the terminator between the promoter and the cre gene was to 
attempt to eliminate low levels of promoter activity, so that only strong promoters 
would be able to activate cre transcription.
To test the system, the cre gene would again be placed under the control of the L- 
arabinose promoter, but this time the construct would contain the entire araB AD 
promoter sequence ( P b a d )- The reasons for using this promoter sequence instead of the 
araBC operon from pACYCaraCre, were that firstly that pBAD promoter is an E. coli 
promoter, so regulation in E. coli was presumed to be more tightly controlled than the S. 
typhimurium araBC promoter in E. coli. Secondly, this cloning strategy would use the 
commercially available vector pBAD-TOPO™ (Invitrogen) (Figure 6.1), as a starting 
vector, which contained several potentially useful cloning sites, compared with the 
pACYCaraCre vector, which did not appear to have useful sites to clone in a 
transcriptional terminator.
Two primers HPcremcs+ and HPcrebcl- (section 3.1.10) were designed to PCR amplify 
a promoterless cre gene. The upstream primer HPcremcs+ incorporated three restriction 
sites (Hindlll, Smal and Pstl), a ribosomal binding site (RBS), and an ATG start codon
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so that the PCR product would create a transcriptional fusion with the P b a d  promoter 
when cloned into the pBAD-TOPO vector. As the P b a d  fragmentalso contained an ATG 
codon and RBS downstream of the promoter sequence, HPcremcs+ was designed so 
that the ATG provided by the cre gene would remain in the same frame as the ATG 
provided by the promoter.
The cre gene was PCR amplified with the proofreading Pwo polymerase using 
pACYCaraCre as the template, with primers HPcremcs+ and HPcrebcl-. The PCR 
product was A-tailed and cloned into pBAD-TOPO, in the TA cloning site of the vector, 
to produce pBAD-TOPO-Cre, (Figure 6.1).
The predicted sequence and frame of the fusion between the P b a d  promoter and the cre 
gene is illustrated in Figure 6.2.
pBAD
pcrcre
1098 bp
Figure 6.1. Construction o f  plasmid vector pBAD-TOPO-Cre
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Predicted sequence:
ATG GGC TCT GGA TCC GGT GAT GAG GAT GAC AAG CTC GCC CTT
CCC AAG CTT CCC GGG CTG CAG CCA TGC CAA TTT CAC AGT AAG 
GAG GTT TAA CTT ATG TCC AAT
Key:
Red = ATG start codon
Blue = First two codons of cre gene after ATG start codon 
Black = sequence from promoter 
Pink = sequence from cre insert forming transcriptional fusion 
Pink underline = Hind\\\, Smal and Ps/1 restriction sites 
Turquoise = ribosome binding site
Figure 6.2. Predicted sequence and frame o f the fusion between the Pbad promoter and cre  gene
The pBAD-TOPO-Cre construct was sequenced using the upstream primer pBAD 
forward (section 3.1.10) to make sure the ATG of the gene was in frame with an ATG 
provided by the vector (Figure 6.3).
start a o d a n  
f r c m  FBAD 
ptaroter
Figure 6.3. Sequence data showing that the prom oterless cre  gene has been cloned in the correct reading frame 
producing a transcriptional fusion with the P Bad prom oter in pBAD-TOPO-Cre
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6.2. T4 transcriptional terminator
Primers HPT4termPst+ and HPT4termPst- (section 3.1.10) were used to PCR amplify 
the T4 terminator sequence, using pUS1604 (which contains two T4 terminator 
sequences in the Q  fragment) as the template (Figure 6.4).
Q
2 kb
T4 14
Stem loop
t a g
C  A 
C -G  
C -G  
A-T 
G -C
stop codons
..TGG ATG A C C  TTT TGA ATG A C C  TTlT AAiT AGlA  TTA TAT TAC TAA n A  ATT G -C  TTT TTT ATT TTA AAA ATT TTT1CA CAA AAC
T4 translation & term ination signals
Figure 6.4. Diagram showing (A) structure o f f2  fragm ent, and (B) structure and sequence o f T4 terminator
The PCR product was digested with Pstl and cloned into pBAD-TOPO-Cre cut with the 
same restriction enzyme, creating the construct pBAD-TOPO-CreTerm (Figure 6.5). 
This plasmid now contained a T4 terminator sequence upstream of the promoterless cre 
gene, to suppress any weak promoter activity, but yet could allow strong promoter 
activity that could cause cre induction.
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pBAD
pcrMtem
185 Op
Figure 6.5. Construction o f the plasmid vector pBADCreTerm
The construct pBADCreTerm was digested with Pstl to release the 175bp T4 terminator 
fragment to confirm the cloning of the fragment (Figure 6.6).
5.4
-  0.175
Figure 6.6. Electrophoresis o f pBADCreTerm  digested with Pstl to release the T4 term inator fragm ent 
through a 2% agarose gel stained with ethidium bromide
Lane 1: XHindlll (200ng)
Lane 2: lOObp DNA ladder (500ng)
Lane 3: pBADCreTerm digested with Pstl releasing a 175 bp fragment 
Lane 4: T4 terminator PCR product (175bp)
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To ensure the cloned fragment was in the correct orientation, a PCR screen was 
performed using HPT4termPst+, and HPantimcs (an antisense primer with homology in 
the cre gene). Only clones that had a PCR product of 250bp contained the correctly 
orientated terminator (Figure 6.7).
1 2  3 4 5 6 7 8 9  10 11
250 bp
Figure 6.7. Electrophoresis confirm ing that the T4 term inator is in the correct orientation in plasmid vector 
pBADCreTerm
Lanes 1-10: clones screened by PCR (using colony as template). Lanes 1, 3, 4, 7 & 10 
contain a correctly orientated T4 terminator 
Lane 11:1 OObp marker (500ng)
6.3. Low copy number cre vector
Previous experiments performed by L. Docherty had demonstrated that locating the cre 
gene on a high copy vector led to high constitutive levels of Cre expression. The pBAD- 
TOPO parental vector utilised an origin of replication from pUC, which has a high copy 
number in E. coli. Therefore, in order to move the cre gene away from the high copy 
vector, the fragments of pBAD-TOPO-CreTerm and pBAD-TOPO-Cre were cut out of 
the two vectors respectively on Ndel-Bctl fragments. The sticky ends of the fragments 
were blunt ended, using the Klenow fragment of DNA polymerase, and were cloned 
into the low copy number vector backbone of pACYC184 with the P15A origin of 
replication. This was digested with HindlU-Bcfl, and blunt ended with Klenow. The
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Ndel-Bcll fragments containing cre and terminator, and cre only were cloned into the 
vector producing the plasmids pUS1624 and pUS1625 respectively (Figure 6.8).
Pst\
Had III Psll
Figure 6.8. Construction o f  plasmid vectors pUS1624 and pUS1625
Both pUS 1624 and pUS1625 were electroporated into the DH5a cells that already had 
been transformed with pUS1604 and made competent, and these were recovered in
104
minimal RM media. The cells were plated onto LB agar containing streptomycin (25 pg 
ml"1) and chloramphenicol (25pg ml"1).
6.4. Arabinose induction assay using method from pBAD-TOPO TA  
Cloning Kit™  Version G (Invitrogen)
Streptomycin resistant colonies co-transformed with pUS1624 or pUS1625 were grown 
overnight in 2ml cultures in RM media. The next morning, six tubes were inoculated 
with a 1:100 dilution of overnight culture into a 5ml volume of RM media. Each culture 
was grown to an OD600 of 0.6. The cultures in tubes 1-5 were then induced with a 
specific concentration of L-arabinose (0.2-0.00002%, final concentration), whilst the 
culture in tube 6 was repressed 0.2% D-glucose (final concentration) for 4 hours. 
Volumes of lOOpl were plated out in triplicate onto LB agar containing either 
streptomycin (25pg ml"1), ampicillin (lOOpg ml"1), chloramphenicol (25pg ml"1), or 
kanamycin (50pg m l'1), ampicillin (lOOpg ml"1) and chloramphenicol (25pg ml"1), in a 
10-fold dilution series (neat-10"6).
It was found that similar numbers of colonies grew 011 both streptomycin and 
kanamycin-containing plates with both pUS1624 and pUS1625 plasmids. Table 6.1 
shows the average numbers of colonies isolated on the 10"6 dilution plates on both 
streptomycin and kanamycin.
Table 6.1
Plasmids Average no. of streptomycin 
resistant colonies
Average no. of kanamycin resistant 
colonies
1 2 3 4 5 6 1 2 3 4 5 6
pUS1624 + 
pUS1604
12 19 23 13 14 19 12 21 20 13 16 20
pUS1625 + 
pUS1604
167 189 155 150 143 168 115 169 147 138 163 166
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Thirty colonies from each kanamycin plate were plated onto LB agar- containing the 
streptomycin to determine whether the colonies selected on kanamycin had undergone 
full loxP recomibination. Indeed, all of the colonies plated were resistant to both 
antibiotics, demonstrating that the colonies recovered consisted of mixed populations of 
cells. It seems a proportion of these cells containing intact pUS1604 plasmid had 
retained the Q  fragment (streptomycin resistant) whilst other cells contained plasmid 
where the Q  fragment had looped out (kanamycin resistant), or the same cell harboured 
both streptomycin and kanamycin resistant plasmids.
To determine whether this was indeed the case, plasmid DNA was extracted from six 
colonies (3 containing pUS1624 and 3 containing pUS1625) grown overnight in LB 
broth containing streptomycin (25 pg m l'1), kanamycin (50pg m l'1), and 
chloramphenicol (25|iig ml"1), shaking (250rpm) at 37°C. The DNA minipreps were then 
digested with the restriction enzyme Seal, to linearise both pUS1604 and 
pUS 1624/1625 plasmids to determine their sizes (data not shown). In each digest, it was 
clearly seen that there were two bands running at 6.1 kb and 3.9 kb, corresponding to the 
two sizes of the pUS1604 plasmid (i.e. plasmid that does not show loxP recombination 
by containing an intact Q  cassette, and plasmid that has lost the Q  cassette through loxP 
recombination). Therefore, it was clear that each colony contained both the 
streptomycin and kanamycin resistant species of pUS1604, producing the mixed 
phenotype. The sizes of pUS 1624/1625 remained constant (5.4kb and 5.2kb 
respectively) in the digested samples.
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6.5. Mixed cell phenotype population
The reasons why the outcome of the arabinose experiment indicated that all the colonies 
recovered consisted of a mixed population of cells could be due to a variety of factors. 
It is known that only two molecules of Cre recombinase are required to mediate two 
loxP sites to recombine (Guo et. al., 1997). If there were an instance where there is a 
low level of Cre protein expression, then only a small proportion of the loxP sites would 
recombine in some of the cells within each colony. There would be however, enough 
cells exhibiting a kanamycin resistant phenotype to produce the mixed population of 
cells within each colony, even if the majority of loxP sites had not recombined and the 
cells remained streptomycin resistant.
The mixed phenotype cell populations could be due to a combination of events. Firstly, 
the P b a d  promoter may have been too strong as a test promoter. It could be that the 
promoter was not as tightly regulated as required, so that it was able to drive the cre 
gene at all times, regardless of whether it was being induced or repressed. Secondly, the 
cre gene appears to be extremely sensitive with respect to its expression and so was 
induced at low levels of promoter activity, so that may mean that the promoter was 
behaving as expected under the conditions of repression and induction. This however, 
does not explain why a complete conversion to kanamycin resistance was not seen in 
any of the colonies from the samples that were induced with high levels of arabinose.
6.6. Western blot analysis
It was decided to investigate the first possibility that the P Ba d  promoter did not have the 
desired tight regulation needed by Western blot analysis with an antibody to the Cre 
recombinase. To do this, the arabinose induction assay was repeated using the E.coli
DH5a cells carrying the plasmid pUS1604, and either pUS1624 or pUS1625. After 4
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hours, of induction/repression of the P b a d  promoter, 1ml samples from each of the 7- 
induced/repressed samples were taken. The lml samples were centrifuged briefly so 
that the bacterial cells formed pellets at the bottom of the tubes, and the supernatant was 
discarded. The tubes were then stored at -20°C until required for Western blot analysis.
The Western blot analysis (sections 3.2.25-3.2.26) using a 1:10000 dilution of primary 
anti Cre antibody (Novagen) and a 1:5000 dilution of secondary HRP-conjugated 
streptactin antibody (Biorad) was performed to detect Cre expression. At first glance 
this analysis appears to show that the P b a d  promoter was regulating the expression of 
the cre gene as expected in pUS1625. When induced with high concentrations of L- 
arabinose (0.2-0.002%, Figure 6.9, lanes 2-4) it appeared there was a reasonable level of 
Cre expression that reacted with the anti Cre antibody (shown by the dark bands on the 
Western blot). There was also a lower level of Cre expression when the promoter was 
induced with 0.0002% arabinose (shown by the faint band in Figure 6.9, lane 5). No Cre 
expression appeared to be detected when the promoter was induced with lower levels of 
arabinose (0.00002 & 0.000002%, Figure 6.9, lanes 6 & 7), or when the promoter was 
repressed with 0.2% D-glucose (Figure 6.9, lane 8). Lane 10 (Figure 6.9) contained E. 
coli lysate without plasmid, and no band is seen. Lane 9 (Figure 6.9) contained 
denatured purified Cre recombinase (lU/pl) as the positive control (expected to run at 
the size of 38kD on the gel). However, no band was detected, even upon repeating the 
experiment and using greater quantities of Cre. The reason for this may be due to 
degradation of Cre prior to loading onto the gel.
Although Figure 6.9 shows the expected banding pattern, the bands are running at a 
lower molecular weight than was anticipated. Cre recombinase has a molecular weight
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of 38kD and the dark band seen in Figure 6.9 are running at approximately 32kD. 
Furthermore, there are faint bands in lanes 2-8 running at approximately 38 kD. If these 
bands are showing Cre expression, then the E. coli P b a d  promoter is not behaving in the 
correct fashion. However, as the dark bands are showing the anticipated banding 
pattern, it may be possible that Cre is running at a smaller size due to degradation or 
post-translational modification, or that the samples display a 'smile' profile (i.e. the 
electrophoretic motility of the samples on the gel are skewed and run in a curved way). 
The faint bands seen may be due to non-specific binding of the probing antibodies.
kD
50 
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Figure 6.9. W estern blot o f E. coli lysate containing pUS1625 (after arabinose induction) probed with primary 
anti Cre antibody and secondary HRP streptactin-conjugated antibody
Lane 1: Precision Protein marker (Biorad)
Lane 2: E. coli lysate induced with 0.2% L-arabinose 
Lane 3: E. coli lysate induced with 0.02% L-arabinose 
Lane 4: E. coli lysate induced with 0.002% L-arabinose 
Lane 5: E. coli lysate induced with 0.0002% L-arabinose 
Lane 6: E. coli lysate induced with 0.00002% L-arabinose 
Lane 7: E. coli lysate induced with 0.000002% L-arabinose 
Lane 8: E. coli lysate repressed with 0.2% glucose 
Lane 9 Purified Cre recombinase (lU/pl)
Lane 10: E. coli lysate
In contrast. Figure 6.10 showing the E. coli lysate samples containing pUS1624 (with 
the terminator) only shows the faint bands (again running at approximately 38kD, lanes
2-9) but not the dark bands. As pUS1624 contains the T4 terminator, which should 
reduce the trancriptional signal of the P b a d  promoter, and thereby the expression of the
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Cre recombinase. the result is consistant with the identification of the dark bands in
Figure 6.8 as Cre recombinase.
kd 1 2 3 4  5 6  7 8 9
25 -
Figure 6.10. W estern blot o f  E. coli lysate containing pUS1624 (after arabinose induction) probed with 
primary anti Cre antibody and secondary HRP streptactin-conjugated antibody
Lane 1: Precision Protein marker (Biorad)
Lane 2: E. coli lysate induced with 0.2% L-arabinose 
Lane 3: E. coli lysate induced with 0.02% L-arabinose 
Lane 4: E. coli lysate induced with 0.002% L-arabinose 
Lane 5: E. coli lysate induced with 0.0002% L-arabinose 
Lane 6: E. coli lysate induced with 0.00002% L-arabinose 
Lane 7: E. coli lysate induced with 0.000002% L-arabinose 
Lane 8: E. coli lysate repressed with 0.2% glucose 
Lane 9 Purified Cre recombinase (1 U/pl)
Whilst the Western blot results are puzzling, the P b a d  promoter appears to be 
functioning correctly, in that addition of arabinose induces Cre expression. However, it 
appears (from the genetic results, section 6.4) that a degree of transcriptional signal 
from the promoter is able to override the T4 terminator and cause a low level of Cre 
expression, which is enough to cause partial recombination of loxP sites within a 
proportion of cells, producing the mixed populations of streptomycin and kanamycin 
resistant cells.
6.7. Discussion
The results from Chapters 5 and 6 contradict each other. In Chapter 5, using pUS1604
in conjunction with pACYCaraCre caused complete loxP recombination and produced
entirely kanamycin resistant colonies without any induction of the cre gene by the
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araBC promoter. Conversely, in Chapter 6, using pUS1604 with pUS1624 or pUS1625 
produced mixed populations of cells so that each colony was now resistant to both 
streptomycin and kanamycin. At this stage in the project, the options were either to 
proceed with the Cre/loxP IVET system, or to abandon it and switch to an entirely 
different approach.
Apart from the Cre-loxP method, other IVET systems have been used to identify ivi (in 
vzvo-induced) genes. Methods that have been previously described are (i) the use of 
purine auxotrophic strains of S. typhimurium and P. aeruginosa into which a cassette 
containing the promoterless gene (purA and purEK  respectively) is fused to a promoter 
library. Therefore only promoter fusions that are induced in vivo and able to drive 
expression of the pur reporter gene, enabling the auxotrophic mutant to survive in vivo 
(see sections 2.1.2 and 2.1.3). However, one disadvantage of this method is that the 
promoter fusions need to be expressed throughout the infection. Therefore, it is possible 
that certain genes required for only one stage of the infection process may be missed.
(ii) A second method developed by Mahan et. al. (1995) involved making promoter 
fusions to promoterless cat-lacZ genes in S. typhimurium and then injecting the mutants 
into mice. The next stage was to administer chloramphenicol to the mice. Only 
promoters able to drive expression of the cat gene and provide resistance to the 
antibiotic were able to survive, thereby selecting for active ivi promoters. Finally, a 
second in vitro screen was performed to select for lacZ inactivity in vitro. Significantly, 
when the ivi genes selected from the experiment using pur A  fusions (section 2.1.2) 
were compared with the ivi genes selected from the cat fusions, only 50% were highly
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linked. This highlights the importance of using different selections to isolate different 
genes, and this method may not be suitable for a definitive screen.
(iii) A third option would be promoter fusion to another site specific recombinase 
reporter gene and selecting for gene expression by its targetting of specific sites 
resulting in the deletion of an antibiotic resistance marker (e.g. the tnpR gene used to 
identify Vibrio cholerae ivi genes by deleting an antibiotic resistance marker flanked 
between two res sites - section 2.1.3). Again, this method is likely to be highly sensitive 
to weak promoter activity and could also produce the mixed cell populations.
Whilst switching to another IVET system seemed attractive, it was unlikely that a new 
system would be 'up and ready' within the time constraints of this project. Therefore the 
decision was made that although the Cre-loxP system had not yet produced the desired 
results, it still had the potential to work, and so it remained a viable project to persevere 
with during the remaining time. This was decided because of the way in which the araC 
promoter being such a strongly expressed promoter, had caused a strong Cre response 
that was adequate to completely recombine all the loxP sites. Hence, it was felt that a 
strong promoter (e.g. from a library preparation) may be able to act upon the cre gene in 
the same way and cause complete loxP recombination.
In order for the system to work it was crucial that regulation of the cre gene was 
tightened, possibly by altering the way in which the gene was fused to the promoter. A 
transcriptional terminator had been cloned upstream of the cre gene to prevent 
readthrough of weaker promoter activity. It appears to have worked in the sense of the 
Western blot results (section 6.6). However, the weakness of this strategy is that many
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of the ivi promoters will be weakly expressed and therefore the Cre-loxP system may 
not be able to isolate these promoters. Even though the use of the transcriptional 
terminator does place a severe constraint on the system, it was felt that by keeping it 
would make it more likely to successfully be able to differentiate between an active 
promoter and inactive promoter.
Ultimately, the system was to be placed in the meningococcus to probe for 
meningococcal promoters specifically upregulated in vivo. This would involve placing 
the loxP-Q-aph cassette onto the meningococcal chromosome and constructing a shuttle 
vector. This would contain the promoterless cre gene, suitable antibiotic resistance 
marker (i.e. compatible for use in the meningococcus), uptake sequence (for efficient 
transformation into the meningococcus), and two compatible origins of replication (to 
provide replication in N. meningitidis and E. coli).
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7. Results: Using XLl-Blue E. coli strain
7.1. Introduction
Whilst it can be argued that the Western blot results (section 6.6) show that the Pbad 
promoter appears to function as predicted, and that the T4 transcriptional terminator 
does limit transcriptional signals from the promoter, there was obviously a low level of 
Cre expression in all the samples producing the mixed population of cells. However, 
these P b a d  promoter results contradict the circiBC results described in section 5.2. When 
the plasmid pACYCaraCre was transformed into cells already containing pUS1604, all 
the colonies recovered were kanamycin resistant and streptomycin sensitive and no 
colonies consisted of the mixed cell population. This indicated that the araBC promoter 
was very strong, and was not tightly regulated, so that cre gene expression was driven 
continuously. Hence, it appears that the P b a d  promoter may not be as strong as the 
araBC promoter, unable to induce to cre gene to full expression levels that would cause 
a complete shift from streptomycin resistance to the kanamycin resistance phenotype.
7.2. M aking cells competent
As there was the mixed population problems in DH5a E. coli cells it was decided to test 
the system in the XL 1-Blue E. coli strain, another recAl mutant available in the 
laboratory at this time. This was because the DH5a strain was grown in the laboratory 
and so there was the possibility that the cells were not actually correct recAl mutants. 
The XL 1-Blue strain had been commercially manufactured and therefore there was 
greater confidence that the cells were correct recAl mutants.
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XL 1-Blue cells were made electrocompetent and pUS1604 was electroporated into the 
cells. Transformants were recovered on LB plus streptomycin (25pg m l'1) and 
ampicillin (lOOpg m l'1), and again made electrocompetent. These cells were then 
further electroporated with either pUS1624 or pUS1625, and the double transformants 
were selected on the above antibiotics plus chloramphenicol (25 pg m l'1).
Similar numbers of colonies were recovered on both streptomycin and kanamycin- 
containing plates. Again, thirty colonies from each plate were plated onto plates 
containing the other antibiotic, and each colony was found to be resistant to both 
antibiotics.
7.3. Arabinose induction
The arabinose induction experiment was repeated with both pUS1624 and pUS1625- 
transformed XL 1-Blue cells. This time however, the samples were only induced with
0.2% L-arabinose (because it was known that this level of arabinose produced Cre 
expression in pUS1625), and repressed with 0.2% glucose. The numbers recovered on 
the 10'6 dilution plates were again similar and are shown in Table 7.1.
T a b le  7.1
0.2% L-arabinose 0.2% D-glucose
Streptomycin
resistant
Kanamycin
resistant
Streptomycin
resistant
Kanamycin
resistant
XLI-Blue + 
pUS1624 + 
pUS1604
19 23 20 23
XL 1-Blue + 
pUS1625 + 
pUS1604
56 59 45 41
115
Fifteen colonies from each plate were then cross-streaked onto plates containing the 
other antibiotic. It was found that all the colonies cross-streaked comprised of mixed 
populations of cells. This was in contrast to the earlier result showing that when the 
plasmid pACYCaraCre (section 5.2) was transformed into cells already containing 
pUS1604 (loxP plasmid), complete loxP recombination occurred so that all the cells 
were kanamycin resistant. It was therefore concluded that the P b a d  promoter was not as 
strong as the ctrciBC promoter used in the previous experiment.
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8. Results: In vitro assessment of the activity of Cre
recombinase
8.1. Introduction
Still unclear, was the discrepancy between the results using the plasmids containing the 
arcBC promoter (section 5.2), and the P b a d  promoter (sections 6.4 & 7.3). The former 
plasmid (pACYCaraCre) caused complete loxP recombination, when introduced into E. 
coli cells already containing pUS1604, so that streptomycin resistance was entirely lost 
and the cells became fully kanamycin resistant. In contrast, the plasmids containing the 
P b a d  promoter (pUS1624 and pUS1625) always produced a mixed population of 
antibiotic resistance phenotypes, after induction or repression of the promoter.
This difference could be due to the regulatory elements in the promoters and the level of 
cre expression that results from the activities of the promoters. It appears that the 
araBC promoter was causing the over expression of cre with no regulation, resulting in 
complete looping out of all the loxP sites. Conversely, the P b a d  promoter was not 
tightly regulating cre expression so that there was always a low level of Cre, able to 
recombine a proportion, but not all, of the loxP sites. Also, the copy number of the 
plasmids (500-700 copies of pUS1604 per cell; 10-12 copies of pUS1624/5 per cell) 
could also influence the relative ratios of Cre molecules: loxP sites within the cellular 
environment. It was therefore decided to conduct an in vitro assay to find the level of 
Cre required for complete loxP recombination in pUS1604, without cellular elements 
that could affect the expression of the gene and the recombination events.
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It is known that only two molecules of Cre are required for one loxP recombination 
event to occur (Guo et. a l, 1997). The plasmid pUS1604 carries the pMBl replicon, 
which provides a high copy number within a host cell. This means that there can be 
between 500-700 copies of pUS1604, each containing two loxP sites. Consequently, 
there will be twice as many molecules of Cre recombinase required per host cell (as 
there is copies of the pUS1604) for complete loxP recombination. If the cre gene is 
expressed at a low level (induced by very weak promoter activity), then not enough Cre 
recombinase will be present in the host bacterial cell for complete loxP recombination. 
Therefore only a proportion of sites would then recombine resulting in mixed 
populations of streptomycin and kanamycin resistant cells.
8.2. In vitro assay to assess the amount of pure Cre recombinase 
required to recombine loxP  sites in pUS1604
An in vitro experiment was performed to determine the amount of pure Cre 
recombinase required for complete loxP recombination in pUS1604. Duplicate samples 
of pUS 1604 were incubated at 37°C for 1 hour with various amounts of pure Cre 
recombinase (Novagen). The protocol supplied by Novagen recommended the use of 1 
unit (60 - 80ng) of the pure Cre recombinase for the recombination of 250-500ng of 
DNA containing loxP sites in an in vitro reaction.
The reaction samples comprised of lOOng of pUS1604, Cre recombinase (0, 0.1, 0.5, 1, 
2, 4, 10 units), and Cre buffer in a total reaction volume of 30j.il. After incubation, the 
reaction was terminated by heating at 70°C for 5 minutes and then was allowed to cool 
at room temperature, lj.il of a 1/10 dilution of each reaction mix (containing 
approximately 0.8ng of plasmid DNA) was transformed into 20pl of competent E. coli
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DH5a cells. After the tranformation procedure, 100j.il of 10'1 dilution was plated onto 
streptomycin and kanamycin plates.
It was expected that cells transformed with the negative control samples (in which there 
was no Cre present in the reaction) would be streptomycin resistant and kanamycin 
sensitive because loxP recombination would not have taken place. Also anticipated was 
that a high amount of Cre would cause the antibiotic resistance to shift from 
streptomycin to kanamycin resistance. However, at this stage it was unclear whether a 
low amount would also shift the antibiotic resistance.
The actual results from the experiment are shown below as mean results from the 
duplicate samples in Table 8.1 and Figure 8.1.
Table 8.1
Amount of Cre added to 
reaction (Units)
Mean no. of streptomycin 
resistant colonies
Mean no. of kanamycin 
resistant colonies
0 550 2
0.1 65 480
0.5 71 595
1 56 615
2 69.5 525
4 59 640
10 50 510
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Number of colonies recovered on Streptomycin and Kanamycin plates with increasing units of Cre
■  Streptomycin resistant Q Kanamycin resistant
1000 ---
0  0.1  0 .5  1 2 4  10
Units of Cre (U)
Figure 8.1. Graph showing the mean results from the in vitro experim ent
The result for the negative control was as expected, with high numbers of streptomycin 
resistant colonies recovered, and negligible numbers recovered on kanamycin. Indeed, 
the percentage of kanamycin resistant colonies recovered was 0.36% of the number of 
streptomycin colonies recovered. This result appears to agree with the result from the 
experiment investigating the level of background resistance to kanamycin in the 
absence of Cre (section 4.6), where again, the percentage level of kanamycin resistance 
was less than 0.5%.
Cells transformed with the samples that were incubated with different amounts of Cre 
all showed similar numbers of kanamycin resistant colonies. This result showed that 
complete loxP recombination (under in vitro conditions), had occurred in all the 
samples, which indicated that the pure Cre recombinase was extremely active, because 
1/10th the recommended amount of Cre (0.1U) showed a similar recombining ability to 
that from an excess of Cre (10U).
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As similar levels of loxP recombination had occurred in all the samples, it would be 
expected that coinciding with the high numbers of kanamycin resistant colonies, the 
numbers of streptomycin colonies would be negligible. However, there was still 
significant numbers of streptomycin resistant colonies recovered, although there was a 
drop compared to the numbers recovered from the negative control.
8.3. Calculation to estimate the number of Cre molecules and loxP  
sites
An estimate can be made of the number of Cre molecules required for complete loxP 
recombination. Firstly, the number of pUS1604 molecules is calculated as follows:
lpg  of lOOObp double stranded DNA = 9.1 x 1011 molecules (NEB 2000 catalogue)
.-. 1 pg 6105bp pUS 1604 DNA = (1000/6105) x 9.1 x 1011 = 1.49 x 1011 molecules 
.-. lOOng pUS 1604 DNA = 1.49 x 1010 molecules
Number of loxP sites = (1.49 x 1010) x 2 = 2.98 x 10l° (2 sites per pUS1604 
molecule)
Four Cre molecules are required per loxP recombination event (between 2 sites) 
i.e. 2 Cre molecules per loxP site
.'. Minimum number of Cre molecules required to recombine all loxP sites = (2.98 x 
10i0) x 2 = 5.96 x 1010 molecules
Next, the number of moles of 1 unit of Cre is calculated:
Number of moles = mass (g) / molecular weight (Da)
1 2 1
1 unit = 60-8Ong average mass = 70ng = 7 x 10~8 g
Molecular weight of Cre = 38kDa = 3.8 x 104 Da 
.-. Number of moles = 7 x 10'8 / 3.8 x 104 = 1.84 x 10'12
Finally, the number of molecules in 1 unit of Cre is calculated:
1 mole contains Avogadro’s number of molecules = 6.02 x 10
1.84 x 10"12 moles contains 1.84 x 10"12 x 6.02 x 1023 = 1.11 x 1012
i.e. There is 1.11 x 1012 Cre molecules in 1 unit
8.4. Discussion
The theoretical minimum number of Cre molecules required to recombine the loxP sites 
in lOOng of plasmid was estimated as 5.96 x 1010. The estimated number of Cre 
molecules in each of the samples in the assay ranged between 1.11 x 1011 and 1.11 x 
1013 (0.1-10 units). Therefore, it would be expected that the 10-1000-fold excess of Cre 
molecules would be able to completely recombine all of the loxP sites within each of 
the samples containing Cre, resulting in all of the transformed cells being resistant to 
kanamycin and senstive to streptomycin. However, this does not take into account the 
enzyme kinetics of Cre in vitro.
Cre is a Type I isomerase enzyme that does not require cofactors or energy to 
recombine the loxP sites. This means that the reaction will not be pushed all the way to 
produce a final product (in this case, the final product being kanamycin resistance) and 
a state of equilibrium will be reached instead. Indeed, the results from the in vitro 
experiment show this. All of the samples containing Cre and then transformed into the 
E. coli cells produced similar, maximum numbers of kanamycin resistant colonies, but
1 2 2
also streptomycin resistant colonies were recovered (approximately 10-fold less in 
number than the kanamycin resistant colonies).
Also, it should be considered that there might be instances of intermolecular 
recombination instead of intramolecular recombination. Intramolecular recombination 
occurs between two loxP sites within a single plasmid, resulting in the looping out of 
the streptomycin resistance gene (jQ fragment) and the reconstitution of a funtional 
kanamycin resistance (aph) gene. Intermolecular recombination however, occurs 
between two loxP sites, each from different plasmids, creating plasmid dimers that 
would harbour more than one copy of the streptomycin resistance gene.
These two descriptions can be used to explain the result from the Cre-loxP system in the 
in vitro experiment. However, in living bacterial cells the system will behave 
differently. The production of plasmid dimers from intermolecular recombination is 
possible, but the plasmids would be unstable and unlikely to exist in the host cell. 
Furthermore, in the bacterial cell the kinetics of the Cr e-loxP reaction can be pushed 
away from the equilibrium point, as demonstrated in section 5.2 when Cre was able to 
completely recombine the loxP sites, so that the cells were fully kanamycin resistant 
and streptomycin sensitive.
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9. Results: Attempt to integrate the loxP-Q-aph cassette into 
the N. meningitidis chromosome
9.1. Introduction
It was felt that the Cre-loxP system was as good as it was going to get within the time 
constraints of the project. Until this point, the system designed to identify N. 
meningitidis promoters was applied in E. coli. This had been convenient because 
working with E. coli is relatively safe. Furthermore, there are various fully characterised 
E. coli vectors that were suitable for the various cloning stages, compared with the few 
cloning vectors that contain the neisserial origin replication, which are largely 
uncharacterised, making cloning strategies relatively difficult. Although there are 
advantages in placing the CrQ-loxP system in E. coli, obviously it would be preferable 
to have the system working in N. meningititdis because the promoters will function 
optimally in the correct host, the eventual aim of the project.Furthermore, it had been 
considered that a reason why there were mixed populations of cells was because the 
loxP plasmid (pUS1604) carries the pMBl replicon that provides 500-700 copies of the 
plasmid per host cell. Therefore, there could be too many copies of loxP sites for Cre to 
recombine.
In order for ultimate success, both the Cre and loxP components would have to be 
transferred into the meningococcus. To make the improvements to the system we aimed 
to integrate the loxP-12 -aph cassette into the chromosome of N. meningitidis H44/76 
strain, and also construct a shuttle vector containing the promoterless cre gene, a 
transcriptional terminator, and neisserial and E. coli origins of replication. As the cre 
constuct was to provide two origins, the aim was to clone a meningococcal genomic 
library in E. coli and then to transform the recombinant clones into N. meningitidis
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(containing the loxP-Q-aph cassette), and perform the desired experiments to identify 
ivi promoters.
There is only one known neisserial plasmid available [pMGC18.1 derived from pLES2 
(Nassif et. al., 1991)] that has been partially characterised. It was intended that the cre 
gene and genomic DNA library fragments were to be cloned into this plasmid. As there 
is no other known neisserial plasmid with a complementary origin of replication (i.e. 
required to co-exist with the pMGC 18.1-derived cre plasmid), it was decided that the 
loxP-Q-aph cassette was to be integrated into the chromosome instead of being cloned 
into a plasmid. This would solve the problem of mixed cell phenotypes, but also means 
the risk that low levels of Cre expression (not necessarily due to promoter activity) 
would lead to 100% loxP recombination and the looping out of the streptomycin 
resistance gene under all circumstances.
To allow for the integration of the loxP-Q-aph cassette into the meningococcal 
chromosome, a strategy involving double crossover homologous recombination was to 
be performed. This would involve transforming a plasmid vector into N. meningitidis 
(carrying the loxP-Q-aph cassette) that would target two sequences within a specific 
gene in the N. meningitidis chromosome and ‘knock out’ a portion of that gene. The 
‘knocked out’ gene fragment would then be replaced by the loxP-Q-aph cassette, 
rendering the gene non-functional (Figure 9.1).
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Wild type chromosome
Chromosome after double crossover
Double crossover
= wild type DNA
_ regions of 
homology
= plasmid DNA to be integrated
Figure 9.1. Schematic diagram to show integration of plasmid DINA by double crossover homologous 
recombination
The gene that was to be targeted for the ‘knockout’ by double crossover was the recA 
gene. In E. coli, the recA gene product is essential for homologous recombination 
(Smith, 1987) and DNA repair (Ossanna et. al., 1986). The recA gene was chosen 
because mutating this gene eliminates the possibility of homologous recombination 
within the plasmid DNA and therefore remains stable within the bacterial cell. Also, the 
gene is dispensible because it is not essential for bacterial survival and growth. 
Furthermore, E. coli recA mutants were used in the previous experiments to minimise 
the chances of loxP recombination being due to homologous recombination rather than 
Cre-induced site-specific recombination. There is substantial evidence that an analogous 
protein functions similarly in N. gonorrhoeae (Koomey & Falkow, 1987). Therefore,
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for the same reasons as outlined above, the recA gene was targeted for mutation by 
knockout for the integration strategy of the loxP-Q-aph cassette into the chromosome.
9.2. Construction of vectors for targeting knockout integration of 
loxP-f2  cassette into recA  gene
The components necessary for a knockout integration of the loxP-Q-aph cassette into 
the recA gene of the N. meningitidis chromosome was a lObp neisserial uptake 
sequence (necessary for transformation of the plasmid into N. meningitidis, section
1.2.9), and two sequences of homology to regions within the recA gene. The starting 
plasmid would be pUS 1604.
Firstly, the lObp neisserial uptake sequence (GCCGTCTGAA) was to be cloned. Dr. C. 
Johnson (MGL) provided oligonucleotide primers UptakeFT and UptakeRR (section
3.1.10), which had already been annealed and ldnased. The DNA fragment contained 
EcoRl and Sacl restriction ends, and therefore the fragment was compatible to clone 
into the pUS1604 vector that also contained these restriction sites. The insert DNA was 
cloned into the vector and the plasmid pUS1607 was produced (Figure 9.2a) and was 
confirmed by sequence analysis (Figure 9.2b).
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uptake sequence
2 2  b p
Figure 9.2a. Diagram showing plasmid construction o f pUS1607
fccRi uptake sequence saci
Figure 9.2b Sequence data confirm ing that the uptake sequence was cloned into pUS1607
The next step was to remove the bla gene from the plasmid. This was necessary because 
the bla gene codes for resistance to the antibiotic ampicillin. Ampicillin is related to the 
antibiotic benzyl penicillin, which is used in the treatment of meningococcal disease. If 
the bla gene were present in a plasmid that was to be transformed into the 
meningococcus, there would be a risk of producing a N. meningitidis mutant that could 
resist killing by benzyl penicillin.
The bla gene was excised from pUS1607 by digesting the plasmid with the restriction 
enzymes AspEl and AatlI, producing two DNA fragments of 5.2kb and 0.9kb in size.
128
The 5.2kb fragment was excised from a 1% agarose gel, and the DNA was extracted 
through a Qiagen gel extraction column. As the sticky ends produced were 
incompatible, these had to be blunt-ended with the T4 polymerase enzyme before 
ligation to circularise the DNA. The resulting plasmid, pUS1608 (Figure 9.3) was now 
0.9kb smaller than pUS1607, and this size difference was confirmed by agarose gel 
analysis (Figure 9.4).
Figure 9. 3. Construction o f plasmid pUS1608
kb 1 2 3
23.0
9.4
6.5
4.3
Figure 9.4. Electrophoresis showing size difference between linear plasmids pUS1607 and p(JS1608 through a 
1% agarose gel stained with ethidium bromide
Lane 1: X Hindlll marker (200ng)
Lane 2: linear pUS1608 (5.2kb) (75ng)
Lane 3: linear pUS1607 (6.1 kb) (400ng)
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Integration of plasmid DNA into a chromosome by the knockout method requires two 
sequences of homology cloned into the delivery plasmid to flank the DNA that is to be 
integrated. Two sequences were chosen as the homology regions from the N. 
meningitidis recA gene (Figure 9.5).
HpK° l HPK03
 ►  ►
homology 1 homology 2
<----- <-----
HPK02 HPK04
RecA
1043 bp
N. meningitidis genome sequence coordinates: 1489585 to 1488542 (reverse 
Strand) (http ://w w w .tig r.org)
Figure 9.5. Schematic diagram showing the two homology regions from the recA  gene to be PCR amplified 
and the PCR primer annealing sites
The first homology sequence was amplified in a PCR reaction using the primers 
HPKOl and HPK02 to produce a 243bp PCR product with the restriction sites NdeI 
and EcoRl incorporated at either end (Figure 9.6). This PCR product was named 
homology 1.
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Figure 9.6. Electrophoresis o f homology 1 PCR product through a 2% agarose gel stained with ethidium  
bromide
Lane 1: lOObp marker (500ng)
Lanes 2-4: homology 1 PCR products (243bp)
The second homology sequence was amplified in a PCR reaction using the primers 
HPK03 and HPK04. This reaction produced a 225bp PCR product with the restriction 
sites Still and AflWI at either end (Figure 9.7).
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Figure 9.7. Electrophoresis o f hom ology 2 PCR product through a 2% agarose gel stained with ethidium  
bromide
Lane 1: 1 OObp marker (500ng)
Lanes 2-4: homology 2 PCR products (225bp)
The homology 1 PCR product was digested with Ndel and EcoKl and cloned into 
pUS1608 that had been digested with the same restriction enzymes. The resulting 
plasmid, pUS1609 (Figure 9.8) was confirmed to contain the homology 1 insert by PCR 
screening using HPKOl and HPK02 primers to produce the expected 243bp PCR 
product (Figure 9.9).
homology 1
2 5 6  bp
Figure 9.8.Construction o f plasmid pUS1609
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Figure 9.9. Electrophoresis confirm ing the presence o f homology 1 (243bp insert) in pUS1609 through a 2%  
agarose gel stained with ethidium bromide
Lane 1: lOObp marker (5 OOng)
Lanes 2-12: clones screened by PCR (using colony as template)
Lane 13: positive control (using meningococcal genomic DNA as template)
Lane 14: negative control (using pUS1608 as template)
The homology 2 PCR product was digested with Stul and AfRW and cloned into 
pUS1609 that had been digested with these restriction enzymes. This cloning step 
constructed the plasmid pUS1610 (Figure 9.10), and 4 out of 10 clones screened were 
confirmed to contain the homology 2 insert by PCR analysis using the primers HPK03 
and HPK04 to produce the expected 225bp product (Figure 9.11).
Figure 9.10. Construction o f plasmid pUS1610
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Figure 9.11. Electrophoresis confirm ing the presence o f homology 2 (225bp insert) in pUS1610 through a 2% 
agarose gel stained with ethidium bromdide
Lane 1: lOObp marker (500ng)
Lanes 2-11: clones screened by PCR (using colony as template). Lanes 2, 6, 7 & 11 are 
positive, indicating the presence of homology 2 insert in pUS1610 in clones 2, 6, 7 & 
11
Lane 12: positive control (using meningococcal genomic DNA as template)
Lane 13: negative control (using pUS1609 as template)
Using circular DNA increases the chances of integration by single crossover that would 
integrate the entire plasmid instead of just the \oxP-Q-aph cassette. This was not 
desirable because of the instability associated with plasmid integration by single 
crossover, with a high chance of the plasmid ‘looping’ back out from the chromosome. 
It was decided therefore to linearise pUS1610 because the chance of integrating plasmid 
DNA by double crossover is greater with linear DNA than with circular plasmid. As a 
final step (before the introduction of the loxP-Q-aph cassette into the meningococcus) 
the two homology sequences and the loxP-O-aph cassette were excised from pUS1610 
by digesting with the restriction enzymes Ndel and AftllI. This produced a 3.8kb linear 
fragment (Figure 9.12) that was cut from a 1% agarose gel and the DNA extracted 
through a Qiagen gel extraction column and used for integration into the meningococcal 
genome (Figure 9.13).
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Figure 9.12. Production o f linear fragm ent to be used to integrate the loxP-O -aph  cassette 
Figure 9.13. Strategy to integrate the loxP-O -aph  cassette into N. m eningitidis chromosome
Wild type recA g en e  
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crossover
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9.3. Confirmation that the wild type N. meningitidis H44/76 strain is 
sensitive to streptomycin and kanamycin
The loxP-O-aph cassette contains two antibiotic resistance markers, providing 
resistance against streptomycin in the first instance, and kanamycin resistance upon 
loxP recombination. It was therefore critical to make sure that the meningococcal strain 
that was to be transformed with pUS1610 was sensitive to the two antibiotics. The 
meningococcal strain chosen was the group B strain H44/76, from which genomic DNA
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had been previously extracted and digested for the genomic DNA library production in 
E. coli (Section 3.1.8 & Chapter 11).
The wild type H44/76 strain was streaked onto blood agar plates containing 
streptomycin (25pg m l'1), and kanamycin (30jag m l'1). A negative control plate that did 
not contain any antibiotics was also streaked. The plates were incubated for 48 hours at 
35°C, 6% CO2, and the plates were then checked for growth. There was no growth seen 
011 the streptomycin and kanamycin plates, and there was confluent growth on the 
control plate that did not contain any antibiotics. This demonstrated that the wild type 
H44/76 strain was suitable as a host strain because there was no background antibiotic 
resistance, which would mask the antibiotic resistance markers on the integrated 
cassette.
9.4. Transformation of linear pUS1610 into N. meningitidis H44/76 to 
produce knockout mutant
A fresh subculture of H44/76 wild type strain was grown overnight on the blood agar 
that did not contain any antibiotics at 35°C, 6% C 02. Incubation at 35°C is the optimal 
temperature for pilus formation that is required for natural competence of Neisseria. 
Approximately 50ng of the linearised plasmid DNA was transformed into N. 
meningitidis (section 3.2.19). A negative control of lp l of water was also transformed 
into the strain. A volumes of 0.5ml of the transformed cell culture was plated onto a 
blood agar plates containing either streptomycin (25pg ml"1) or kanamycin (30pg ml"1) 
and incubated for 48 hours at 35°C, 6% C 02. The numbers of colonies recovered are 
shown in Table 9.1.
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Table 9.1
Transformation Number of colonies 
recovered on streptomycin
Number of colonies 
recovered on kanamycin
Linear pUS1610 129 0
Water control 0 0
The results looked promising as it appeared that the loxP-Q-aph gene had integrated 
into the meningococcal chromosome because the cells transformed with the DNA 
produced colonies that were resistant to streptomycin, whilst the negative control cells 
transformed with water remained sensitive to streptomycin. Also, the cells remained 
sensitive to kanamycin, indicating that no loxP recombination had taken place if the 
cassette had integrated into the chromosome.
9.5. PCR screening of streptomycin resistant meningococci
Ten colonies from the 129 that were recovered were Gram stained and examined by
microscopy. The cells were confirmed as Gram-negative diplococci. The next stage step 
to screen the streptomycin resistant colonies by PCR to check for integration of the 
cassette. The primers and HPKAN+ and HPK04 were used to produce a PCR product 
of 1.2kb if successful integration had occurred, but no product if integration had not 
occurred (Figure 9.14).
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Figure 9.14. Schematic diagram showing positive PCR screening result from successful integration o f loxP- 
Oaph  cassette
All 129 colonies were screened. The results however, indicated that integration of the 
loxP-Q-aph cassette had not occurred because all the PCR results were negative. This 
result contradicted the transformation results showing the meningococcal cells 
transformed with the linear plasmid DNA produced streptomycin resistant colonies 
(whereas the cells transformed with water remained streptomycin sensitive), indicating 
that the cells transformed with the plasmid DNA contained the streptomycin resistance 
gene, provided by the loxP-Q-aph cassette. It was therefore decided to carry out a final 
check to determine whether integration of the cassette had occurred or not by Southern 
blot analysis.
9.6. Southern blot analysis
It was decided to use a 427bp fragment from the aph gene as the hybridising probe in 
the Southern blotting procedure. Digesting pUS1610 with Clal and HindlU restriction 
enzymes isolated this fragment, which was excised from a 2% agarose gel and the DNA 
extracted through a Qiagen gel extraction column. The DNA fragment was then labelled 
with Digoxigenin-11-dUTP (section 3.2.21).
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Genomic DNA was extracted from eight of the streptomycin resistant colonies. 
Approximately 500ng of each DNA sample was digested with Clal and Narl restriction 
enzymes. The digests were run on a 1% agarose gel alongside a positive control sample 
of the 427bp Hindlll-Clal fragment from the aph gene, and a negative control of Clal- 
Narl digested wild type H44/76 DNA. Next, the digested DNA fragments on the 
agarose gel were transferred onto a nitrocellulose membrane by the Southern blotting 
procedure, and the DIG-labelled probe was incubated with the membrane (section 
3.2.22). If the loxP-Q-aph cassette had integrated into the meningococcal chromosome, 
then the 1.2kb Clal-Narl fragment (containing the hybridisation site for the probe) 
would be seen on a developed X-ray film because of the presence of the DIG-labelled 
probe that would be detected by the chemiluminescent reaction. Conversely, if 
integration had not occurred, then the probe would not hybridise and consequently there 
would be a negative result (Figure 9.15).
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1663 bp
450 bp
uptake sequence P(aph) Clal HinMX
linear pUS1610 cassette I | ==H
homology 1
to*P  ^ Iprobe homology 2
hybridisation
In aph gene
1238 bp 
<  ►
Figure 9.15. Schematic diagram showing positions o f restriction sites and probe hybridisation site
The Southern blot results showed final confirmation that the loxP-Q-aph cassette had 
not integrated into the N. meningitidis chromosome in the eight samples that were 
analysed (Figure 9.16). This established the PCR results were correct. An explanation 
why there were streptomycin resistant colonies recovered from the transformation, 
could be that the plasmid may have re-circularised and integrated by a single crossover 
event to provide streptomycin resistance, and then looped back out because of 
instability. It is unlikely that the plasmid itself provided the resistance because pUS1610 
was a suicide plasmid, as it did not carry a neisserial origin of replication that is 
necessary for plasmid multiplication independently from the main bacterial 
chromosome.
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integrated cassette
probe
hybridisation 
In aph gene
Figure 9.16. Southern blot o f genomic DNA extracted from streptomycin resistant meningococcal colonies 
probed with a 450bp DIG-labelled aph gene fragment
Lane 1: DIG-labelled X HindlU marker (250ng)
Lane 2: positive control (aph gene fragment) (lOng)
Lanes 3-9: streptomycin resistant genomic digest samples (approximately 500ng)
Lane 10: negative control (wild type genomic digest sample) (approximately 500ng)
Due to time constraints, the work to integrate the loxP-Q-aph cassette into the 
meningococcal chromosome was taken over by Dr. C. Johnson. Also, the cre- 
containing plasmid would require modification so that it could replicate in N. 
meningitidis. This would involve constructing a shuttle vector, capable of conjugation, 
by placing the promoterless cre gene and terminator sequence into a conjugative 
plasmid containing both the E. coli and neisserial origins of replication. This would 
enable the construction of a meningococcal genomic DNA library in E. coli, and then 
transferring the library clones from the E. coli to N. meningitidis by conjugation. Again, 
Dr. Johnson took on this work, which is currently underway.
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10. Results: Construction and testing of a translational fusion 
of the Pbad promoter with promoterless cre gene in an
arabinose assay
10.1. Introduction
Both the arabinose and serum experiments used transcriptional fusions of the promoters 
with the cre gene in the vectors. A transcriptional fusion occurs when a promoterless 
reporter gene that carries the translational signal (ribosome binding site and ATG start 
codon) is joined to a DNA fragment to be tested for promoter activity (Figure 10.1 A). 
Ideally, a transcriptional fusion should be used when attempting to identify promoter 
activity from a genomic DNA library because all that is required from the potential 
promoter would be the consensus sequences.
However, because results from the arabinose assay showed that there were mixed 
populations of cells within each colony, it appeared that regulation of the cre gene by 
the P b a d  promoter was not optimal. This is because there was little difference in the 
number of colonies recovered on the streptomycin and kanamycin plates from the 
samples induced with arabinose, or repressed with glucose. Therefore, it was considered 
that the level of promoter control on the regulation of the cre gene could be significant. 
It was decided to investigate this further by constructing a vector containing a 
translational fusion of the P Ba d  promoter with the promoterless cre gene. In 
translational fusions, the promoter contains the translational signals, and the gene must 
be joined with the promoter fragment in such a way that the correct reading frame is 
maintained (Figure 10.I B ) .  A translational fusion between the cre gene and P b a d
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promoter could result in tighter regulation of the gene because the translational fusion 
incorporates translational as well as transcriptional signals.
A. Transcriptional P bad -35 -10 | RBS ATG cre
B. Translational Pbad -35 -10 RBS “ I cre
□ promoter test sequence □ reporter gene
Figure 10.1. Schematic diagram showing comparison of transcriptional and translational fusion between the 
P b a d  promoter and cre  gene
Newman and Shapiro (1999) have compared gene regulation using transcriptional and 
translational fusions. The authors studied the differential regulation of the fiu  locus (an 
E. coli iron-regulated OMP) by making transcriptional and translational fusions o ffiiu- 
lacZ. Regulation of the fiu gene changes during colony morphogenesis, because of iron 
availability in the growth medium. Cells in the centre of a colony express Fiu early in 
development whilst iron is available. During late colony development, cells in the 
centre are growing under iron limiting conditions and show decreased expression of 
Fiu, whilst cells at the edges are growing in high levels of iron and show increased 
levels of expression of Fiu. The researchers measured fiu  expression (by measuring p- 
galactosidase activity) of cells in the centres and outer edges of colonies grown on 
media containing high and low levels of iron, and were able to compare the expression 
levels of the transcriptional and translational fusions. They found that there was a higher 
ratio offiu  expression between the cells in the edges and centres of colonies when using 
translational fusions rather than transcriptional fusions.
143
With this in mind, it was hoped that making a translational fusion between the cre gene 
and the P b a d  promoter would also produce a higher ratio, making it easier to 
differentiate between the numbers of strepomycin and kanamycin resistant colonies 
recovered after performing the arabinose induction assay.
10.2. Construction of the translational fusion vector
The aim was to PCR amplify a promoterless cre gene without an ATG start codon. The
P b a d  promoter sequence would provide E. coli consensus sequences, ribosomal binding 
site, and ATG codon, so the new cre gene would be ligated to the P b a d  promoter with 
the coding sequence in frame with the ATG start codon, creating a translational fusion 
of the promoter with gene.
A new upstream PCR primer HPCreNoATG+ (section 3.1.10) was designed so that a 
promoterless cre gene without an ATG start codon could be amplified. The restriction 
site Pstl was incorporated into the primer, immediately adjacent to the cre gene 
homologous sequence. The downstream PCR primer to be used in the PCR reaction was 
HPCremcs- (used in the previous PCR amplification of the original cre gene, section
3.10), that incorporated a stop codon and a Bell site into the PCR product. The 
HPCreNoATG+ and HPCremcs- primers were used in conjunction with Pwo 
polymerase (because of its high proofreading ability) to PCR amplify a l.Okb PCR 
product (Figure 10.2). The new cre gene PCR product was digested with Pstl and Bell 
and then purified by ethanol precipitation.
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Figure 10.2. Electrophoresis showing the new cre gene PCR product run on a 2% agarose gel stained with 
ethidium bromide
Lane 1: lOObp marker (500ng)
Lane 2: promoterless cre gene (without ATG or RBS) PCR product (lkb)
The digested PCR product was cloned into the vector pBAD-TOPO-Cre, also digested 
with Pst\ and Bell restriction enzymes to remove the original transcriptionally fused cre 
gene. The vector (now 4.2kb) was ligated with the new cre gene to produce a 5.2kb 
construct, pUS1629 (Figure 10.3).
excise old
PC R  newcre
1053 bp
P(txjd)
RBS
pMB1 ori
cre gen e  
from vector
Ptfxicf)
replace 
wilti new 
c re  gene
pMB1 ori
Figure 10.3. Construction o f plasmid vector pUS1629
The Pstl end of the new cre gene insert joined with the P b a d  promoter creating a 
translational fusion, and remained in the same frame as the coding sequence of the 
original cre gene. Figure 10.4 shows a comparison between the transcriptional and the 
predicted translational fusion sequences and the reading frames. The ATG start codons 
are shown in red, the Pstl restriction sites are shown in pink, and the coding sequence of 
the cre gene is shown in blue.
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Transcriptional fusion:
ATG GGC TCT GGA TCC GGT GAT GAC GAT GAC AAG CTC GCC CTT CCC AAG CTT
CCC GGG CTG CAG CCA TGC CAA TTT CAC AGT AAG GAG GTT TAA CTT ATG TCC 
AAT
Translational fusion:
ATG GGC TCT GGA TCC GGT GAT GAC GAT GAC AAG CTC GCC CTT CCC AAG CTT
CCC GGG CTG CAG TCC AAT
Key:
Red = ATG start codon 
Green =  Ps/1 restriction site
Blue = First two codons of cre gene after ATG start codon 
Black = sequence from Pbad promoter
Pink = sequence from old cre insert forming transcriptional fusion 
Turquoise = ribosome binding site
Figure 10.4. Diagram to show the sequence reading frames o f the transcriptional and translational fusions of  
the Pbad promoter with the promoterless cre  gene
Sequence analysis confirmed the translational fusion of the P b a d  promoter to the cre 
gene maintained the correct reading frame (Figure 10.5).
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start codon 
provided by 
promoter P™ first codon in
,; ■ i|c c dp  g eloTocTjilic c cre sequence
(correct frame)
Figure 10.5. Sequence data showing the translational fusion o f PBAD promoter with cre gene in pUS1629
The next step was to clone the promoter-gene translational fusion into the vector 
pACYC184 so that the cre gene would be on a low copy number plasmid, and that the 
plasmid would co-exist in cells containing the loxP plasmid (pUS1604) due to the 
compatability of the two plasmid replicons. Both pACYC184 and pUS1629 were 
digested with Seal and Sphl to release the respective 2.4kb and 3.5kb fragments. These 
were excised from a 1% agarose gel and the DNA was extracted through gel extraction 
columns. The cloning procedure produced the construct pUS1630 (Figure 10.6), which 
was selected after the transformation procedure by providing chloramphenicol 
resistance to the transformed E. coli DH5a cells, and confirmed by restriction analysis 
by digesting the construct with Seal and Sphl releasing 2.4kb and 3.5kb fragments 
(Figure 10.7, lane 2).
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Cat
Figure 10.6. Construction o f  plasmid vector pUS1630
Figure 10.7. Electrophoresis confirm ing the construction o f pUS1630 by digesting with 5ca l and Sphl
Lane 1: XHindlll (200ng)
Lane 2: pUS1630 digested with with Seal and Sphl to release 2.4kb and 3.5kb 
fragments
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10.3. Arabinose induction assay
The pUS1630 plasmid was transformed into competent XL 1-Blue cells containing 
pUS 1604 and recovered on a plate containing streptomycin (25jug m l'1) and 
chloramphenicol (25pg m l'1). A 5ml culture containing both plasmids was grown 
overnight in RM media. The following day, the overnight culture was diluted and 
grown in RM media to an ODeoo of approximately 0.6. The arabinose induction assay 
was performed as previously described (section 3.2.23) using duplicate samples. 
Samples 1-4 were induced for 3 hours with 0.2, 0.02, 0.002, and 0.0002 % L-arabinose 
respectively, whilst sample 5 was repressed with 0.2% D-glucose as the negative 
control. The samples were serially diluted 10-fold (neat-1 O'6) and lOOjal from each 
dilution plated onto LB agar plates containing either streptomycin (25jag ml'1) and 
chloramphenicol (25jag m l'1) or kanamycin (50pg m l'1) and chloramphenicol (25pg ml' 
1)-
The numbers recovered on plates containing streptomycin were 103-105 -fold less in 
numbers than the numbers of colonies recovered on the plates containing kanamycin. 
Table 10.1 and Figure 10.8 show the average numbers recovered on the 10'4 dilution 
plates with the actual number counted on the streptomycin plates, and the number 
estimated from the count on the 10'6 kanamycin plates.
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Table 10.1
Sample
number
Arabinose
(%)
Mean no. of 
streptomycin  
resistant 
colonies
Mean % 
streptomycin  
resistant 
colonies
Mean no. of 
kanamycin 
resistant 
colonies
Mean % 
kanamycin 
resistant 
colonies
Mean no. o f  
total colonies 
(ampicillin 
resistant)
1 0.2 156 0.10 142,000 95.3 149,000
2 0.02 29 0.02 130,000 91.5 142,000
3 0.002 36 0.08 39,000 86.7 45,000
4 0.0002 10 0.08 10,000 83.3 12,000
5 0.2 (glucose) 29 0.03 86,000 85.1 101,000
Mean percentage of Streptomycin and Kanamycin resistant colonies recovered after arabinose 
assay using translational fusion vector
■  Streptomycin resistant n  Kanamycin resistant
1 2 3  4  5
Sample number
Figure 10.8. Graph showing results from the arabinose experim ent using p(JS1630
The results showed that in all the samples containing arabinose the cre gene was 
expressed, resulting in the loss of the Q  fragment (containing the streptomycin 
resistance gene) and the gain of kanamycin resistance. However, there were also high 
numbers of kanamycin resistant colonies recovered from the negative glucose control, 
indicating that the P b a d  promoter had not been fully repressed, or that the promoter had 
not been able to regulate expression of the cre gene sufficiently.
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In all the samples, the numbers of streptomycin resistant colonies declined to below 
0.1% of the total number of colonies isolated on ampicillin, which could possibly be 
regarded as a negligible number. This result supports the early results using 
pACYCaraCre (section 5.2). Where complete loxP recombination took place upon the 
introduction of the plasmid to cells containing pUS1604, the cells were completely 
resistant to kanamycin and sensitive to streptomycin.
Due to time constraints, it was not possible to clone a transcriptional terminator 
upstream of the new cre gene in pUS1630. This may or may not have the desired effect 
of obtaining tight regulation of the cre gene by the P b a d  promoter during the arabinose 
induction experiment. Obviously this would be the next step in gaining a clearer picture 
of cre gene regulation using the system, and would help in determining whether or not 
the cre-loxP system could be used as an effective reporter system to identify 
meningococcal promoter induced in vivo.
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11. Results: Library construction and experimental testing
11.1. Introduction
Despite the problems controlling the level of Cre expression, the results from the in 
vitro assay indicated that the system could potentially be used to identify in vivo active 
promoters. Our attempts to clone the system into the meningococcus were however 
unsuccessful. We therefore chose to construct and test a meningococcal library in E. 
coli in the time left available. In light of the fact that targetting of the loxP-Q-aph 
cassette into the bacterial host chromosome would avoid the problem of mixed cell 
phenotypes, a strategy to do this in E. coli was considered. However, because of time 
shortage and the possiblity of 100% looping out of the cassette from low levels of Cre 
activity, it was decided against proceeding down this route.
E. coli can cause both septicaemia and meningitis in humans, like the meningococcus. 
Neisseria and E. coli belong to the same proteobacterium group of the eubacteria and 
may share many signalling and regulatory pathways. It was hoped therefore that 
promoters that were in vivo active in the meningococcus, may also be active in E. coli 
cells exposed to the same in vivo conditions as the meningococcus. Consequently, it 
was decided to prepare a meningococcal genome library in the cre/loxP reporter system 
(to be tested in E. coli), to identify active promoters.
It should be recognised that the compromise of probing the Cr e-loxP system with a 
library meningococcal genomic DNA in E. coli is not an ideal way to identify 
meningococcal ivi genes. There are shared regulatory and signal transduction pathways 
in N  meningitidis and E. coli such as the CPS biosynthetic pathway (Edwards et. al., 
1994), and the pathway responsible for the coupling of fimbrial adhesins to receptors on
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the host cell (Abraham et. al., 1998). However, these pathways may not function 
identically plus there are also distinct pathways between the two species. However, by 
placing the system into E. coli will serve to demonstrate how the project would proceed 
in N. meningitidis if there had been suceessful integration of the loxP-f2-aph cassette 
into the chromosome and construction of a suitable cre shuttle vector. Therefore, the 
experiments in E. coli should be viewed as a source of direction that would be taken 
once the Cre-loxP system had been successfully developed in N. meningitidis.
Another option considered was to place the system into the pathogenic E. coli K1 strain 
because this organism shares the same capsular polysaccharide [i.e. poly (2-8)-a- 
NeuNAc] which is poorly immunogenic (Sarvamangala et. al., 1991). Furthermore, E. 
coli K1 causes neonatal meningitis (Glode et. a l, 1977). However there was insufficient 
time to resolve the genetic manipulation issues, required by the Health and Safety 
Executive. Another potential problem that could arise through the genetic manipulation 
of E. coli K1 with N. meningitidis genes is that there is a risk of selecting for a 
pathogenic E. coli mutant strain that displays an increased virulent phenotype. 
Therefore, it was decided to proceed in the non-pathogenic DH5a laboratory strain that 
does not possess the poly (2-8)-a-NeuNAc linked capsule virulence factor.
11.2. Construction of library cloning vector
The library-cloning vector would consist of the promoterless cre gene downstream of a 
unique restriction site into which the library would be cloned. The origin of replication 
would again be the P15A replicon from the pACYC184 plasmid, providing a low copy 
number.
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The cre gene and the T4 terminator were excised from the vector pBAD- 
TOPOCreTerm (Chapter 6, Figure 6.5) on a Hindlll-Bcll fragment and cloned into the 
vector pACYC184 digested with the same enzymes, thereby replacing the tet gene 
(encoding tetracycline resistance). This produced the library vector pUS1623 (Figure 
11.1).
T4 term Smal Hitd III
cat
Figure 11.1. Plasmid vector pUS1623
The restriction site Smal had been incorporated into the HPcremcs+ primer sequence so 
that this site would be engineered upstream of the promoterless cre gene during the 
PCR reaction. Since Smal generates blunt-ended fragments, its inclusion in the library 
vector allows cloning of restriction enzyme digested genomic DNA fragments that are 
blunt-ended. 1 pg of N. meningitidis genomic DNA was digested for 2 hours separately 
by each of the different restriction enzymes (shown in Table 11.1). The digested DNA 
was then purified though a Qiagen purification column, and tested for ‘clonability’.
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11.3. Preparation and testing of cloning efficiency of library insert 
DNA
Each purified digestion sample was diluted accordingly so that the vector: insert ratio 
was approximately 3:1, using 50ng of vector per ligation reaction. The ligation reactions 
were incubated overnight at 8°C. The following day, lj.il of each ligation reaction mix 
was transformed into 50pi of DH5a cells that had a transformation efficiency of 
approximately 1 x 109cfu pg"1 DNA. Table 8.1 shows the numbers of colonies 
recovered the following day on LB plates containing chloramphenicol (25 pg ml"1), from 
50pl volumes plated from each of the samples.
Table 11.1
Restriction digest Number of colonies recovered from 
transformation reactions
A M 28
BbrVl 3
Bst\J I 710
Dpnl 4
Dral 7
EcoRV 20
Haelll 1026
Hpal 2
Pvull 8
Rsal 109
Seal 1
SnaBl 4
Sspl 71
Vector only n
The results in Table 11.1 show that the iLdJI and Haelll digested genomic library DNA 
ligated to the vector produced the highest number of transformants per transformation 
reaction. Therefore, it was decided to use these two digestion samples to produce the 
recombinant library clones in the pUS1623 vector on a larger scale.
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11.4. Size fractionation of complete genomic digests
Complete genomic digests require size fractionating before production of a library. If 
this procedure is not performed, then very small genomic DNA fragments are likely to 
ligate together and produce recombinants that would be difficult to analyse. 
Furthermore, if very large genomic insert DNA fragments are present, this could alter 
the vector: insert ratio, thereby reducing cloning efficiency. It was therefore decided to 
size fractionate the BstUL and HaeIII complete genomic digests to maximise cloning 
efficiency by selecting DNA fragments between lkb and lOObp in size for ligation.
The two digests were run 011 a 1% agarose gel (Figure 11.2, lanes 2 & 3) and size 
fractionated by cutting out the DNA fragments with sizes between lOObp and lkb from 
the gel (Figure 11.3, lanes 2 & 3). The DNA fragments were then purified using the 
Qiagen gel extraction kit (Figure 11.4, lanes 2-5).
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Figure 11.2 Figure 11.3
Figure 11.2. Electrophoresis o f fls/UI and H aeIII digests o f N. m eningitidis strain H44/76 genomic DNA on a 
1% agarose gel stained with ethidium bromide. Figure 11.3. Size fractionation o f these genomic digests by 
excising DNA fragments between Ikb and lOObp from the gel.
Figures 11.2 & 11.3:
Lanes 1: lOkb marker (500ng)
Lanes 2: BstUl genomic digest (lpg)
Lanes 3: Hae III digest (lpg)
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Figure 11.4. Purified size fractionated genomic DNA running on 1% agarose gel
Lane 1: X Hindlll (500ng)
Lanes 2 & 3: Purified TN/UI digest 
Lanes 4 & 5: Purified HaelU digest 
Lane 6: lOkb ladder (500ng)
11.5. Generation of genomic DNA library
The next step was to transfer the N. meningitidis genomic library in pUS1623 (driving 
cre gene expression) into E. coli cells that had already been transformed with pUS1604, 
containing the loxP sites. Approximately 45ng of the genomic DNA fragments was 
used in the ligation reactions (using a 3:1 vector: insert ratio for a 3.5kb vector and lkb 
insert) with 50ng pure vector pUS1623. The vector pUS1623 had been previously 
digested with Smal, and the 5' phosphate groups on the generated blunt ends were 
removed byalkaline phophatase (calf intestinal phosphatase). Three 10pl ligation 
reactions consisting of (i) Rv/UI digested library with vector (ii) HaelII digested library 
with vector, and (iii) vector only were incubated overnight at 8°C. The following day, 
1 pil volumes of the pooled ZN/UI and HaelII ligation reactions were transformed into 20 
x 50pl aliquots of competent DH5a cells (with a transformation efficiency of 1 x 10 
cfu m l'1), that had previously been transformed with pUS1604 (Chapter 4, Figure 4. 14).
159
After the transformation procedure, the aliquots were pooled together and mixed. 50pi 
volumes were plated onto LB agar plates containing streptomycin (25 pg m l'1), 
ampicillin (lOOpg ml"1) and chloramphenicol (25pg ml"1), and also onto agar plates 
containing kanamycin (50pg ml"1), ampicillin (lOOpg m l'1) and chloramphenicol (25pg 
m l'1). These plates were prepared for the purpose of counting the numbers of colonies 
recovered on them. The remaining transformation mix (10ml volume) was plated onto a 
large 20cm2 LB agar plate containing streptomycin (25pg m l'1), ampicillin (lOOpg ml'1) 
and chloramphenicol (25pg m l'1). This primary selection step selected for the library 
fragments of N. meningitidis H44/76 genomic DNA that did not cause the expression of 
the cre gene during the in vitro transformation procedure. Any library fragments able to 
induce expression of Cre at this stage would have been removed, as they would have 
lost the streptomycin resistance gene. An additional transformation sample of vector 
only was also plated out onto both streptomycin and kanamycin LB agar plates.
Two sets of 20 separate transformations were performed to generate the genomic DNA 
library. Table 11.2 shows the number of colonies recovered on both the streptomycin 
and kanamycin plates from 50pi of the pooled transformation reactions plated (the 
count plates), for each of the two sets of 20 aliquots of transfomation reactions.
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Table 11.2
1st transformation set 2nd transformation set
Recombinant
clones
Streptomycin
resistant
Kanamycin
resistant
Streptomycin
resistant
Kanamycin
resistant
Pooled BstUV 
Haelll library
263 150 170 320
Vector only 1 5 5 8
The total number of recombinant library clones selected on the assay plates estimated to 
be approximately a total of 86,600 clones. This figure was calculated as follows:
1st transformation set: 263. streptomycin resistant colonies were selected on 50pi count 
plate. Therefore, from 1 x 50pl transformation reaction (50pl competent cells + 450pl 
SOC = 500pl transformation culture), 2630 streptomycin resistant colonies should be 
selected. 20 transformation reactions were performed. Therefore, a total of 52,600 
colonies were selected on the 1st assay plate (2630 x 20 = 52,600). These colonies were 
scraped from the plate and stored in NB2, 15% glycerol at -70°C in aliquots containing 
5,260 cfu ml"1.
In the same way, the number of colonies recovered from the 2nd transformation set was 
calculated as being approximately 34,000 colonies. Again, these colonies were scraped 
from the plate and stored in NB2, 15% glycerol at -70°C in aliquots containing 3,400 
cfu m l'1.
The ratio of the two batches of frozen library stocks was approximately 1.5: 1. 
Therefore whilst inoculating cultures using each batch of library stock, the ratio of 
inoculum used from 1st transformation set and 2nd tranformation set, was 1: 1.5 
respectively.
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11.6. Library characterisation
The next stage of the library procedure, was to check that pUS1623 had ligated with the 
insert library DNA. A PCR with the primers HPlib+4 and HPantimcs (Figure 11.5) and 
using the colonies as templates was performed.
T4term  . r....insert DNA
cat
Figure 11.5. Location o f primer annealing sites to PCR am plify A. m eningitidis genomic insert DNA ligated 
into pUS1623
The PCR products were run on a 2% agarose gel, shown in Figure 11.6 (lanes 2-28). 
The PCR products are seen to run at different sizes compared to the vector only control 
(lane 29) that contains no cloned insert DNA. The vector only control PCR product size 
is 320bp. Therefore, the sizes of cloned insert DNA could then be estimated by 
subtracting the size of the vector only control, from the sizes of the insert DNA PCR 
products. Therefore the sizes of the cloned inserts were estimated as ranging between 
100-1 OOObp by looking at the sizes of the PCR products on the gel.
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Figure 11.6. Electrophoresis o f PCR products o f insert library DNA fragments from recombinant library 
pUS1623 clones on a 2% agarose gel stained with ethidium bromide
Lanes 1 & 30: lOObp ladder(200ng)
Lanes 2-28: PCR products of library insert DNA 
Lane 29: PCR product from vector only control
The percentage of positive PCR results indicating the presence of cloned library insert 
in pUS1623 was estimated at 75% of the total number of clones screened by PCR. as 
these products all ran at sizes greater than that of the negative control. In the remaining 
25%, the PCR reaction had not produced a PCR product. This seems to have been due 
to the failure of the PCR rather than there being no insert present, because if the latter 
explanation were true, then a PCR product would be seen running at the same size as 
the vector only control.
The recombinant library clones recovered on the 20cm" plate were scraped off in 5mls 
of NEE and centrifuged at 3000rpm for 5 minutes to pellet the cells. The pellet was then 
resuspended in lml of NEL so that there was a known amount of clones per ml. The 1ml 
volume of concentrated library stock was aliquoted into lOOpl volumes and stored at -  
70°C. This process was repeated with the second library.
1 5 10 15 20 25 30
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11.7. Testing of recombinant library clones to activate Cr e-loxP  IVET 
system in an ex vivo human serum experiment
Human serum was chosen as an ex vivo model in which to test the cre-loxP system in 
the recombinant library clones because meningococci encounter this environment 
during infection. Some of the components of blood serum encountered by the organism 
may induce a genetic response by upregulation of a set genes required for survival and 
growth within this environment. This test condition would comprise of a mixture of 
50% healthy human serum and 50% PBS. The reason for the ratio of serum to PBS used 
in the experiment was to create a correctly balanced pH buffered environment.
Another reason why the serum model was chosen as opposed to using whole blood was 
because of the simplicity of the experiment. Serum only contains complement that 
exhibits bactericidal activity, and heating at 56°C for 12 minutes can easily inactivate 
the complement pathway. Conversely, a .whole blood model contains a variety of 
bactericidal agents, some of which are not so easily inactivated. Therefore, a relatively 
complicated bactericidal killing assay would have had to be performed prior to the Cre- 
loxP experiment to determine the killing activity towards E. coli cells in the whole 
blood model.
An aliquot from library stocks 1 and 2 (produced separately from the two sets of 
transformations) was defrosted and mixed in the ratio of 1: 1.5 respectively, so that 
there was an approximate equal representation of library clones within the starting 
inoculum. A volume of 5pi of inoculum was pipetted into 5mls of LB broth containing 
streptomycin (25pg m l'1), ampicillin (lOOpg ml"1), and chloramphenicol (25pg ml"1).
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The library culture was grown overnight shaking at 250rpm, 37°C. The following 
morning, 0.5ml of the overnight culture was inoculated into 9.5mls of fresh LB broth 
containing the same three antibiotics and grown to an OD6oo value of 0.6. The 10ml 
culture was centrifuged at 3000rpm for 5 minutes to pellet the cells. The pellet was 
washed twice in lOmls PBS and finally resuspended in 0.5ml PBS. Meanwhile, 1ml of 
human serum (from a healthy human volunteer) that had been stored at -70°C was 
thawed and then heat-treated at 56°C for 12 minutes to inactivate complement. 20pl 
volumes of the PBS culture were inoculated into duplicates of 2mls of (a) 50% heat 
inactivated serum, 50% PBS, and (b) 100% PBS.
The samples were incubated at 37°C, shaking at 250rpm for 3 hours and then lOOpl 
from each sample was serially diluted 10-fold from neat to 10'6. Volumes of lOOpl were 
plated from each dilution sample onto LB agar containing streptomycin (25pg ml'1), 
ampicillin (lOOpg ml"1), and chloramphenicol (25pg ml"1), and also kanamycin (50pg 
ml"1), ampicillin (lOOpg ml"1), and chloramphenicol (25pg ml"1).
It was expected that the outcome of this experiment would show that at time To (when 
1 OOpl samples had been taken and plated out immediately upon the introduction of the 
cells to the serum), the colonies recovered on LB agar would be streptomycin resistant 
and kanamycin sensitive. This was because at this initial stage of the experiment, any in 
vivo active promoters would not yet be active and therefore would not have induced cre 
expression.
Presumably some of the meningococcal genes required for survival and growth in 
serum are also required by the meningococcus during infection of the blood, therefore
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could possibly be regarded as potential virulence factors. There would also be cells still 
resistant to streptomycin and sensitive to kanamycin in which cre remained inactive in 
the serum either because the cloned insert fragments do not contain promoters, or that 
there are promoters that are not expressed in serum. After 4 hours of incubation in the 
serum, it was hoped that there would be an increased number of colonies isolated that 
were now resistant to kanamycin and sensitive to streptomycin recovered from the 
samples plated out at time T 4 . This would then indicate that some of the insert library 
fragments cloned upstream of cre contained promoter-like regions that had been 
upregulated upon the bacterial cells encountering certain components in the serum.
The negative controls for the experiment were the 100% PBS samples in which the 
library containing cells recovered were expected to remain streptomycin resistant and 
kanamycin sensitive at both time points To and T 4 . This is because the promoter 
fragments able to induce cre during in vitro growth should have largely been selected 
out at the first selection stage when the library had initially been recovered on 
streptomycin.
The actual results of the experiment showed that overall, the numbers appeared to be 
very similar between the numbers of kanamycin and streptomycin resistant colonies 
recovered. Table 11.3 shows the numbers of colonies recovered on both streptomycin 
and kanamycin plates (from the duplicate samples taken from the 50% serum, 50% 
PBS, and 100% PBS cultures), and also the mean averages of the plate counts are 
illustrated in Figure 11.7.
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Table 11.3
50% serum, 50% PBS count (10"6) 100% PBS count (10^)
Duplicate
sample
1 2 mean 1 2 mean
Streptomycin
Resistant
159 57 108 141 25 83
kanamycin
resistant
156 39 97.5 172 20 96
Numbar of resistant colonies In each type of culture media
■  Streptomycin resistant ■  Kanamycin resistant
Type of culture madia
Figure 11.7. Bar chart showing results from the serum experim ent
11.8. Screening by replica plating to identify clones containing 
potential promoters strongly induced in the serum, causing a complete 
loxP  recombination by Cre.
The library plating experiment indicated that under both conditions (PBS or serum), E. 
coli cells were generated that were resistant to both streptomycin and kanamycin. It was 
considered that this result might have been caused by weak cre gene activation that 
resulted in loxP recombination taking place within some, but not all copies of the 
reporter plasmid in each cell. It was felt that strong expression of Cre should result in 
cells that had completely lost the streptomycin resistance gene, due to loxP
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recombination being completed in all copies of the plasmid. Because we were searching 
for genes that were strongly expressed after exposure to serum, we decided to use 
replica plating to identify E. coli colonies that were kanamycin resistant and 
streptomycin sensitive.
The serum experiment was repeated which again showed a pattern that indicated there 
were mixed populations of cells in the colonies. Instead of screening the colonies by the 
laborious method of cross-streaking onto streptomycin and kanamycin plates, it was 
decided to screen the colonies by replica plating (section 3.2.28), which would make the 
screening of thousands of colonies feasible. The aim was to identify colonies that had 
grown on kanamycin, but not on streptomycin.
Approximately 10,000 colonies were screened by replica plating. All the colonies were 
found to be resistant to both streptomycin and kanamycin. It has already been 
established that loxP recombination on the pUS1604 plasmid in the absence of the cre 
plasmid only occurred with an approximate 0.3% frequency (section 4.6), so it was 
unlikely that the mixed population of cells within the colonies was due to background 
loxP recombination.
An explanation could be that the cre gene was expressed at a low level in a proportion 
of cells in each of the colonies analysed, or that each cell harboured both streptomycin 
resistant loxP plasmids and kanamycin resistant loxP plasmids as well as the cre 
plasmid.
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11.9. Transferring the library into E. coli XLl-Blue strain
It was decided to repeat construction of the library and transform into another recA
negative strain of E. coli, XLl-Blue cells in an attempt to find whether the mixed 
population result would be repeated in a different E. coli strain. This was because there 
was the possibility that the laboratory grown DH5a strain was not a correct recAl 
mutant strain, whilst there was a greater certainty that the commercially manufactured 
XLl-Blue strain was a genuine recA\ mutant strain. Again, the cells were transformed 
with pUS1604 and made heat shock competent. A fresh ligation of the library insert 
DNA with purified Smal digested and alkaline phosphatased pUS1623 was set up. After 
overnight ligation at 8°C 1 pil of the ligation mix was transformed into 50pl of the 
competent cells. The following day, the colonies were checked by PCR using the 
primers HPlib+4 and HPantimcs- for the presence of insert. However, as Figure 11.8 
below illustrates, only 20% of the colonies checked by PCR were shown to contain 
insert by a positive PCR result detected on a 2% agarose gel (lanes 2-14).
b p  1 1 5
1500
500 
100
Figure 11.8. Electrophoresis o f PCR products o f insert /V. m eningitidis DNA in pUS1623 (in X L l-B lue cells) 
through a 2% agarose gel stained with ethidium bromide
Lane 1: lOObp ladder(200ng)
Lanes 2-14: library insert PCR samples 
Lane 15: vector only PCR sample
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The ligation and transformation procedure was then repeated several times using 
different batches of ligation mix with different vector preparations, although the insert 
DNA used throughout was from the original batch that had previously been used to 
produce the library containing insert (detected by PCR). However, the results showed a 
similar or worse outcome, with a very low rate of positive PCR product produced.
Failure to isolate high proportions of PCR product from the recombinant library clones 
meant that the DNA surrounding the library cloning site in the pUS1623 vector was 
likely to be corrupted. It seemed as though the PCR primer hybridisation sites could 
also be corrupted even though the sites were a considerable distance away from the 
Smal cloning site (approximately 200bp upstream and downstream from the Smal site). 
If this were the case, then any clones isolated would be regarded as being unsuitable 
because they would be difficult to analyse by sequencing.
In order to try and determine if one or both primer sites, flanking the cloning site were 
corrupted a clone that failed to produce PCR product using these primers was 
sequenced using both the upstream and downstream primers in separate sequencing 
reactions. Indeed, both primers failed to sequence the plasmid DNA extracted from the 
clone, indicating that the vector was somehow corrupted, possibly during the alkaline 
phosphatase process, or the ligation process.
As an alternative approach, it was decided to use the library previously constructed in 
DH5a cells that had been positively confirmed by PCR to contain the insert DNA 
(section 11.6). The aim was to extract the plasmid DNA and isolate the recombinant cre 
plasmids containing different N. meningitidis DNA insert fragments that would
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subsequently be transformed into XL 1-Blue cells. It would be necessary to remove the 
loxP plasmid (pUS1604) present in the extract prior to transformation because it was 
thought that the two plasmids would compete to enter the cells. This would be achieved 
by digesting pUS1604 with restriction enzymes that should not cut the cre plasmid. It 
was hoped that this strategy would produce positive PCR results from the colonies, 
confirming the presence of insert DNA, and ultimately that the some of the colonies 
recovered after the serum experiment would be completely kanamycin resistant, 
indicating the presence of strongly induced promoters in serum. The strategy is 
illustrated in Figure 11.9.
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Dh5a
library
extract
plasmid
DNA
digest
loxP
plasmid
transform into 
XLl-Blue cells 
containing loxP
XLl-Blue
library
Figure 11.9 Schematic diagram to show strategy to transfer o f cre  plasmids (positively confirmed by PCR to 
contain insert DNA) from DH 5a cells to X L l-B lue cells
The first step was to thaw aliquots of the two library batches and then inoculate 5ml LB 
broth containing chloramphenicol (25pg ml'1) in the ratio of 1.5: 1. This was to ensure 
approximately equal representation of the different meningococcal genomic DNA insert 
fragments as described in section 11.5. The culture was grown overnight at 37°C, 
250rpm and the plasmid DNA was extracted through a Qiagen miniprep column the 
following day.
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Once the DNA had been extracted, the restriction enzymes Bgll, Kpnl, Nsil, Sphl, and 
XJwl were used in separated digestion reactions each using 1 pg of the extracted plasmid 
DNA. The reason for using these enzymes was because they were known to cut the 
pUS1604 plasmid more than once therefore eliminating the possibilty of pUS1604 re- 
circularising and competing with pUS1623 during the transformation process. Also, the 
enzymes were chosen to not cut the pUS1623 plasmid, unless the particular restriction 
sites were within the library insert DNA fragments. Therefore five enzymes were used 
so that within each digested sample, there would be different copies of recombinant 
library plasmids remaining intact and supercoiled, that would have the ability to 
transform the competent cells.
The five digests were pooled together and purified through a Qiagen column, lng of 
DNA was transformed into 10 x 50pi aliquots of competent XL 1-Blue cells containing 
pUS 1604. After the procedure, the aliquots were pooled together and mixed, and 5pi 
was plated onto LB agar containing streptomycin (25pg m l'1), ampicillin (lOOpg m l'1), 
and chloramphenicol (25pg m l'1), and also kanamycin (50pg ml"1), ampicillin (lOOpg 
m l'1), and chloramphenicol (25pg m l'1). The remainder was plated onto a large LB agar 
assay plate containing streptomycin (25pg m l1), ampicillin (lOOpg m l'1), and 
chloramphenicol (25pg m l'1).
Streptomycin resistant clones recovered the following day were scraped from the plate 
and stored in lOOpl aliquots in NB2, 15% glycerol at -70°. Fifty of the kanamycin 
resistant colonies were cross-streaked onto streptomycin plates to check to find whether 
the streptomycin resistance gene had looped out in all the cells within the colonies. The
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plate results showed that all of the colonies streaked were completely streptomycin 
sensitive.
The transformation process was repeated 4 times and the plate counts from the 5pi 
volumes of transformation mix that were plated onto both streptomycin and kanamycin 
containing media are shown below in Table 11.4.
Table 11.4
Transformation Number of clones recovered 
on streptomycin
Number of clones recovered 
on kanamycin
1 13 109
2 20 206
3 10 197
4 12 107
The total number of colonies recovered on each of the 4 assay plates containing 
streptomycin was calculated as follows:
From transformation 1, a total of 5mls of transformation mix was plated onto the 
streptomycin-containing agar in the assay plate. 13 colonies were isolated from 5pi of 
transformation mix on streptomycin containing agar plate. Therefore a total of 
approximately 13,000 colonies were isolated on the assay plate because 1000-fold more 
transformation mix was plated out. Similarly, transformations 2, 3 & 4 yielded 20,000, 
10,000, and 12,000 colonies respectively.
The PCR analysis of the colonies using the primers PIPlib+4 and HPantimcs showed on 
a 2% agarose gel PCR products of different sizes between 100 and 500bp (Figure 11.10,
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lanes 2-19 on both gel photographs), as with the original library in DH5a cells. 
Therefore the new library in the XLl-Blue cells were now regarded as suitable to use 
test the cre-loxP system and attempt to isolate kanamycin resistant, streptomycin 
sensitive clones after repeating the serum experiment described earlier in section 11.7.
1 5 10 15 20
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Figure 11.10. Electrophoresis o f PCR products o f  N. meningitidis insert DNA from X L l-B lue library clones 
through a 2% agarose gel stained with ethidium bromide
Lanes 1 & 21: 1OObp ladder(200ng)
Lanes 2-19: library PCR products 
Lane 2: vector only PCR product
11.10. Results from serum experiment using X Ll-Blue cells containing 
Cre-loxP  system
The serum experiment was repeated and lOOpl volumes of the 50% serum and 100% 
PBS cultures were plated onto LB plates containing (i) streptomycin (25pg m l'1) and 
chloramphenicol (25pg m l'1), (ii) kanamycin (50pg ml'1) and chloramphenicol (25pg 
m l'1), and also (iii) ampicillin (lOOpg m l'1) and chloramphenicol (25pg m l'1). The mean 
plate count results from the serum experiment are shown in Table 11.5.
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Table 11.5
Time of
plating
(hours)
Mean no. o f colonies 
isolated on streptomycin  
and chloramphenicol
Mean no. of colonies 
isolated on kanamycin 
and chloramphenicol
Mean no. o f colonies 
isolated on ampicillin 
and chloramphenicol
50% serum, 
50% PBS
100%
PBS
50% serum, 
50% PBS
100%
PBS
50% serum, 
50% PBS
100%
PBS
To 215.5 210.5 144 124 225 217.5
t 4 1655 224.5 1917.5 117 2102 268
The numbers of colonies recovered after 4 hours of incubation in the serum culture had 
greatly increased compared to the numbers recovered from the PBS culture. This was 
because serum is rich in nutrients compared to PBS, and so the E. coli cells would grow 
and multiply at a faster rate in the serum than in the PBS. Therefore it was necessary to 
interpret the number of streptomycin and kanamycin colonies recovered as a percentage 
of the total number of colonies that was recovered after the assay. The percentage 
recovery of streptomycin and kanamycin resistant colonies was possible to calculate 
because pUS1604 (loxP plasmid) also contains the bla gene encoding ampicillin 
resistance, which should be present on the plasmid at regardless of whether loxP 
recombination has occurred or not. Therefore the total number of colonies recovered 
after the assay would be ampicillin and chloramphenicol resistant and the numbers of 
streptomycin and kanamycin resistant colonies could be expressed as a percentage of 
the total number of colonies recovered. The mean percentage recoveries of streptomycin 
and kanamycin resistant colonies from the serum experiment are shown in Table 11.6 
(also showing percentage variation in the duplicate results) and illustrated in Figure
11.11.
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Table 11.6
Time of 
plating (hours)
Mean percentage of total no. 
of colonies: Streptomycin 
resistant (%)
Mean percentage of total no. 
o f colonies: Kanamycin 
resistant (%)
50% serum, 
50% PBS
100% PBS 50% serum, 
50% PBS
100% PBS
T0 95.8 +/- 4.9% 96.8+/- 1.2% 64.0 +/- 5.6% 57.0 +/- 0.8%
t 4 78.7 +/- 5.9% 83.8 +/- 3.8% 91.2+/-0.8% 43.7 +/- 3.4%
100
90
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Although nearly 100% of the maximum number of colonies (recovered on ampicillin) 
were recovered on streptomycin at time T0 from both the serum and PBS cultures, there 
was also a relatively high percentage of colonies growing on kanamycin, albeit in 
slightly lower numbers. At time T4, there were a higher percentage of kanamycin 
resistant colonies than streptomycin resistant colonies recovered from the serum culture. 
This indicated that promoter fragments were induced to cause expression of Cre during 
the incubation time in the serum. The negative control samples grown in 100% PBS
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Mean percentage of resistant colonies in each type of culture media before Cre induction (T=0) and 
after 4 hours of Cre induction (T=4)
■  Streptomycin resistant ■  Kanamycin resistant
50 % serum, 50 % PBS 100%  PBS 50 % serum, 50 % PBS 100%  PBS
Type of culture media
Figure 11.11
showed that the proportion of streptomycin and kanamycin resistant colonies recovered 
remained largely similar to the T0 levels. This suggested that even though there was a 
higher than expected number of kanamycin resistant colonies (the expected result was 
negligible numbers), the proportion of kanamycin resistant colonies did not increase 
over the four hours of incubation. Therefore, the promoters in the cells growing in the 
PBS medium were not induced any further to activate cre. The variation between the 
duplicate results was less than 6% (Table 11.6), indicating the reproducibility of the 
results.
These results suggest that the system may work to an extent. However, there is not a 
significant pattern of change between the two antibiotic resistances for the two 
parameters of (i) incubation in human serum for the T4 time period, and (ii) a To time 
period to merit a solid conclusion that the system was working optimally. There was 
also a relatively high level of resistance to kanamycin in both the negative PBS controls 
and the time To samples taken, both of which were expected to show relatively high 
proportions of resistance to streptomycin and low proportions of resistance to 
kanamycin. Again, this suggests that the cre gene is extremely active and is responsive 
to very low levels of promoter activity.
Thirty kanamycin colonies that were isolated on kanamycin were cross-streaked onto 
streptomycin to check that loxP recombination had fully occurred in the cells so that the 
streptomycin resistance gene had looped out. Of the 30 colonies streaked, 8 were 
resistant to both streptomycin and kanamycin, indicating the mixed populations of cells 
within these colonies. The colonies that were fully kanamycin resistant showed that cre 
had been induced to recombine all the loxP sites present within each cell.
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Eight of the fully kanamycin resistant colonies were used as templates in PCR reactions 
using HPlibseq+4 and HPantimcs. The PCR products were purified and sequenced 
using HPlib+4 as the sequencing primer. These samples potentially contained promoter 
sequences that were induced under in vivo conditions. Also, six PCR product samples 
that had been previously amplified from the kanamycin resistant colonies initially 
selected at the library production stage (section 11.5) were also sequenced. These 
samples were assumed to contain promoter sequences that were induced under in vitro 
conditions. Five out of the eight in vivo selected samples and five out of the six in vitro 
selected samples that were sequenced produced results that could be analysed using 
Internet sequence databases to identify potential promoters. The remaining four samples 
did not produce readable sequence results, and therefore were unable to be further 
analysed.
11.11. Sequence analysis
The ten comprehensible sequence results were analysed by cross-searching the N. 
meningitidis group B strain MC58 genome sequence database with the library insert 
sequence using the ‘grasta’ program at the website http ://www.tigr.org. The result 
output listed genome ‘contigs’. Each of the contigs has been assigned a number and the 
coding sequences have been putatively identified. The highest scoring sequence 
matches for both the in vivo and in vitro selected insert fragments are shown in Tables 
11.7 and 11.8.
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Table 11.7 Sequence matches o f the insert fragments from the in vivo selected clones
Contig Coordinates Putative Identification Score
NMB0896 916312-917381 
(forward strand)
Integrase 100% identity in 150 
nucleotide overlap
NMB1077 1099652-1099104 
(reverse strand)
ABC transporter, ATP- 
binding protein, truncation
99.1% identity in 109 
nucleotide overlap
NMB0063 72965-71901 
(reverse strand)
DTDP-D-glucose 4,6- 
dehydratase oy&B-i)
80.8% identity in 130 
nucleotide overlap
NMB0643 675641-677464 
(forward strand)
MafB-related protein 98.0% identity in 151 
nucleotide overlap
NMB1847 1947319-1950406 
(forward strand)
PilCl protein 96.8% identity in 62 
nucleotide overlap
Table 11.8 Sequence matches o f the insert fragm ents from the in vitro selected clones
Contig Coordinates Putative Identification Score
NMB1797 1885139-1886545 
(forward strand)
Penicillin-binding 
protein 3
100% identity in 166 
nucleotide overlap
NMB1458 1506576-1507961 
(forward strand)
Fumarate hydratase, 
class II (fumC)
98.5% identity in 268 
nucleotide overlap
NMB1463 1513027-1512625 
(reverse strand)
IS 1106 transposase, 
degenerate
94.9% identity in 157 
nucleotide overlap
NMB0781 806761-807822 
(forward strand)
Uroporphyrinogen 
Decarboxylase (hemE)
100% identity in 59 
nucleotide overlap
NMB0264 269226-267373 (reverse 
strand)
ABC transporter, ATP- 
binding protein
100% identity in 178 
nucleotide overlap
All of the sequences showed high percentage homology to group B N. meningitidis 
sequence, confirming that the insert DNA was meningococcal genomic DNA. The next 
stage would be to find which of the sequences were located upstream of meningococcal 
open reading frames and transcribed by RNA polymerase in the same direction 011 the 
genome as it was in the pUS1623 vector, upstream of the cre gene (Figure 11.12).
The contig sequences were next translated to show open reading frames using the 
Vector NTI program. Each of the insert fragment sequences was located within the 
contigs and orientated to show the directions each was transcribed, relative to the cre 
gene (Figures 11.13 and 11.14).
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Criteria used to identify putative promoter sequences isolated from serum experiment
direction ot 
transcription
a
b N. meningitidis genome
open reading frame
N. meningitids 
genome
open reading frame
a). Direction of transcription in pUSl 623 that is initiated from the inserted genom ic DNA fragment. 
G enom ic DNA fragm ent induces c re  gene expression
b). Insert DNA is located upstream of N. m ening itid is  ORF, and is transcribed in the same direction as in 
pUSl 623 (relative to  the c re  gene). Therefore the isolated genom ic DNA fragm ent is assumed to  be 
ab le to induce m en ingococca l gene expression
c). Insert DNA is located upstream of N. m ening itid is  ORF, but is transcribed in the opposite direction to 
the N. m eningitid is  ORF. Therefore the isolated genom ic DNA is assumed to be a false positive result 
and does NOT Induce m en ingococca l gene expression
Figure 11.12.
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Positions of In wvo-selected DNA insert sequences 
relative to N. m e n in g it id is  open reading frames
coordinates
916312-917381 
(forward strand)
NMB0896
1070  bp
NMB1077
54 9 bp
1099652-1099104 
(reverse strand)
NMB0063
1065  bp
72965-71901 
(reverse strand)
675641-677464 
(forward strand)
1947319-1950406 
(forward strand)
NMB1847
3088 bp
insert sequence open reading frame
direction of 
transcription 
relative to 
cre gene
Figure 11.13
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r i
Positions of in  v itro -s e lected DNA insert sequences 
relative to N. m e n in g it id is  open reading frames
coordinates
NMB1797
1405 bp
1885139-1886545 
(forward strand)
1506576-1507961 
(forward strand)
NMB1458
1386 bp
I  '  " T  1
1513027-1512625 
(reverse strand)
NMB1463
403 bp
806761-807822) 
(forward strand)
269226-267373 
(reverse strand)
insert sequence open reading frame
direction of 
transcription 
relative to 
cre gene
Figure 11.14
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The insert sequences that were located upstream of an open reading frame and were 
transcribed in the same direction in the genome as they were to the cre gene in the 
pUS 1623 vector, were considered to be potential promoter fragments. These were the in 
vivo selected insert sequences from contigs NMB0063, NMB0643, and NMB1847 
(Figure 11.13), and the in vitro selected insert sequences from NMB1458 and 
NMB0264 (Figure 11.14). Further identification of the potential promoter sequences 
involved the analysis of the insert, sequences for prokaryote consensus sequences using 
of the Promoter Prediction by Neural Network (NNPP) software (Reese, 1994; Reese & 
Eeckman, 1995; Reese et. al., 1996) at the website
http://www.fruitfly.org/seci tools/promoter.htnil.
The output of NNPP is a list of a 46-base region of sequence that the network judges 
most likely to contain promoters, spanning from -41 to +5, where +1 is the predicted 
transcription start site. NNPP was set to score the output data between 0.01 and 1. As 
the score increases, the chance of NNPP finding a potential promoter sequence is lower, 
but the chance of finding a false positive is also lower. The insert sequences were to be 
analysed on both the forward and reverse strands for potential promoters.
First it was necessary to determine what score would be given to a sequence that should 
not contain promoters so that any of the sequences with scores similar or lower could be 
ruled out at this stage. In order to do this, three 1 OObp sequences that were in the middle 
of three separate N. meningitidis genes (and not upstream of any other open reading 
frames) were analysed by NNPP. The three scores ranged between 0.3 and 0.36. 
Therefore the score cutoff was set at 0.4 because any promoter with a score below 0.4 
was extremely unlikely to be a promoter. The sequences were then analysed by NNPP
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and Tables 11.9 and 11.10 show the highest scores assigned to each of the in vivo and in 
vitro selected sequences.
Table 11.9 NNPP highest scores: in vivo positive clones
Coutig Promoter prediction (highest score)
Forward strand Reverse strand
NMB0896 No promoter No promoter
NMB1077 No promoter No promoter
NMB0063 No promoter No promoter
NMB0643 0.92 0.87
NMB1847 0.68 0.56
Table 11.10 NNPP highest scores: in vitro positive clones
Contig Promoter prediction (highest score)
Forward strand Reverse strand
NMB1797 No promoter No promoter
NMB1458 0.95 0.89
NMB1463 0.69 0.86
NMB0781 No promoter No promoter
NMB0264 No promoter No promoter
At this stage it was possible to identify which of the insert sequences that induced cre 
gene expression in the vector pUS1623, also induced meningococcal genes when 
transcribed in the same direction as in pUS1623 in relation to cre. If one compares the 
NNPP output data with Figures 11.13 and 11.14 (showing the mapped position of the 
insert sequences and the direction of transcription relative to the cre gene), only three of 
the insert sequences appear to be acting as promoters on both a meningococcal open 
reading frame and the cre gene. These were the in vivo selected sequences from contigs
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NMB0643 and NMB1847, and the in vitro selected sequence from contig NMB1458. 
Each of these sequences is located upstream of an open reading frame, transcribed in 
the same direction as in pUS1623 indicated by a high promoter score on the correct 
DNA strand.
Until the NNPP analysis, the insert sequence from contig NMB0063 also appeared to be 
a potential promoter because it was located upstream of an open reading frame, and the 
orientation in which the sequence was read was in the same direction in relation to the 
cre gene. However, the NNPP output showed that the NMB0063 insert did not contain 
any promoter sequences that produced an output score greater than 0.4 (the score 
cutoff).
Bacterial promoters consist of two separate sequences located at the -35 and -10 
regions upstream of the transcriptional start site (located at +1). These three signals are 
necessary for an RNA polymerase molecule to bind to the DNA and initiate 
transcription of a downstream gene. The -35 and -10 promoter regions are well 
characterised in E. coli and found to be highly conserved (Harley & Reynolds, 1987). 
These two sequences are known as consensus sequences. The consensus sequences of 
N. meningitidis promoters have also been reported, and show similarities with the E. 
coli sequences (Forng et. al., 1997). Table 11.11 shows the two sets of consensus 
sequences from E. coli and N. meningitidis.
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Table 11.11
Organism -35 sequence -10 sequence
E. coli TTGACA TATAAT
N. meningitidis TTGAA- TA-AAT
The insert sequences identified as potential promoters are shown in Figure 11.15. The - 
35 and -10 regions are shown in red and underlined, and three bases on either side 
surrounding the two regions are shown in bold and underlined. This is because the 
promoter elements may appear at different relative positions, so therefore the positional 
accuracy of NNPP output is +/-3bp. The transcriptional start site is located at +1 and 
shown in bold. This is also subject to a position change of +/-3bp.
Promoter prediction for insert from NMB0643 contig from in vivo positive clone
Forward strand
Score: 0.92 CGGCTTGCCGACCGTTTCCACAATGCCCGTACTATGCTGa C g CAAGGAG 
-35 -10 +1
Promoter prediction for insert from NMB1847 contig from in vivo positive clone
Reverse strand
Score: 0.68 GCTTTTCTTGGTCAGCTTGCCGCCGTCGGCAGTATTNATg C c CAANATGG 
-35 -10 +1
Promoter prediction for insert from NMB1458 contig from in vitro positive clone
Forward strand
Score:0.95 TANTGTGGCAGACCGGTTCCGGCACGCAGTCCAATATG AACATG AACNAA  
-35 -10 +1
Figure 11.15 Locations o f consensus sequences and transcriptional start site in the promoter sequences 
identified by NNPP
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Each of the promoter sequences identified by NNPP only partly share homology (a 
maximum of 3bp homology) with the N. meningitidis and E. coli consensus sequences. 
This could be because the NNPP software has been designed to recognise promoters 
from a wide variety of prokaryotes, with a variety of consensus sequences, and is not 
specific enough to only identify promoters that are closely related to E .coli promoters.
11.12. Discussion
It must be remembered that the results from the serum experiment are not a reliable 
model of a meningococcal infection in the blood because the signal transduction 
pathways essential for environmentally regulated gene expression are not the same in E. 
coli and N. meningitidis. The two sequences that were isolated after the serum 
experiment were from the contig sequences NMB0643 and NMB1847 which have been 
putatively identified to code for MafB and PilCl gene products. PilCl and PilC2 are 
pilus-associated proteins and have been identified as being involved in meningococcal 
virulence (Rahman et. al., 1997). These proteins are surface structures and are 
associated with epithelial cell adherence, necessary for disease pathogenesis and DNA 
competence for cellular transformation processes (section 1.2.8). The MafB-related 
protein has an unknown function in N. meningitidis. It shares homology with the N. 
gonorrhoeae MafB protein that has been identified as a possible adhesin (Eickernjaeger 
et. al., 1999), a term describing minor proteins in pili.
It has been previously reported that a-l,3-Galactosyl antibodies (anti-Gal) are 
unbiquitous natural human serum antibodies. These antibodies are able to block lysis of 
enteric gram-negative bacteria, which is mediated by the alternative complement
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pathway. This occurs because the bacteria are able to bind to these anti-Gal antibodies 
and survival in human serum is thereby increased. Hamadeh et. a l (1995) found that 
total serum anti-Gal (IgG, IgA and IgM) blocked complement-mediated lysis of a 
piliated meningococcal strain that bound anti-Gal to its pili. This could explain the 
isolation of the two promoter fragments (from the PilCl and MafB contigs) isolated 
from the serum experiment.
The potential promoter sequence selected under in vitro conditions was from the contig 
NMB1458 that has been putatively identified to code for the gene product FumC, a 
class II fumarate hydratase enzyme (Guest, et .a l, 1985; Woods et. a l,  1988). Fumarate 
hydratase is involved in part of the tricarboxylic acid (TCA) cycle, one of the central 
metabolic pathways in bacteria, which oxidises Acetyl-CoA to carbon dioxide. Coupled 
to the respiratory chain, the TCA cycle generates most of the ATP required for bacterial 
growth, and is certainly required in an in vitro environment.
Clearly, more kanamycin resistant clones need to be sequenced, but owing to time 
constraints, this was not possible. Three out of the ten clones (30%) that were 
sequenced were found to contain possible N. meningitidis group B strain H44/76 
promoter sequences that were transcribed in the meningococcal genome in the same 
direction relative to the promoterless cre gene. However, the frequency of promoter 
identification seems low. A larger scale of sequence analysis of the kanamycin resistant 
clones recovered after incubation in human serum would need to be conducted, in order 
to determine a statistical frequency of isolating sequences that follow all the criteria for 
being a promoter. If the percentage of isolating promoter sequences remains or is less
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than 30% then it is highly likely that the sequences were isolated by chance rather than 
correct selection by the CrQ-loxP system.
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12. General Discussion
12.1. Introduction
As there is no effective vaccine against group B meningococcal disease using 
established anitgens such as capsular polysaccharides, lipopolysaccharides, and outer 
membrane proteins (including porA), to provoke a long-term bactericidal immune 
response against a wide variety of strains, it is necessary to investigate novel antigens as 
vaccine candidates.
Traditionally, in vitro culture-based methods using reporter genes have been used to 
experimentally examine gene expression of bacterial pathogens. However, these 
methods may require addition of foreign substrate to assay the reporter gene product, 
which may not be possible in the in vivo situation. Another limitation is that the assay 
must take place during the test condition but this may not always be practical. During 
this project, a vector reporter gene system using CrQ-loxP recombination was developed 
in an attempt to identify the promoters of meningococcal genes that are specifically 
induced under environmental conditions that simulate the in vivo environment in which 
meningococcal infection and disease occurs.
12.2. Summation of using Cr e-loxP  as a reporter system
The Cre-loxP IVET system was designed to detect active promoters by a Cre-mediated
loxP recombination event resulting in irreversible excision of the streptomycin 
resistance gene, and the reconstitution of the kanamycin resistance gene. This design 
was hoped to allow the identification of transiently active promoters that are active
191
during the test condition (in vivo) but are subsequently inactive during the recovery 
phase.
However, there were many problems associated with our Cre-loxP system. The cre gene 
appeared to be extremely active, even when placed downstream of a transcriptional and 
translational terminator. After both the serum and arabinose assays, the negative control 
samples that should have contained an uninduced cre gene (i.e. the PBS control sample 
in the serum assay, and the glucose-repressed sample in the arabinose assay) produced 
high levels of kanamycin resistant colonies. Also there were mixed populations of cells 
within colonies demonstrating that a proportion of cells contained plasmid that had 
undergone loxP recombination (kanamycin resistant), whilst other cells contained intact 
pUS1604 (streptomycin resistant), or both streptomycin and kanamycin resistant 
plasmids.
In an attempt to rectify this problem, the loxP and Cre vectors were introduced into the 
E. coli strain XLl-Blue, with the hope of the regulation being more tightly controlled 
than in the DH5a strain. Although mixed populations of cells were still recovered, the 
serum experiment did produce fully kanamycin resistant and streptomycin sensitive 
colonies, indicating that strongly induced promoters may be driving Cre expression in 
these cells. To attempt to tighten the regulation of Cre expression by the promoter, a 
translational fusion between the P b a d  promoter and the cre gene was constructed. 
Again, Cre was shown to be active in all of the samples (including the glucose- 
repressed sample), but the number of streptomycin resistant colonies declined to a 
negligible level of less than 0.1% of the total number of cells recovered. In this instance, 
the problem of the mixed populations of cells did not occur at any significant level.
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However, after overall consideraton of the project, the major conclusion is the C y q - I o x P  
system is unlikely to operate with sufficient discrimination ever to be useful in 
identifying in vivo-regulated genes. The project has since been taken up by Dr. Chris 
Johnson who was able to integrate the loxP-Q-aph cassette into the meningococcal 
chromosome and construct a cre vector with the N. meningitidis porA  promoter 
controlling the cre gene. Since the porA  gene is constitutively expressed in N. 
meningitidis, it was expected that there would be 100% looping out of the loxP-Q-aph 
cassette leading to full kanamycin resistance. However, the results to date have not 
shown any consistency at all, and the project has not been worked on since.
Dr. Grainne Sheridan has also attempted to use to system in Mycobacterium smegmatis 
and tested it using two mycobacterial inducible promoters to control the expression of 
the cre-lacZ cassette. She found that both promoters were correctly induced because 
there was production of |3-galactosidase (lacZ expression produced blue colonies), yet 
no Cre-mediated loxP recombination was detected as all the colonies recovered 
remained resistant to streptomycin and sensitive to kanamycin. A possible explanation 
for this may be due to incorrect codon useage in M. smegmatis, again making the 
system unsuitable for IVET. Again, this work has been abandoned.
12.3. Comparison with Cre-loxP  IVET system reported to identify 
Salmonella typhimurium  induce promoters
Since initiating this project, Altier and Suyemoto (1999) reported the development of a 
similar IVET system using Cvc/loxP recombination to identify in vivo regulated 
promoters in S. typhimurium. As in our system, the method of selection was based on a
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permanent and selectable change in bacterial phenotype (see section 2.1.3) induced by 
Cre-mediated recombination.
The authors also tested their system using the araBAD promoter in an arabinose 
induction assay. Their results showed that 2% of the colonies recovered from the 
glucose-repressed sample and 39% of the colonies recovered from the sample induced 
with the highest amount of arabinose (0.2%) had undergone Cre-mediated loxP 
recombination. These results differed from the results described in this thesis because 
they showed a relatively low level of Cre activity in the repressed samples, yet did not 
achieve very high levels of Cre activity in the induced samples. This indicated that they 
had achieved a tighter level of control of regulation by the promoter, although they were 
not able to completely shut off Cre activity. However, as in this study, the authors 
reported that they obtained mixed populations of cells and also had to differentiate 
between the colonies containing a mixed population of cells, and colonies containing 
cells that had undergone complete Cre-mediated loxP recombination. The reasons for 
the difference in performance of the two systems are unclear but may relate to the 
differing genetic background of the respective hosts (Salmonella vs E. coli). Overall, 
the strategy did successfully isolate several S. typhimurium promoters induced 
specifically in vivo (see section 2.1.3 for details) despite the mixed population 
problems.
12.4. Identification of promoters using Cr e-loxP  system
Despite the problems outlined in section 12.2, the Cre recombinase system was pursued
and resulted in the identification of five in vitro-active and five putative in vz'vo-active 
promoters. These were analysed by sequencing the genomic insert DNA fragments to
194
identify promoters containing the -35 and -10 consensus sequences, which were 
transcribed in the correct orientation. Two of the in vivo and one of the in vitro selected 
clones contained DNA sequences that matched the promoter identification criteria.
The two in vivo selected clones contained sequences from the contigs coding for MafB 
and PilCl gene products, both constituents of pili. Pili are involved in meningococcal 
virulence, by facilitating attachment to epithelial cells, DNA competence for cellular 
transformation, and also increased survival in human serum through binding of piliated 
cells to anti-Gal antibodies that block complement-mediated lysis of the meningococci. 
The in vitro selected promoter is part of the contig coding for FumC, involved in part of 
the TCA cycle that produces ATP needed for bacterial growth, an essential requirement 
in all types of environment.
Whilst the system did appear to correctly select two in vivo induced promoters that are 
transcriptionally active in a human serum environment, and also a promoter that is 
necessary for a housekeeping function from the initial in vitro screen, this is likely to be 
due to chance isolation rather than the system accurately selecting the promoters. Only 
30% of the insert sequences that were analysed met the criteria indicating the presence 
of promoter sequences that were transcribed in the correct direction (relative to the cre 
gene in pUS1623 and also within the contig in the meningococcal genome). This is a 
low rate of success for a system designed to identify promoters, and obviously a greater 
number of sequences isolated from kanamycin resistant clones would have to be 
analysed to determine a statistically significant success rate. Furthermore, the predicted 
-35 and -10 regions generated from the NNPP output data only shared a maximum of 
50% homology with the E. coli and N. meningitidis consensus sequences. Again, larger
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numbers of insert sequences would have to be analysed to determine a statistically 
significant rate of obtaining a greater percentage homology with the consensus 
sequences. Previous reported N. meningitidis promoters such as the porA  promoter 
(Van der Ende et. a l, 1995), fbpA  promoter (Forng et. a l, 1997), and opa promoters 
(Belland et. al., 1997) show higher homology to the E. coli -35 and -10 consensus 
sequences, but a detailed analysis of neisserial promoters has not yet been performed.
12.5. Future work
The C y q - I o x P  system is unlikely to be useful as an IVET strategy to identify i v i  genes. 
Throughout the project there was a lack of discrimination between induced and non­
induced promoters, and even in the report by Altier and Suyemoto (1999) there is 
reference to the system producing mixed populations of cells. Moreover, there are no 
other reports of using the C y q - I o x P  system as an IVET strategy in bacteria, which 
probably further indicates the unsuitability of the system.
As the general conclusions to come out of this project are that the C y q - I o x P  system as it 
stands is unsuitable, as a method to reliably identify in vzvo-regulated genes, and that 
further work to try and improve the system may be futile. Clearly the use of IVET 
methods, either by using auxotrophic mutants or by recombinase gene fusions, have 
been shown to be extremely useful as tools to identify bacterial virulence factors 
specifically induced in host tissues (Slauch & Camilli, 2000). Therefore, other IVET 
systems could still be developed in order to proceed to find novel vaccine candidates in 
the meningococcus. Such a system could use an antibiotic resistance gene as the 
reporter, analogous to the cat-lacZ reporter system in S. typhimurium (section 6.7).
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Another option would be to use an auxotrophic strain of the meningococcus 
complemented by the missing biosythetic gene fused with a genomic DNA library. This 
strategy would be analogous to the original IVET system developed by Mahan et. al.
(1993) (section 2.1.2). Another IVET system making use of an auxotrophic mutant 
strain of Listeria monocytogenes was recently reported by Gahan and Hill (2000). The 
authors used a listeriolysin negative mutant strain, which is non-haemolytic on blood 
agar plates and also shows a significant reduction of virulence in the mouse. They were 
able to identify several genes specifically expressed in vivo through fusions of promoter 
fragments to the reporter gene, the hly gene that encodes listeriolysin. As hly only 
functions in the host phagosome, it was possible to identify ivi promoters that are likely 
to be expressed in the phagosome environment, and therefore essential for L. 
monocytogenes virulence. A corresponding strategy could be employed in N. 
meningitidis, utilising an auxotrophic mutant (e.g. deficient in a gene encoding a known 
virulence factor such as the CPS) and using that gene as a reporter to identify promoters 
induced in a suitable in vivo model of infection.
Alternatively, a reporter gene such as GFP could be used to probe for active 
meningococcal promoters. GFP has recently been shown to be successful in 
demonstrating that pili and Opa proteins are important for mediating gonococcal 
interactions with human endometrial cells and inducing the secretion of cytokines and 
chemokines (Christodoulides et. al., 2000).
Ideally, any new system would need to be placed into the meningococcus and shown to 
work reliably by accurate discrimination between in vitro and in vivo regulated genes. 
This could be done by placing the reporter gene on a suitable shuttle plasmid with a
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neisserial origin of replication such as pMGC18.1 (Nassif et. a l, 1991). Alternatively, a 
shuttle vector that incorporates a genetically defined origin of replication has recently 
been shown to be capable of replicating in N. gonorrhoeae, Haemophilus spp., and E. 
coli (Pagotto et. al. 2000). A similar shuttle vector could possibly be used in the 
meningococcus. The authors also demonstrated the expression of GFP using the shuttle 
vectors in each of the organisms, again indicating the potential value of GFP as a tool in 
the genetic analysis of these organisms. Again, a similar strategy could be adapted for 
use in the meningococcus.
Since the project commenced, the complete group B meningococcal genome sequence 
has become available (Tettelin el. a l, 2000). This has enabled the putative identification 
of the insert sequences that were selected by the C y q - I o x P  system and has also directed 
subsequent studies to identify possible vaccine candidates by alternative methods such 
as protein expression studies (Pizza et a l,  2000), and signature-tagged mutagenesis 
(Sun et. al., 2000) However, whilst the publication of the genome sequence makes the 
whole process of gene identification easier, it also emphasises the inadequacies in the 
understanding of meningococcal pathogenesis. It is known that there are 2,158 N. 
meningitidis genes yet a significant proportion of these genes have no known function. 
Whilst the CrQ-loxP system is a method that can be used to isolate potential in vivo 
induced promoters and the genes they regulate, it is unable to determine the expression 
patterns of a number of different genes interacting with each other under specific 
conditions.
To take full advantage of the sequence data that are available, new technologies are 
required. The most powerful and versatile tools to do this include DNA microarrays
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(reviewed by Lockhart & Winzeler, 2000), and proteomics (reviewed by Pandey & 
Mann, 2000). These methods make it possible to analyse thousands of genes in parallel 
in different environmental conditions to examine and compare regulatory expression 
patterns. Protein-based methods have the additional advantage of measuring the final 
expression product (protein) rather than intermediate products (e.g. mRNA). In 
addition, proteomics can answer certain questions that cannot be solved by DNA or 
RNA analysis such as: the relative amount of protein, post-translational modification, 
subcellular localisation, turnover, function, and interaction with other proteins.
It is likely that in the coming years the techniques of microarrays and proteomics will 
take the lead in gene expression studies. However, there will still be situations (e.g. in 
vivo) where it may be difficult or impossible to access sufficient material to perform 
microarray or proteomics analysis. In these situations, reporter gene systems, such as 
IVET and also promoter-probe strategies (e.g. using GFP) may still have a role to play.
199
13. Bibliography
1. Abraham, S.N., Jonsson, A.B., Nonnark, S. (1998): Fimbriae-mediated host- 
pathogen cross-talk. Current Opinion in Microbiology, 1: 75-81.
2. Abremski K. and Hoess R. (1984): Bacteriophage PI site-specific recombination. The 
Journal o f  Biological Chemistry, 259:1509-1514.
3. Abremski, IC., Hoess, R., and Sternberg, N. (1983): Studies on the properties of PI 
site-specific recombination - evidence for topologically unlinked products following 
recombination. Cell, 32:1301-1311.
4. Abremski, IC. and Hoess, R. (1984): Bacteriophage-pl site-specific recombination - 
purification and properties of the Cre recombinase protein. Journal o f  Biological 
Chemistry, 259:1509-1514.
5. Abshire, IC.Z. and Neidhardt, F.C. (1993): Analysis of proteins synthesized by 
Salmonella typhimurium during growth within a host macrophage. Journal o f  
Bacteriology, 175:3734-3743.
6. Achtman, M, Wall, R. A., Bopp M. (1991). Variation in class 5 protein expression by 
serogroup A meningococci during a meningitis epidemic. Journal o f  Infectious 
Diseases, 164: 375-82.
7. Aho, E. L, Botten, J. W, Hall, R.J, Larson, M. IC, Ness, J. K. (1997): Characterisation 
of a class II pilin expression locus from Neisseria meningitidis: Evidence for increased 
diversity among pilin genes in pathogenic Neisseria species. Infection and Immunity, 
65: 2613-2620.
8. Aho, E. L, Dempsey, J. A., Hobbs, M. M., Klapper, D. G., Cannon, J. G. (1991): 
Characterisation of the opa (class 5) gene family of Neisseria meningitidis. Journal o f  
Infectious Diseases, 164: 375-382.
9. APAldeen, D.A.A., Bordello, S.P. (1996): The meningococcal transferrin-binding 
proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable 
of killing homologous and heterologous strains. Vaccine, 14: 49-53.
10. Al'Aldeen, D.A.A., Cartwright, IC. A. (1996): Neisseria meningitidis: vaccines and 
vaccine candidates. Journal o f  Infection. 33: 153-157.
11. Albert, H., Dale, E.C., Lee, E., and Ow, D.W. (1995): Site-specific integration of 
DNA into wild-type and mutant lox sites placed in the plant genome. Plant Journal, 
7:649-659.
12 Altier, C. and Suyemoto, M. (1999): A recombinase-based selection of differentially 
expressed bacterial genes. Gene, 240:99-106.
13. Ambrosch, F., Wiedermann, G., Crooy, P., A. M. (1983): Immunogenicity and side 
effects of a new tetravalent meningococcal polysaccharide vaccine. Bulletin o f the 
World Health Organization, 61: 317-323.
2 0 0
14. Apicella, M. A., Westerink, M.A., Morse, S.A., Schneider, H., Rice., P.A., Griffiss, 
J. (1986): Bactericidal antibody response of normal human serum to the 
lipooligosaccharide of Neisseria gonorrhoeae. Jonnal o f  Infectious Disease, 153: 520- 
526.
15. Arhin, F., Moreau, F., Coulton, J. W., Mills, E. L. (1998): Sequencing of porA  from 
clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic 
regulation. Canadian Journal o f  Microbiology, 44: 56-63.
16. Austin, S., Ziese, M., Sternberg, N. (1981): A novel role for site-specific 
recombination in maintenance of bacterial replicons. Cell: 25: 729-736.
17. Baubonis, W. and Sauer, B. (1993): Genomic targeting with purified Cre 
recombinase. Nucleic Acids Research, 21:2025-2029.
18. Belland, R. J., Morrison, S. G., Carlson, J. H., Hogan, D. H. (1997): Promoter 
strength influences phase variation of neisserial opa genes.
19. Bjune, G., Hfiby, E. A., Grfnnesby, J. K., Arnesen, O., Fredrikesen, J. H., 
Halstensen, A., Holten, E., Lindbak, A. K., Nfkleby, H., Rosenqvist, E., et. al. (1991): 
Effect of outer membrane vesicle vaccine against group B meningococcal disease in 
Norway. Lancet, 338: 1093-1096.
20. Blank, J.L., Gerwins, P., Elliott, E.M., Sather, S., and Johnson, G.L. (1996): 
Molecular cloning of mitogen-activated protein ERK kinase kinases (MEKK) 2 and 3 - 
Regulation of sequential phosphorylation pathways involving mitogen-activated protein 
kinase and c-Jun kinase. Journal o f  Biological Chemistry, 271:5361-5368.
21. Broome, C.V. (1986): The carrier state: Neisseria meningitidis. Journal o f  
Antimicrobial Chemotherapy, 18 (Supplement A): 25-34.
22. Boyle-Vavra, S., Seifert, H.S. (1996). Uptake-sequence-independent DNA 
transformation exists in Neisseria gonorrhoeae. Microbiology, 142: 2839-2845.
23. Buchmeier, N.A. and Heffron, F. (1990): Induction of Salmonella stress proteins 
upon infection of macrophages. Science, 248:730-732.
24. Camilli,_A., Beattie, _D.T., Mekalanos,_J.J. (1994). Use of genetic recombination as 
a reporter of gene expression. Proceedings o f the National Academy o f Sciences o f the 
United States o f  America, 91: 2634-2638.
25. Cartwright, IC. (1995). Meningococcal Disease. John Wiley & Sons Ltd.
26. Chang, A., Cohen, S. (1978). Construction and characterisation of amplifiable 
multicopy DNA cloning vehicles derived from the P I5A cryptic miniplasmid. Journal 
o f Bacteriology. 134: 1141-1156.
27. Claassen,_I., Meylis,__J., Van Der Ley P., Peeters,_C., Brons,_H., Robert, J., 
Borsboom,_E>., Van Der Ark, A., Van Straaten,_I., Roholl,_P., Kuipers,_B., 
Poolman,_J. (1996). Production, characterisation and control of a Neisseria meningitidis 
hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine, 14: 
1001-1008.
2 0 1
28. Christodoulides, M., Everson, J.S., Liu, B.L., Lambden, P.R., Watt, P.J., Thomas, 
E.J., Heckels, J.E. (2000): Interaction of primary human endometrial cells with 
Neisseria gonorrhoeae expressing green fluorescent protein. Molecular Microbiology, 
35: 32-43.
29. Dale, E.C. and Ow, D.W. (1991): Gene-transfer with subsequent removal of the 
selection gene from the host genome. Proceedings O f The National Academy O f 
Sciences O f The United States O f America, 88:10558-10562.
30. Danve, B., Mignon, M., Dumas, P., Maitre, G., Colombani, S., Lissolo, L., et. al.
(1992): Evaluation of the potential of transferrin binding proteins as meningococccal 
vaccine candidates. In: Conde-Giez, C. J., Calderon, E., Morse, S.A., eds. Eighth 
International Pathogenic Neisseria Conference (Abstracts). Cuernavaca: National 
Institute of Public Health, Mexico, 1992; 32.
31. De Klein, E.D., De Groot, R., Labadie, J., Lafebar, A.B., et. al. (2000): 
Immunogenicity and safety of a hexavalent meningococcal outer-membrane -vesicle 
vaccine in children of 2-3 and 7-8 years of age. Vaccine, 1456-1466.
32. Dellagostin, O. (1994): Ph.D. Thesis. School of Biological Sciences, University of 
Surrey.
33. De Moraes, J. C., Perkins, B. A., Camargo, M. C., Hidalgo, N. T., Barbosa, H. A., 
Sacchi, C. T., Landgraf, I. M., Gattas, V. L., Vasconcelos, H., et. al. (1992). Protective 
efficacy of a serogroup B meningococcal vaccine in Sao Paulo. Lancet: 340: 1074- 
1078.
34. Devi, S. J. N., Robbins, J. B., Schneerson. R. (1991). Antibodies to poly[2-8)-a-JV- 
acetylneuranamic acid] are elicited by immunisation of mice with Escherichia coli IC92 
conjugates: Potential vaccines for groups B and C meningococci and E. coli K l. 
Proceedings o f  the National Academy o f  Sciences o f The United States o f America USA. 
88: 7175-7179.
35. Devoe, I. W., Gilchrist, J. E., (1973): Release of endotoxin in the form of cell wall 
blebs during in vitro growth of Neisseria meningitidis. Journal o f  Experimental 
Medicine, 138: 1156-1167.
36. Diaz, J.L., Virji, M., and Heckels, J.E. (1984): Structural and antigenic differences 
between 2 types of meningococcal pili. Ferns Microbiology Letters, 21:181-184.
37. Docherty, L. (1997): Ph.D. Thesis. School of Biological Sciences, University of 
Surrey.
38. Dyer, D.W., West., E.P., McKenna, W., Thompson, S.A., Sparling, P.F. (1988): A 
pleotropic iron-uptake mutant of Neisseria meningitidis lacks a 70-kilodalton iron- 
regulated protein. Infection and Immunity, 977-983.
39. Edwards, U., Muller, A., Hammerschmidt, S., Gerady-Sehann, R., Frosch, M.
(1994): Molecular analysis of the biosynthesis pathway of the alpha-2, 8 polysialic acid 
capsule by Neisseria meningitidis serogroup B. Molecular Microbiology, 14: 141-149.
2 0 2
40. Eickernjaeger, S., Meyer, T., Fischer, E., Maier, J., Manning, P., Rudel, T., 
Scheuerpflug, I., Schulz, E., Schwan, E. (1999). Paper submitted 13.4.99 to Molekulare 
Biologie.
41. Elkins, C. (1991): Species-specific uptake of DNA by gonococci is mediated by a 
10-base pair sequence. Journal o f  Bacteriology, 173: 3911-3913.
42. Engelsberg, E., Irr, J., Power, J., Lee, N. (1965). Positive control of enzyme 
synthesis by gene C in the L-arabinose system. Journal o f Bacteriology). 90: 946-957.
43. Fairley, C., Begg, N., Borrow, R., Fox, A., Jones, D., Cartwright, K. (1996). 
Conjugate meningococcal serogroup A and C vaccine: reactogenicity and 
immunogenicity in United Kingdom infants. Journal o f Infectious Disease, 174: 1360- 
1363.
44. Fimie, J., Leinonen, M., Malcela, P. H. (1983): Antigenic similarities between brain 
components and bacteria causing meningitis. Implications for vaccine development and 
pathogenesis. Lancet, 2:355-357.
45. Fisch, I., Kontermann, R., Finnern, R., Hartley, O., Soler-Gonzalez, A., Griffiths,
A., Winter, G. (1996). A strategy of exon shuffling for making large peptide repertoires 
displayed on filamentous bacteriophage. Proceedings o f  the National Academy o f  
Sciences o f  the United States o f America. 93: 7761-7766.
46. Forng, R, Y., Ekechukwu, C. R., Subbarao, S., Morse, S. A., Genco, C. A. (1997): 
Promoter mapping and transcriptional regulation of the iron-regulated Neisseria 
gonorrhoeaefbpA gene. Journal o f Bacteriology, 179: 3047-3052.
47. Frasch, C.E. (1987): Prospects for the prevention of meningococcal disease: special 
reference to group B. Vaccine. 5: 3-4.
48. Frasch, C.E., Chapman, S. S. (1973): Classification of Neisseria meningitidis group 
B into distinct serotypes. 3. Application of a new bactericidal-inhibition technique to 
distribution of serotypes among cases and carriers. Journal o f Infectious Diseases, 127: 
149-154.
49. Frasch, C. E., Peppier, M. S. (1982): Protection against group B Neisseria 
meningitidis disease: preparation of soluble protein and protein-polysaccharide 
immunogens. Infection and Immunity, 37: 271-80.
50. Frasch, C. E., Zollinger, W.D., Poolman, J.T. (1985). Serotype antigens of Neisseria 
meningitidis and a proposed scheme for designation of serotypes. Reviews o f  Infectious 
Diseases. 1: 504-510.
51. Fukushige, S. and Sauer, B. (1992): Genomic targeting with a positive-selection lox 
integration vector allows highly reproducible gene-expression in mammalian-cells. 
Proceedings o f  the National Academy o f Sciences o f  the United States o f America, 
89:7905-7909.
203
52. Gahan, C.G., Hill, C. (2000): The use of listeriolysin to identify in vivo induced 
genes in the Gram-positive intracellular pathogen Listeria monocytogenes. Molecular 
Microbiology, 36: 498-507.
53. Gemmill, I. (1992): An outbreak of meningococcal disease in Ottawa-Carleton. 
December 1991-February 1992. Canadian Journal o f  Public Health, 83:134-137.
54. Glauser, M.P., Zanetti, G., Baumgartner, J.-D., Cohen, J. (1991): Septic shock: 
pathogenesis. Lancet, 338: 732-736.
55. Glode, M.P., Sutton, A., Robbins, J.B., McCracken, G.H., Gotschlich, E.C., Kaijser,
B., Hanson, L.A. (1977): Session III. Neonatal bacterial meningitis and enteric diseases 
of infants and children. Journal o f  Infectious Diseases, 136: S93-S99.
56. Gold, R., Goldschneider, I., Lepow, M.L., Draper, T.F., Randolf, M. (1978): 
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. 
Journal o f  Infections Diseases, 137: 112-121.
57. Goldschneider, I., Gotschlich, E., Artenstein, M. (1969): Human immunity to the 
meningococcus. Journal o f  Experimental Medicine. 129: 1307-1348.
58. Goodman, S.D., Scocca, J.J. (1988). Identification and arrangement of the DNA 
sequence recognized in specific transformation of Neisseria gonorrhoeae. Proceedings 
o f the National Academy o f Sciences o f  the United States o f  America, 85: 6982-6986.
59. Gopaul, D.N., Guo, F., van Duyne, G.D. (1998): Structure of the Holliday junction 
intermediate in CrQ-loxP site- specific recombination. EMBO Journal, 17:4175-4187.
60. Gossen,_M., Freimdlieb,_S., Bender,_G., Mueller,_G., Hillen,_W., Bujard,_H. 
(1995). Transcriptional activation by tetracyclines in mammalian cells. Science, 268: 
1766-1769.
61. Greenblatt, J., Schleif, R. (1971): Arabinose C protein: regulation of the arabinose 
operon in vitro. Nature (London) New Biology>. 233: 166-170.
62. Greenwood, B. M., Wali, S. S. (1980): Control of meningococcal infection in the 
African meningitis belt by selective vaccination. Lancet, 1: 729-732.
63. Greenwood, B. M., Greenwood, A. M., Bradley, A. K., Williams, K., Hassan-King, 
M., Shenton, F.C., et. al. (1987): Factors influencing susceptibility to meningococcal 
disease during an epidemic in The Gambia, West Africa. Journal o f  Infection, 14: 167- 
184.
64. Griffiss, J. Bactericidal activity of meningococcal antisera: blocking by IgA of lytic 
antibody in human convalescent sera. Journal o f Immunology, 114: 1779-1784.
65. Griffiss, J., Bertram, M. (1977): Immunoepidemiology of meningococcal disease in 
military recruits. II Blocking of serum bactericidal activity by circulating IgA early in 
the course of invasive disease. Journal o f  infectious diseases. 136: 733-739.
204
66. Griffiss, J., Goroff, D.K. (1983): IgA blocks IgM and IgG-initiated immune lysis by 
separate molecular mechanisms. Journal o f  Immunology, 130: 2882-2885.
67. Gu, H., Marth, J. D., Orban, P. C., Mossmann, H., Rajewsky, K. (1994): Deletion of 
a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. 
Science, 265: 103-106.
68. Guest, J. R., Miles, J. S., Roberts, R. E., Woods, S. A. (1985): The fumarase gene of 
Escherichia coli: location of the fumB  gene and discovery of a new gene (fumC). 
Journal o f  General Microbiology. 131: 2971-2984.
69. Guo, F., Gopaul, D.N., and vanDuyne, G.D. (1997): Structure of Cre recombinase 
complexed with DNA in a site-specific recombination synapse. Nature, 389:40-46.
70. Hamadeh, R. M., Estabrook, M. M., Zhou, P., Jarvis, G. A., Griffiss, J. M. (1995): 
Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks 
complement-mediated killing. Infection and Immunity. 63: 4900-4906.
71. Hammersclnnidt, S. V., Hilse, R., Van Putten, J. P. M., Gerardy-Schahn, R., 
Unkmeir, A., Frosch M. (1996). Modulation of cell surface sialic acid expression in 
Neisseria meningitidis via a transposable genetic element. EMBO Journal, 15: 192-198.
72. Hanahan, D. (1983): Studies on transformation of Escherichia coli with plasmids. 
Journal o f  Molecular Biology, 166: 557-580.
73. Handfield, M. and Levesque, R.C. (1999): Strategies for isolation of in vivo 
expressed genes from bacteria. Ferns Microbiology> Reviews, 23:69-91.
74. Haneberg, B., Dalseg, R., Wedege, E., Hoiby, E.A., Haugen, I.L., Oftung, F., 
Andersoen, S.R., Naess, L.M., Aase, A., Michaelsen, T.E., Holst, J. (1998): Intranasal 
administration of a meningococcal outer membrane vesicle vaccine induces persistent 
local mucosal antibodies and serum antibodies with strong bactericidal activity in 
humans. Infection and Immunity, 66: 1334-1341.
75. Harb, O.S. and AbuKwaik, Y. (1999): Probing the microenvironment of 
intracellular bacterial pathogens. Microbes and Infection, 1:445-453.
76. Harley, C. B., Reynolds, R. P. (1987): Analysis of E. coli. promoter sequences. 
Nucleic Acids Research, 15: 2343-2361.
77. Hayrinen, J., Jennings, H., Raff, H. V., Rougnon, G., Hanai, N., Gerady-Schahn, R., 
Finne, J. (1995): Antibodies to polysialic acid and its N-propyl derivative: binding 
properties and interaction with human embryonal brain glycopeptides. Journal o f  
Infectious Disease, 171: 1481-1490.
78. Heckels, J.E. (1989): Structure and function of pili of pathogenic Neisseria species. 
Clinical Microbiology Reviews, 2: S66-73.
79. Heffernan, E. J., Wu, L., Louie, J., Okamoto, S., Fierer, J., Guiney, D. G. (1994): 
Specificity of the complement resistance and cell association phenotypes encoded by 
the outer memebrane protein genes rck from Salmonella typhimurium and Yersinia 
enterocolitica. Infection and Immunity, 62:5183-5186.
205
80. Hensel, M., Shea, J.E., Gleeson, C., Jones, M.D., Dalton, E., and Holden, D.W. 
(1995): Simultaneous identification of bacterial virulence genes by negative selection. 
Science, 269:400-403.
81. Herrick, W. (1918). Early diagnosis and intravenous serum treatment of epidemic 
cerebrospinal meningitis. JAMA. 71: 612-617.
82. Hitchcock, P. J. (1989). Unified nomenclature for pathogenic Neisseria species. 
Clinical Microbiological Review’s, 2: S64-S65.
83. Hoess R.H., Ziese M., and Sternberg N. (1982): PI site-specific recombination: 
Nucleotide sequence of the recombining sites. Proceedings o f  the National Academy o f  
Science, 79:3398-3402.
84. Hoess R.H. and Abremski K. (1984): Interaction of the bacteriophage PI 
recombinase Cre with the recombining site loxP. Proceedings o f  the National Academy 
o f Science, 81:1026-1029.
85. Hoess, R.H., Ziese, M., and Sternberg, N. (1982): PI site-specific recombination - 
nucleotide-sequence of the recombining sites. Proceedings o f  the National Academy o f  
Sciences o f  the United States o f  America, 79:3398-3402.
86. Holten, E. (1979): Serotypes of Neisseria meningitidis isolated from patients in 
Norway during the first six months of 1978. Journal o f Clinical Microbiology’, 9: 186-
188.
87. Horwitz, A., Hefferman, L., Morandi, C., Lee, J., Timko, J., Wilcox, G. (1981). 
DNA sequence of the araBAD-araC controlling region in Salmonella typhimurium 
LT2. Gene. 14: 309-319.88.
88. Ikeda, H., Tomizawa, J. (1968): Prophage PI, and extrachromosomal replication 
unit. Cold Spring Harbour Symposium Quantum Biology: 33: 791-798.
89. Invitrogen Product Catalogue (1999): 45.
90. Jarvis, G., Vedros, N. (1987). Sialic acid of group B Neisseria meningitidis 
regulates alternative complement pathway activation. Infection and Immunity. 55: 174-
180.
91.Jennings, H.J., Gamian,_A., Ashton,_F.E. (1987). JV-propionylated group B 
meningococcal polysaccharide mimics a unique epitope on group B Neisseria 
meningitidis. Journal o f  experimental medicine, 165: 1207-1211.
92. Jennings, H.J., Lugowski, C. (1981): Immunochemistry of groups A, B, and C 
meningococcal polysaccharide tetanus toxoid conjugates. Journal o f  Immunology, 127: 
1011-1018.
93. Jennings, H.J., Roy, R., Gamian, A. (1986): Induction of meningococcal group B 
polysaccharide-specific IgG antibodies in mice by using an A-propionylated B 
polysaccharide-tetanus toxoid conjugate vaccine. Journal o f Immunology, 137: 1708- 
1713.
206
94. Jones, D. M., Elridge, J. (1979). Development of antibodies to meningococcal 
protein and lipopolysaccharide serotype antigens in healthy carriers. Journal o f  Medical 
Microbiology, 12: 107-111.
95. Jones, D.M., Kaczmarski, E.B., Meningococcal infections in England and Wales. 
Communicable Disease Reports and Reviews, R129-131.
96. Jones, D.M., Mallard, R.H. (1993): Age incidence of meningococcal infections, 
England and Wales 1984-1991. Journal o f Infection, 27: 83-88.
97. Jonsson, A. B., Nyberg, G., Normarlc, S, (1991). Phase variation of gonococcal pili 
by frameshift mutilation in pilC, a novel gene for pilus assembly. EMBO Journal, 10: 
477-488.
98. Kim, J. J., Mandrell, R. E., Griffiss, J. M. (1989). Neisseria lactamica and 
Neisseria meningitidis share lipooligosaccharide epitopes but lack common capsular 
and class 1, 2, and 3 protein epitopes.
99. Klugman, K.P., Gotschlich, E.C., Blake, M.S. (1989): Sequence of the structural 
gene (rmpM) for the class 4 outer membrane protein of Neisseria meningitidis, 
homology of the protein to gonococcal protein III and Escherichia coli OmpA, and 
construction of meningococcal strains that lack class 4 protein. Infection and Immunity, 
57:2066-2071.
100. Koomey, J.M., Falkow, S. (1987): Cloning of the recA gene of Neisseria- 
gonorrhoeae and construction of gonococcal recA mutants.
101. Kremastinou,_J., Tzanakaki,_G., Pagalis,_A., Theodondou,_M., Weir,_D.M., 
Blackwell,_C.C. (1999). Detection of IgG and IgM to meningococcal outer membrane 
proteins in relation to carriage of Neisseria meningitidis or Neisseria lactamica. FEMS 
immunology and medical microbiology, 24: 73-78.103.
102. Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995): Inducible gene 
targeting in mice. Science, 269:1427-1429.104.
103. Lakso, M., Sauer, B., Mosinger, B. J., Lee, E. J., Maiming, R. W., Yu, S. H., 
Mulder, K. L., Westphal, H. (1992): Targeted oncogene activation by site-specific 
recombination in transgenic mice. Proceedings o f  the National Academy o f Sciences o f 
the United States o f  America, 89: 6232-6236.
104. Last, J., A dictionary of epidemiology (2nd ed.). (1988). Oxford University Press.
105. Leach, A., Twumasi, P., Greenwood, B. (1997). Induction of immunological 
memory in Gambian children by vaccination in infancy with a group A plus group C 
meningococcal polysaccaride-protein conjugate vaccine. Journal o f Infectious Disease, 
175:200-204.
106. Lee, N., Wilcox, W., Gielow, J., Arnold, P., Cleary, P., Engelsberg, E. (1974). In 
vitro activation of the transcription of araB AD operon by araC activator. Proceedings 
o f the National Academy o f Sciences o f  the United States o f  America, 71:634-638.
207
107. Lee, B.Y. and Horwitz, M.A. (1995): Identification of macrophage and stress- 
induced proteins of Mycobacterium tuberculosis. Journal o f Clinical Investigation, 
96:245-249.109.
108. Lemion, D., Gellin, B., Hood, D., Voss, L., Heffernan, LI., Thakur, S. (1992): 
Successful intervention in a group A meningococcal outbreak in Auckland, New 
Zealand. Pediatric Infectious Diseases Journal, 11: 617-623.
109. Liu, T.-Y., Gotschlich, E. C., Dunne, F. T., Jonssen, E. K. (1971): Studies on the 
meningococcal polysaccharide. II. Composition and chemical proerties of group B and 
group C polysaccharide. J. Biol. Chem, 246: 4703-4712.111.
110. Lockhart, D. J., Winzeler, E. A. (2000): Genomics, gene expression and DNA 
arrays. Insight review article. Nature, 827-836.112.
111. Lowe, A.M., Beattie, D.T., and Deresiewicz, R.L. (1998): Identification of novel 
staphylococcal virulence genes by in vivo expression technology. Molecular 
Microbiology, 27:967-976.
112. Lowell, G.H., Smith, L.F., Griffiss, J., Brandt, B.L. (1980): IgA-dependent 
monocyte-mediated antibacterial activity. Journal o f Experimental Medicine, 152: 452- 
457.
113. Mahan M.J., Slauch, J.M., Mekalanos, J. J. (1993): Selection of bacterial virulence 
genes that are specifically induced in host tissues. Science, 259:686-688.
114. Mahan, M.J., Tobias, J.W., Slauch, J.M., Hanna, P.C., Collier, R.J., and 
Mekalanos, J.J. (1995): Antibiotic-based selection for bacterial genes that are 
specifically induced during infection of a host. Proceedings o f  the National Academy o f  
Sciences o f  the United States o f  America, 92: 669-673.
115. Mandrell, R.E., Zollinger, W.D. (1989). Human immune response to 
meningococcal outer membrane protein epitopes after natural infection or vaccination. 
Infection and immunity, 57: 1590-1598.117.
116. Mandrell, R. E., Kim, J. J., John, C. M., Gibson, B. W., Sugai, J. V., Apicella, M. 
A., Griffiss, J. M., Yamasaki, R. (1991). Endogenous sialylation of LOS of N. 
meningitidis. Journal o f Bacteriology, 173: 2823-2832.
117. Maniatis, T., Fritsch, E., Sambrook, J. (1989). Molecular cloning, a laboratory 
manual (2nd ed.). Cold Spring Harbour Laboratory. New York, USA.
118. Marshall, C.J. (1995): Specificity of receptor tyrosine kinase signaling - transient 
versus sustained extracellular signal-regulated kinase activation. Cell, 80:179-185.
119. Marshall Stark, W., Grindley, N.D.F., Hatfull,_G.F., Boocock,_M.R. (1991). 
Resolvase-catalysed reactions between res sites differing in the central dinucleotide of 
subsite. EMBOjournal, 10: 3541-3548.
120. Martin, S.L., Borrow, R., Van der Ley, P., Dawson, M., Fox., Cartwright, K.A.V. 
(2000): Effect of sequence variation in meningococcal PorA outer memebrane protein
208
on the effectiveness of a hexavalent PorA outer membrane vesiscle vaccine. Vaccine, 
2467-2481.
121. McGuinness, B.T., Clarke, I.N., Lambden, P.R., Barlow, A.K., Poolman, J.T., 
Jones, DM., and Heckels, J. E. (1991): Point mutation in meningococcal porA  gene 
associated with increased endemic disease. Lancet, 8740: 514-517.
122. McGuinness, B.T., Barlow, A. IC., Clarke, I.N., Fairley, J. E., Anilionis, A., 
Poolman, J.T., Heckels, J. E.,(1990): Deduced amino acid sequences of class 1 protein 
(PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the 
epitopes responsible for serosubtype specificity. Journal o f Experimental Medicine, 
171:1871-1882.
123. Medberry, S.L., Dale, E., Qin, M.M., and Ow, D.W. (1995): Intra-chromosomal 
rearrangements generated by cre-lox site-specific recombination. Nucleic Acids 
Research, 23:485-490.
124. Meyer Naess, L., Oftung, F., Aase, A., Wetzler, L. M., Sandin, R., Michaelsen, T. 
E. (1998): Human T-cell responses after vaccination with the Norwegian group B 
meningococcal outer membrane vesicle vaccine. Infection and Immunity. 66: 959-965
125. Miller, S. I., Kukral, A. M., Mekalanos, J. J. (1989): A two-component regulatory 
system (phoP-phoQ) controls Salmonells typhimurium viriulence. Proceedings o f the 
National Academy o f Sciences o f  the United States o f America, 86:5054-5058.
126. Minetti, C.A., Blake, M.S., Remeta, D.P. (1998): Characterisation of the structure, 
function, and conformational stability of PorB class 3 protein from Neisseria 
meningitidis. A  porin with unusual physiochemical properties. Journal o f  Biological 
Chemistry, 273: 25329-25338.
127. Moreno, C., Lifely, M. R., Esdaile, J. (1985). Immunity and protection of mice 
against Neisseria meningitidis group B by vaccination, using polysaccharide complexed 
with outer membrane proteins: a comparison with purified B polysaccharide. Infection 
and Immunity, 47: 527-533.
128. Munkley, A., Tinsley, C.R., Virji, M., and Heckels, J.E. (1991): Blocking of 
bactericidal killing of Neisseria meningitidis by antibodies directed against class-4 
outer-membrane protein. Microbial Pathogenesis, 11:447-452.
129. Nassif, X., Puaoi, D., So, M. (1991): Transposition of Tnl545-A3 in the 
pathogenic Neisseriae: a genetic tool for mutagenesis. Journal o f  Bacteriology, 173: 
2147-2154.
130. Newcombe, J., Dyer, S., Blackwell, L., Cartwright, IC., Palmer, W.H., McFadden, 
J. (1997). PCR-single-stranded confirmational polymorphism analysis for non-culture- 
based subtyping of meningococcal strains in clinical specimens. Journal o f clinical 
microbiology, 35: 1809-1812.
209
131. Newcombe, J., Cartwright, K., Dyer, S., McFadden, J. (1998). Naturally occurring 
insertional inactivation of the porA  gene of Neisseria meningitidis by integration of 
IS 1301. Molecular Microbiology, 30: 453-454.
132. New England Biolabs 2000 catalogue, 235.
133. Newman, B. J., Grindley, N. D. (1984): Mutants of the gamma delta resolvase: a 
genetic analysis of the recombination function. Cell, 38: 463-469.
134. Newman, D.L., Shapiro, J.A. (1999): Differential fm-lacL  fusion regulation linked 
to Escherichia coli colony development. Molecular Microbiology, 33: 18-32.
135. Novagen. Cre recombinase protocol. Product reference 69247-3.
136. Ossana, N., Peterson, K. R., Mount, D. (1986). Genetics of DNA repair in bacteria. 
Trends. Genetics. 2: 55-58.
137. Pagotto, F.J., Salimnia, H., Totten, P.A., Dillon, J.R. (2000): Stable shuttle vectors 
for Neisseria gonorrhoeae, Haemophilus spp. and other bacteria based on a single 
origin of replication. Gene, 244: 13-19.
138. Pandey, A., Mann, M. (2000): Proteomics to study genes and genomes. Insight 
review article. Nature, 405: 837-846.
139. Peeters,_C.C.A.M., Ruemke,_H.C., Sundermann,_L.C., Van Der Voort,_E.M.R., 
Meulenbelt,_J., Schuller,_M., Kuipers,_A.J., Van Der Ley,_P., Poohnan,_J.T. (1996). 
Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane 
vesicle vaccine. Vaccine, 14: 1009-1015.
140. Pizza, M., Scarlato, V., Masignani, V., Giuliani, M.M., Arico, B., Comanducci, 
M., et. al. (2000): Identification of vaccine candidates against serogroup B 
meningococcus by whole-genome sequencing. Science, 287: 1816-1820.
141. Poolman, J.T., Lind, I., Jonsdottir, IC., Froholm, L.O., Jones, D.M., Zanen,H.C. 
(1986): Meningococcal serotypes and serogroup B disease in north-west Europe. 
Lancet, ii: 555-558.
142. Potts, W. J. Saunders, J. R. (1988). Nucleotide sequence of the structural gene for 
class I pilin from by Neisseria meningitidis: Homologies with the PilE locus of by 
Neisseria gonorhroeae. Molecular Microbiology, 2: 647-653.
143. Prentlci, P. and Krisch, H.M. (1984): In vitro insertional mutagenesis with a 
selectable DNA fragment. Gene, 29:303-313.
144. Prentki, P. and Krisch, H.M. (1984): Transcription and translation termination by a 
selectable DNA fragment. DNA-A Journal O f Molecular & Cellular Biology, 3:199
145. Prinz, T., Tommassen, J. (2000): Association of iron-regulated outer-membrane 
proteins of Neisseria meningitidis with the RmpM (class 4) protein. FEMS 
Microbiology Letters, 183: 49-53.
2 1 0
146. Public Health Laboratory Service. Meniningococcal Infections working group. 
(1995). Control of meningococcal disease: guidance for consultants in communicable 
disease control.
147. Qin, M.M., Bayley, C., Stockton, T., and Ow, D.W. (1994): Cre recombinase- 
mediated site-specific recombination between plant chromosomes. Proceedings o f  the 
National Academy o f Sciences o f  the United States O f America, 91:1706-1710.
148. Quagliarello, V.J., Scheld, W.M. (1992): Bacterial meningitis: pathogenesis, 
pathophysiology, and progress. New England Journal o f  Medicine, 864-872.
149. Quinn, F.D., Newman, G.W., and King, C.H. (1997): In search of virulence factors 
of human bacterial disease. Trends in Microbiology, 5:20-26.
150. Rahman, M., Kallstrom, H., Normark, S., Jonsson, A. (1997). PilC of pathogenic 
Neisseria is associated with surface. Molecular Microbiology. 25: 11-25.
151. Ramirez-Ronda, C. H., Fuxench-lopez, Z., Nevarez, M. (1981): Increased 
pharyngeal bacterial colonisation during viral illness. Archives o f  Internal Medicine, 
141:1599-1603.
152. Reese, M. (1994): Diploma Thesis. German Cancer Research Centre, Heidelberg.
153. Reese, M., Eeckman, F. (1995). New neural network algorithms for improved 
eukaryotic promoter site recognition. Abstract. Seventh International Genome 
Sequencing and Analysis Conference, Hilton Head Island, S. Carolina, USA.
154. Reese, M, Harris, N., Eeckman, F. (1996). Large scale sequencing specific neural 
networks for promoter and splice site recognition. In: Biocomputing: Proceedings o f  the 
1996 Pacific Symposium, edited by Hunter, L., Klein. 1996. World Scientific Publishing 
Co., Singapore, January 2-7, 1996.
155. Rice, P.A., Vayo, E., Tan, M.R., Blake, M.S. (1986): Immunoglobulin G 
antibodies directed against protein III block killing of serum-resistant Neisseria 
gonorrhoeae by immune serum. Journal o f  Experimental Medicine, 164: 1735-1748.
156. Richmond, P., Borrow, R., Miller, E., Clark, S., Sadler, F., Fox, A., Begg, N., 
Morris, R., Cartwright, K. (1999). Meningococcal serogroup C conjugate vaccine is 
immunogenic in infancy and primes for memory. Journal o f  Infectious Disease, 179: 
1569-1572.
157. Richmond, P., Goldblatt, D., Fusco, P.C., Fusco, J.D., Fleron, I., Clark, S., Borrow, 
R., Michon, F. (1999): Safety and immunogenicity of a new Neisseria meningitidis 
serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine, 18: 641-646.
158. Rosenqvist, E., Hoiby, E. A. Wedege, E., Kusecek, B., Achtman, M., (1993). 
The 5c protein of Neisseria meningitidis if highly immunogenic in humans and induces 
bactericidal antibodies. Journal o f  Infectious Disease, 161: 1065-1073.
159. Rosenqvist, E., Tjade, T., Frfholm, L. O., Frasche, C. E. (1983): An ELISA study 
of the antibody response after vaccination with a combined meningococcal group B
2 1 1
polysaccharide and serotype 2 outer memebrane protein vaccine. NIPH Annals, 6: 139-
149.
160. Rudel, T., Facius, D., Barten, R., Scheuerpflug, I., Nonnenmacher, E., Meyer, T. F.
(1995). Role of pili and the phase-variable PilC protein in natural competence for 
transformation of Neisseria gonorrhoeae. Proceedings o f  the National Academy O f 
Sciences O f The United States O f America, 92: 7986-7990.
161. Sarvamangala, J., Devi, N., Robbins, J.B., Schneerson, R. (1991): Antibodies to 
poly [(2-8)-a-V-acetylneuranaminic acid] are elicited by immunization of mice with 
Escherichia coli K92 conjugates: Potential vaccines for groups B and C meningococci 
and E. coli K l. Proceedings o f  the National Academy O f Sciences O f The United States 
O f America, 88:7175-7179.
162. Sauer, B. and Henderson, N. (1988): Site-specific DNA recombination in 
mammalian-cells by the Cre recombinase of bacteriophage-Pl. Proceedings O f The 
National Academy O f Sciences O f The United States O f America, 85:5166-5170.
163. Sauer, B. (1996): Multiplex Cr el lox recombination permits selective site-specific 
DNA targeting to both a natural and an engineered site in the yeast genome. Nucleic 
Acids Research, 24:4608-4613.
164. Sauer, B. (1998): Inducible gene targeting in mice using the Cre/lox system. 
Methods-A Companion To Methods In Enzymology), 14:381-392.
165. Saukkonen, K., Leinonen, M., Abdillahi, H., Poolman, .T.T. (1989). Comparative 
evaluation of potential components for group B meningococcal vaccine by passive 
protection in the infant rat and in vitro bactericidal assay. Vaccine, 1: 325-328.
166. Saunders, N.B., Shoe maker, D.R., Brandt, B.L., Moran, E.E., Larsen, T., 
Zollinger, W.D. (1999): Immunogenicity of intranasally administered meningococcal 
native outer membrane vesicles in mice. Infection and Immunity, 67: 113-119.
167. Service, R.F. (1998): Microchip arrays put DNA on the spot. Science, 282:396- 
399.
168. Service, R.F, (1998): Genomics - DNA chips survey an entire genome. Science, 
281:1122
169. Sierra, G. V., Campa, FI. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P. L., 
Sotolongo, P. F., Casaneuva, G. V., Rico, C. O., Rodriguez, C. R., Terry, M. H. (1991): 
Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination 
results in Cuba. NIPHAnnals, 14: 195-210.
170. Slauch, J.M., Camilli, A. (2000): IVET and RIVET: use of gene fusions to identify 
bacterial virulence factors specifically induced in host tissues. Methods in Enzymology, 
326: 73-96.
171. Slauch, J.M., Malian, M.J., and Mekalanos, J.J. (1994): In vivo expression 
technology for selection of bacterial genes specifically induced in host tissues. Methods 
In Enzymology, 235:481-492.
2 1 2
172. Smith, G. R. (1987). Mechanism and control of homologous recombination in 
Escherichia coli. Annual Review o f Genetics. 21: 179-201.
173. Smith, A.H., Desousa, M.A., Kwabiaddo, B., Heppellparton, A., Impey, H., and 
Rabbitts, P. (1995): A site-directed chromosomal translocation induced in embryonic 
stem- cells by cre-loxP recombination. Nature Genetics, 9:376-385.
174. Stanwell-Smith, R.E., Stuart, JM., Hughes, A.O., Robinson, P., Griffin, M.B., 
Cartwright, K. (1994). Smoking, the environment and meningococcal disease: a case 
control study. Epidemiology and Infection, 112: 315-328.
175. Stein, D. C. (1991). Transformation of Neisseria gonorrhoeae: physical 
requirements of the transforming DNA. Canadian journal o f  microbiology, 37: 345- 
349.
176. Sternberg, N. and Hamilton, D. (1981): Bacteriophage-P 1 site-specific 
recombination .1. Recombination between loxP sites. Journal o f  Molecular Biology, 
150:467-486.
177. Sternberg, N., Hamilton, D., and Hoess, R. (1981): Bacteriophage-P 1 site-specific 
recombination .2. Recombination between loxP and the bacterial chromosome. Journal 
o f Molecular Biology, 150:487-507.
178. Stephens, D. S., Hoffman, L. H., McGee, Z. A. (1983). Interaction of Neisseria 
meningitidis with human nasopharyngeal mucosa: attachment and entry into columnar 
epithelial cells. Journal o f  Infectious Diseases, 148: 369-376.
179. Stephens, D., Spellman, P., Swartley, J. (1993). Effect of the (a2-8)-linked 
polysialic acid capsule on adherence of Neisseria meningitidis to human mucosal cells. 
Journal o f infectious diseases. 167: 475-479.
180. Stephens, D. S., Whitney, A. M., Hoffman, L. H., Farley, M. M., Frasch, C. E. 
(1986). Analysis of damage to human ciliated nasopharyngeal epithelium by Neisseria 
meningitidis. Infection and Immunity, 51: 579-585.
181. Stephens, D. S., Whitney, A. M., Schoolnik, G.K., Zollinger, W.D. (1988): 
Common epitopes of pilin of Neisseria meningitidis. Journal o f  Infectious Diseases, 
158:332-342.
182. Suker, J., Feavers, I.M., Maiden, M.C.J. (1996). Monoclonal antibody recognition 
of members of the meningococcal PI. 10 variable region family: implications for 
serological typing and vaccine design. Microbiology, 142: 63-69.
183. Sun, Y.H., Bakshi, S., Chalmers, R., Tang, C.M. (2000): Functional genomics of 
Neisseria meningitidis pathogenesis. Nature Medicine, 6: 1269-1273.
184. Swartley, J. S., Aho, J. H., Liu, L.-J., ICahler, C. M., Stephens, D. S. (1996). 
Expression of Sialic Acid in Serogroup B Neisseria meningitidis: Divergent 
Transcription of Biosynthesis and Transport Operons through a Common Promoter 
Region. Journal o f Bacteriology>. 178:4052-4059.
213
185. Tettelin, II., Saunders, N.J., Heidelberg, J., Jeffries, A.C., Nelson, K.E., Eisen, 
J.A., Ketchum, K.A., et. al. (2000): Complete genome sequence of Neisseria 
meningitidis serogroup B strain MC58. Science, 287:1809-1815.
186. Thyagarajan, B., Guimaraes, M.J., Groth, A.C., and Calos, M.P. (2000): 
Mammalian genomes contain active recombinase recognition sites. Gene, 244:47-54.
187. Tommassen J, Vermey P, Struve M, Benz R, Poolman J.T. (1990). Isolation of 
mutants of Neisseria meningitidis deficient in class 1 (por A) and class 3 (por B). 
Infection and Immunity, 58: 1355-59.
188. Troncoso,G., Sanchez,_S., Moreda,_M., Criado,_M.T., Ferreiros,_C.M. (2000). 
Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis 
and commensal Neisseria species. FEMS immunology and medical microbiology, 27: 
103-109.
189. Troy, F. A. (1992): Polysialylation: from bacteria to brains. Glycobiology, 2: 5-23.
190. Tsai, C. M,, Civin, C. I. (1991). Eight lipooligosaccharides of Neisseria 
meningitidis react with a monoclonal antibody which binds Lacto-TV-Neotetraose 
(Galj31-4GlcNAcj31-3 Gal(31-4Glc). Infection and. Immunity, 59: 3604-3609.
191. Tunkel, A., Scheld, W. Pathogenesis and pathophysiology of bacterial meningitis.
(1993). Clinical Microbiology) Reviews. 6: 118-36.
192. VaIdivia,_R.H., Falkow,_S. (1997). Fluorescence-based isolation of bacterial 
genes expressed within host cells. Science, 277: 2007-2011.
193. Van der Elide, A., Hopman, C. T. P., Zaat, S., Oude Essinlc, B. B., Berkhout, B., 
Dakert, J. (1995). Variable expression of class 1 outer membrane protein in Neisseria 
meningitidis is caused by varaiation in the spacing between the -10 and -35 regions of 
the promoter. Journal o f  Bacteriology), 111: 2475-2480.
194. Van Der Ley, P., Heckels, J.E., Virji, M., Hoogerhout, P., and Poolman, J.T. 
(1991): Topology of outer-membrane porins in pathogenic Neisseria spp. Infection and 
Immunity, 59:2963-2971.
195. Van Der Ley, P., Poolman, J. T. (1992). Construction of a multivalent 
meningococcal vaccine strain based on the class 1 outer membrane protein. Infection 
and immunity, 60: 3156-3161.
196. Van Putten, J. P. M., Robertson B. D. (1995). Molecular mechanisms and 
implications for infection of lipopolysaccharide variation in Neisseria. Molecular 
Microbiology, 16: 847-853.
197. Verheul, A. F. M., Snippe, H., Poolman J. T. (1993). Meningococcal 
lipopolysaccharides: virulence factor and potential vaccine component. Microbiological 
Reviews, 57: 34-49.
214
198. Vergunst, A.C. and Hooykaas, P.J. (1998): Cre//ar-mediated site-specific 
integration of Agrobacterium T-DNA in Arabidopsis thaliana by transient expression of 
Cre. Plant Molecular Biology, 38:393-406.
199. Virji, M. and Everson, J.S. (1981): Comparative virulence of opacity variants of 
Neisseria gonorrhoeae strain-P9. Infection and Immunity, 31:965-970.
200. Virji, M. and Heckels, J.E. (1983): Antigenic cross-reactivity of Neisseria pili - 
investigations with type-specific and species-specific monoclonal-antibodies. Journal 
o f General Microbiology, 129:2761-2768.
201. Virji, M. and Heckels, J.E. (1986): The effect of protein-II and pili on the 
interaction of neisseria- gonorrhoeae with human polymorphonuclear leukocytes. 
Journal o f  General Microbiology>, 132:503-512.
202. Viiji, M., Heckels, J.E., Potts, W.J., Hart, C.A., and Saunders, J.R. (1989): 
Identification of epitopes recognized by monoclonal-antibodies SMI and SM2 which 
react with all pili of Neisseria-gonorrhoeae but which differentiate between 2 structural 
classes of pili expressed by Neisseria-meningitidis and the distribution of their encoding 
sequences in the genomes of Neisseria spp. Journal O f General Microbiology>, 
135:3239-3251.
203. Virji, M., Kayhty, H., Ferguson, D.P., Alexandrescu, C., Heckels, J.E., and 
Moxon, E.R. (1991): The role of pili in the interactions of pathogenic neisseria with 
cultured human endothelial-cells. Molecular Microbiology, 5:1831-1841.
204. Virji, M., Makepeace, IC., Ferguson, D.P., Achtman, M., Sarkari, J., and Moxon, 
E.R. (1992): Expression of the Opc protein correlates with invasion of epithelial and 
endothelial-cells by Neisseria-meningitidis. Molecular Microbiology, 6:2785-2795.
205. Viiji, M., Makepeace, K., Ferguson, D.P., Achtman, M., and Moxon, E.R. (1993): 
Meningococcal Opa and Opc proteins - their role in colonisation and invasion of human 
epithelial and endothelial-cells. Molecular Microbiology, 10:499-510.
206. Wachtel,_M.R., Miller. V.L. (1995). In vitro and in vivo characterisation of an ail 
mutant of Yersinia enterocolitica. Infection and Immunity, 63: 2541-2548.
207. Wagner, IC.U., Wall, R.J., St Onge, L., Gruss, P., WynshawBoris, A., Garrett, L., 
Li, M.L., Furth, P.A., and Hennighausen, L. (1997): Cre-mediated gene deletion in the 
mammary gland. Nucleic Acids Research, 25:4323-4330.
208. Wang, J.Y., Lory, S., Ramphal, R., and Jin, S.G. (1996): Isolation and 
characterisation of Pseudomonas aeruginosa genes inducible by respiratory mucus 
derived from cystic fibrosis patients. Molecular Microbiology), 22:1005-1012.
209. Wang, J.Y., Mushegian, A., Lory, S., and Jin, S.G. (1996): Large-scale isolation of 
candidate virulence genes of Pseudomonas aeruginosa by in vivo selection. 
Proceedings o f  the National Academy o f Sciences o f the United States o f  America, 
93:10434-10439.
210. Woods, S. A., Schwartbach S. D., Guest, J. R. (1988): Two biochemically distinct 
classes of fumarase in Escherichia coli. Biochim Biophys Acta, 954: 14-26.
215
211. Yanisch Perron. C., Vieira, J., Messing, J. (1985): Improved M13 phage cloning 
vectors and host strains: nucleotide sequences of the M13mpl8 and pUC19 vectors. 
Gene, 103-119.
212. Zhang, Q., Choo, S., Everard, J., Jennings, R., Finn, A. (2000): Mucosal immune 
responses to meningococcal group C conjugate and group A and C polysaccharide 
vaccines in adolescents. Infection and Immunity, 68: 2692-2697.
213. Zollinger, W. D., Boslego, J., Moran, E., Garcia, J., Cruz, C., Ruiz, S., Brandt, B., 
Martinez, M., Arthur, J., Underwood, P., et. al. (1991): Meningococcal serogroup B 
vaccine protection trial and follow-up studies in Chile. The Chilean National Committee 
for Meningococcal Disease. NIPH Annals: 14: 211-213.
214. Zollinger, W. D., Mandrell, R. E., Altieri, P., Berman, S., Lowenthal, J., Artensein, 
M. S. (1978): Safety and immunogenicity of a Neisseria meningitidis type 2 protein 
vaccine in animals and humans. Journal o f Infectious Diseases, 137: 728-739.
215. Zollinger, W. D., Moran, E. (1991): Meningococcal vaccines present and future. 
Trans. Royal Society o f  Tropical Medicine and Hygiene: 85 Supplement 1: 37-43.
UMverc:- ' s: ~ ~zy libraM
216
